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Résumé 
La maladie de Parkinson (MD) est caractérisée par une perte progressive des 
terminaisons présynaptiques dopaminergiques et reste actuellement incurable. Néanmoins, 
dans les études épidémiologiques, il a été montré que l’utilisation des statines, 
médicaments hypocholestérolémiants, diminue le risque de développer une MD. Les 
statines sont également capables d'inhiber les effets neurodégénératifs dans les modèles 
précliniques in-vitro et in-vivo de la MD. Cependant, les mécanismes moléculaires à 
l’origine de ces effets neuroprotecteurs ne sont pas encore complétement élucidés. 
Ainsi, nous avons étudié les effets potentiels des statines sur l'expression des 
marqueurs synaptiques et sur le transport de la dopamine. Dans nos études, les statines 
induisent la croissance des neurites dans les cellules dopaminergiques et déclenchent une 
augmentation de l’expression des protéines synaptiques dopaminergiques telles que le 
transporteur vésiculaire des monoamines (VMAT2) et le transporteur de la dopamine. Les 
statines induisent une diminution de la recapture de la dopamine cellulaire et des 
changements d’affinités aux niveaux des sites de liaison des inhibiteurs sélectifs du 
VMAT2. L’activation du facteur de transcription nucléaire protéine-1 se liant à l'élément 
de régulation des stérols (SREBP-1), cholestérol-dépendent, serait l’élément inducteur de 
la surexpression des marqueurs dopaminergiques présynaptiques induite par les statines. 
En outre, ces résultats soutiennent un potentiel thérapeutique neuroprotecteur et/ou 
neurorestaurateur des statines précédemment proposées dans la MD et permettent de 
mettre en évidence de nouvelles cibles thérapeutiques comme le facteur SREBP. 
Mots clés: maladie de Parkinson, statine, cholestérol, dopamine, VMAT2, DAT, SREBP 
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Abstract 
Parkinson disease (PD) is characterized by a progressive loss of dopaminergic 
presynaptic terminals and remains incurable. However in epidemiological studies, it has 
been shown that the use of statins, which are hypocholesterolemic drugs, diminishes the 
risk to develop a PD. Statins are able to inhibit the neurodegenerative effects in in-vitro 
and in-vivo models of PD. However, the molecular mechanisms driving neuroprotective 
effects are not yet fully understood. 
Consequently, we investigated the potential effects of statins on the synaptic 
expression and dopamine transport function in the dopaminergic system. In our studies, 
statins enhance the neurite outgrowth in the dopaminergic cells and trigger an increase in 
the expression levels of presynaptic dopaminergic proteins such as vesicular monoamine 
transporter 2 (VMAT2) and dopamine transporter. Statins induce a reduction of dopamine 
cellular uptake and modulate the binding-affinity of the specific inhibitors for VMAT2. 
The activation of the nuclear transcriptional factor sterol regulatory element-binding 
protein 1 (SREBP-1), cholesterol-dependent, could be the key element of the 
overexpression of dopaminergic presynaptic markers induced by the statins. 
Furthermore, these findings highlight the therapeutic neuroprotective and/or 
neurorestorative potentials of statins previously proposed in PD and allow to bring out new 
potential therapeutic targets such as SREBP factor.  
Key words: Parkinson’s disease, statin, cholesterol, dopamine, VMAT2, DAT, SREBP 
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Résumé substantiel 
La maladie de Parkinson (MP) est une maladie neurodégénérative caractérisée par 
une perte des terminaisons présynaptiques dopaminergiques de la voie nigro-striée. Sur un 
plan clinique, cette maladie se traduit principalement par des symptômes moteurs tels que 
l’akinésie, la rigidité articulaire, l’instabilité posturale et les tremblements mais aussi par 
des symptômes non-moteurs. Les symptômes moteurs de la MP sont détectables lorsque 
près de 80% des terminaux présynaptiques sont perdus. Et, les mécanismes conduisant aux 
troubles neurodégénératifs et fonctionnels de la voie nigro-striée sont, à ce jour, inconnus 
et pourrait être multifactoriels.  
Plusieurs mutations génétiques telles que l’α-synucléine (SNCA) ou kinase 2 de 
répétition riche en leucine (LRRK2) sont associées à la MP. Plus particulièrement, la 
mutation α-synucléine A53T et la duplication ou triplication des gènes sont directement 
impliquées dans la neurodégénérescence neuronale, perte caractéristique de la MP. 
Néanmoins, les formes familiales liées à une mutation représentent seulement une minorité 
des cas de la MP (10%) et ne peuvent pas expliquer la majorité des cas sporadiques. Les 
toxines environnementales ont également été identifiées comme des facteurs ou des 
inducteurs de la MP. Plusieurs voies et cibles synaptiques ont été désignées comme ayant 
une implication ou un rôle majeur dans les mécanismes neurodégénératifs de la MP. Entre 
autres, les protéines synaptiques et vésiculaire telles que le transporteur-2 vésiculaire des 
monoamines (VMAT2; SLC18A2) ou le transporteur de la dopamine (DAT; SLC6A3) 
sont affectées par la MP. Ces deux transporteurs jouent un rôle essentiel dans la recapture 
de la dopamine extracellulaire. Le DAT recapture la dopamine de la fente synaptique pour 
la transporter vers le cytosol. Le VMAT2 s’occupe, quant à lui, de la recapture de la 
dopamine cytosolique pour la stocker dans la vésicule synaptique. Cette recapture est 
essentielle pour assurer un bon niveau de libération de dopamine dans la fente synaptique 
en vue de l’activation des récepteurs dopaminergiques postsynaptiques.  
La dérégulation de ces transporteurs pourrait être, en partie, la cause de la MP. 
Lorsque les perturbations motrices se manifestent, 70% de la dopamine et 50% des 
protéines impliquées dans le métabolisme de la dopamine, notamment la tyrosine 
hydroxylase (TH), le DAT ou le VMAT2, sont perdues dans le striatum, tandis que, seuls 
30% des neurones dopaminergiques se trouvant dans la substance noire sont perdues. Ceci 
Résumé substantiel 
8 
implique un dysfonctionnement précoce des terminaux pré-synaptiques. En outre, 
plusieurs études montrent que les neurones exprimant un niveau élevé de DAT sont plus 
vulnérables. Les études in-vivo et in-vitro dans des modèles de la MP ont mis en évidence 
l’implication du DAT dans la recapture des agents neurotoxiques tels que le 1-méthyl-4-
phényl pyridinium (MPP
+
), le 1-méthyl-4-phényl-1,2,3,6-tétrahydropyridine (MPTP), le 
paraquat ou la rotenone. De manière générale, les animaux sur-exprimant le DAT 
présentent une neurodégénérescence. Le DAT semble également être dérégulé par les 
mutations présentes dans la MP. Par exemple, l’α-synucléine mutante renforce la toxicité 
des agents neurotoxiques dans la surexpression du DAT comparé l’α-synucléine sauvage. 
Concernant le VMAT2, plusieurs études génétiques ont pu établir un lien entre la MP et 
l’expression de VMAT2. Des mutations de VMAT2 ou de son promoteur ont des effets 
neuroprotecteurs ou inducteurs de la MP. Les études réalisées sur des animaux qui 
présentent une régulation négative ou positive de l’expression du VMAT2 suggèrent que 
ce dernier a un rôle dans les mécanismes de détoxication de la dopamine et des agents 
neurotoxiques. De plus, les animaux ayant une régulation négative de VMAT2 produisent 
du stress oxydatif mais présentent également des agrégations d’α-synucléine ainsi qu’une 
perte des neurones dopaminergiques de la voie nigro-strié. Enfin, la modulation positive 
du VMAT2 a été identifiée comme ayant des effets protecteurs dans les modèles de la MP 
parce qu’il rétablit les niveaux physiologiques de la dopamine et qu’il séquestre la 
dopamine oxydées et les agents neurotoxiques.  
L’ensemble de ces mécanismes protectifs ou dégénératifs impliquant le DAT ou le 
VMAT2 dépend essentiellement du niveau de dopamine cytosolique. La dopamine est 
instable : elle se transforme et produit de la dopamine-o-quinone, la dopamine oxydés et 
des dérivés réactifs de l'oxygène. Ces métabolites sont extrêmement toxiques pour la 
cellule et dérégulent plusieurs métabolismes physiologiques essentiels pour la cellule 
comme par exemple la production d’ATP par la mitochondrie. Quand la dopamine se situe 
dans le milieu extracellulaire ou dans les vésicules synaptiques, elle est susceptible d’être 
moins toxique. Le pH acide de la vésicule entraîne une stabilisation de la dopamine qui 
n’est donc plus transformée en métabolites toxiques. Il en est de même pour les agents 
neurotoxiques : leur séquestration permet de réduire leur toxicité. De plus, une 
concentration élevée de dopamine au niveau de la fente synaptique peut induire une plus 
forte stimulation post-synaptique potentiellement bénéfique dans la MP. Par ailleurs, 
l’augmentation du stockage de la dopamine dans les vésicules synaptiques peut également 
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contribuer à une libération plus élevée de dopamine dans la fente synaptique, ce qui peut 
induire une plus forte stimulation postsynaptique. Néanmoins actuellement, il n’y a pas de 
substance capable de moduler l’activité ou l’expression à la hausse du VMAT2 et les 
inhibiteurs du DAT n’ont pas montré d’amélioration des symptômes dans la MP malgré 
des effets prometteurs dans les modèles de MP.  
 A ce jour, les traitements de la MP visent à la pallier le manque de dopamine soit 
par l’utilisation de levodopa (L-Dopa, L-3,4-dihydroxyphenylalanine), un précurseur de la 
dopamine, soit par des agonistes dopaminergiques. Il existe également des substances qui 
permettent de réduire la dégradation de la dopamine. Bien que ces substances soient 
efficaces pour le traitement des symptômes moteurs au début de maladie, la progression de 
la maladie rend ces médicaments inopérants. De plus, des effets secondaires peuvent 
apparaitre. Pour ces raisons et en vue d’améliorer la qualité de vie des patients, il est 
nécessaire de trouver de nouvelles substances pharmacologiques neuroprotectrives et 
neurorestauratrices des voies dopaminergiques afin de bloquer l’initiation ou d’endiguer la 
progression de la MP. 
C’est dans ce cadre que les statines ont été identifiées comme ayant un rôle 
potentiel dans la neuroprotection. Elles sont des hypolipidémiants/hypocholestérolémiant 
qui agissent par inhibition de l’enzyme limitant la synthèse du cholestérol, autrement 
appelée HMG-CoA réductase (hydroxyméthylglutaryl-CoA réductase). Les analyses 
épidémiologiques ont mis en évidence une réduction du risque de développer la MP lors de 
l’utilisation des statines, ce qui suggère un potentiel thérapeutique de ces molécules.  
Les données pharmacologiques actuellement disponibles ont montré que les 
statines sont capables d'inhiber les effets neurodégénératifs des neurotoxines telles que la 
6-hydroxydopamine (6-OHDA) et le MPTP dans les cultures neuronales ainsi que dans des 
modèles animaux de la MP. Les effets neuroprotecteurs des statines ont été expliqués par 
des effets pléiotropiques tels que la réduction des réponses pro-inflammatoires 
(interleukines, facteur nucléaire kappa B, facteur de nécrose tumorale), la réduction des 
facteurs oxydatifs et le blocage de l’agrégation de l’α-synucléine. De plus, les statines 
pourraient induire une augmentation de l’expression de l’oxyde nitrique synthase 
endothéliale, enzyme qui joue un rôle neuroprotecteur par une augmentation de la 
circulation sanguine cérébrale et par un relâchement de l’endothélium vasculaire. Ces 
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effets pléiotropiques impliqueraient de nombreuses voies de signalisations comme la voie 
de la phosphoinositide 3-kinase(PI3K) /Akt et la voie de prenylation avec le membre 3 de 
la famille de gènes homologue ras (RhoA). Cependant, les mécanismes moléculaires qui 
conduisent à ces effets neuroprotecteurs ne sont pas encore pleinement caractérisés et 
compris. Par ailleurs, les statines seraient également capables, dans des cellules non-
neuronales, d’augmenter l’expression des marqueurs synaptiques, à l’image de la protéine 
vésicule synaptique 2A (SV2A). C’est également un mécanisme qui a été très peu exploré. 
Des études sur les protéines effectrices de la voie de signalisation du cholestérol peuvent 
expliquer l’augmentation d’expression des protéines synaptiques. En effet, l’activation de 
SREBP (protéines se liant à l'élément de régulation des stérols) serait elle aussi capable de 
moduler l’expression des protéines synaptiques telles que la synaptobrevin ou le SV2A 
comme observé avec les statines. SREBP est un facteur nucléaire connu pour activer la 
transcription des enzymes de la voie du cholestérol. Son activation est sensible à la baisse 
du cholestérol cytoplasmique. SREBP agit comme un système rétrocontrôle pour réguler à 
la hausse le cholestérol quand il est bas. Par l’action inhibitrice de la synthèse du 
cholesterol, les statines seraient capables d’activer SREBP. Elles pourraient ainsi induire 
l’activation de la transcription de protéines synaptiques.  
Dans le cadre de ce projet doctoral, nous avons commencé par étudier le potentiel 
trophique des statines et leur impact sur l'expression des marqueurs synaptiques 
dopaminergiques ainsi que sur les fonctions de transport de la dopamine (DA) dans les 
cellules dopaminergique SH-SY5Y de neuroblatome humain. Nos résultats montrent que 
le traitement des cellules avec les statines induit la croissance des neurites avec un effet 
spécifique sur leur ramification. Les statines augmentent la complexité de l’arborisation 
neuritique, ce qui n’est pas observable avec d’autres substances trophiques telles que 
l’acide rétinoïque ou avec l’inhibiteur de ROCK (Y-27632). 
Ensuite, nous avons voulu vérifier si la croissance neuritique pouvait être 
accompagnée d’une augmentation de l’expression des marqueurs synaptiques. En effet, les 
statines sont capables d’augmenter les biomarqueurs dopaminergiques présynaptiques, 
comme le VMAT2, les vésicules synaptiques 2A et 2C (SV2C), la synaptogyrin-3 
(SYNGR3), ou la TH, observation faite grâce aux méthodes d’immunocytochimie et de 
western blot. L'analyse de l'expression génique, mesurée par RT-PCR (réaction en chaîne 
de polymérase-transcriptase inverse), a confirmé une régulation à la hausse rapide des 
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niveaux de mRNA pour le VMAT2, le SV2C et la SYNGR3 après traitement des cellules 
avec les statines.  
En outre, l’augmentation de l’expression des protéines dopaminergiques peut être à 
l’origine d’une modulation de la fonctionnalité des transporteurs de la dopamine. Nous 
avons donc évalué cette possibilité par la mesure de la recapture d’une dopamine 
radioactive dans les cellules SH-SY5Y traitées avec les statines. Pour mesurer les effets 
relatifs à chacun des transporteurs de la dopamine, nous avons utilisé des inhibiteurs 
spécifiques du VMAT2 comme la réserpine ou la tétrabénazine ainsi que du DAT comme 
le GBR-12935. De manière inattendue, les résultats montrent une réduction du transport de 
la dopamine. Mais, il semblerait aussi qu’il y ait eu des modifications pharmacologiques 
du VMAT2 suite au traitement des cellules avec les statines. Ces changements 
pharmacologiques ont également été observés dans les cellules dopaminergiques Be(2)-
M17 de neuroblastome humain transfectées avec le VMAT2. Ces résultats suggèrent que 
les changements pharmacologiques observés avec les statines pourraient être dus à une 
augmentation du VMAT2. 
Nous avons aussi étudié le rôle de SREBP dans l’augmentation de l’expression des 
protéines synaptiques. Tout d’abord, nous avons pu confirmer que les statines induisent 
bien la translocation du facteur de transcription SREBP à l’intérieur du noyau. Ceci 
renforce la possible implication des statines dans la régulation des protéines synaptique via 
SREBP. A l’aide d’un activateur et d’un inhibiteur spécifique de SREBP, nous avons pu 
confirmer la translocation nucléaire de SREBP. L’activation de SREBP a également 
montré qu’il est possible d’augmenter l’expression des mêmes marqueurs synaptiques que 
ceux induit par les statines. L’analyse par RT-PCR des cellules traitées avec l’activateur de 
SREBP a confirmé une augmentation de l’expression des marqueurs VMAT2, SYNGR3 et 
SV2A. Enfin, la répression par siRNA de l’expression de SREBP induit une diminution de 
l’expression du mRNA de protéine SV2C et VMAT2  
Pour conclure, les résultats montrent que les statines induisent la différenciation 
phénotypique des cellules SH-SY5Y, caractérisée à la fois par une augmentation de la 
croissance des éléments synaptiques de structure ainsi que par une augmentation de 
l’expression des protéines de vésicules synaptiques impliquées dans la fonction du système 
dopaminergique. La modulation des protéines synaptiques par SREBP suggère que leur 
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expression est partiellement cholestérol-dépendante. Les changements observés peuvent 
être à l’origine des effets neuroprotecteurs dans la MP. Premièrement, l’induction de la 
croissance neuritique pourrait avoir des conséquences bénéfiques au niveau de la 
neurorestauration des projections axonales. Deuxièmement, la chute de la recapture de 
dopamine par le DAT peut aider à réduire le stress oxydatifs dû à l’excès de dopamine 
dans le cytosol. Troisièmement, la baisse de la recapture de la dopamine peut entrainer une 
augmentation du niveau de dopamine extracellulaire, ce qui aide ainsi à prolonger la 
stimulation post-synaptique. L’augmentation de l’expression de VMAT2 peut compléter 
les effets neuroprotecteurs en réduisant également le stress oxydatif par la recapture de la 
dopamine et des agents neurotoxiques dans les vésicules. Il a été démontré que la 
SYNGR3, une protéine vésiculaire, pourrait également potentialiser l’effet de la recapture 
de VMAT2. L’interaction de la SYNGR3 avec le DAT serait à l’origine de cet effet 
potentiateur. Enfin, SV2C serait également un modulateur du niveau de la dopamine. Des 
études génétiques ont d’ailleurs montré un potentiel effet neuroprotecteur de SV2C dans la 
MP. Dans l'ensemble, ces résultats mettent en évidence des effets pléiotropiques des 
statines dans le système dopaminergique et ils soutiennent le potentiel thérapeutique 
neuroprotecteur et neurorestaurateur des statines précédemment proposé dans la MP et 
permettent de mettre en évidence de nouvelles cibles thérapeutiques comme le facteur 
SREBP. 
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Introduction - Literature review 
I.  Parkinson’s disease 
I. 1.  Generality and historical background 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after 
Alzheimer’s disease, characterized by a progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta of the midbrain (Hassler, 1938). PD has been described for 
first time in 1817 in “An essay on the shaking palsy” by James Parkinson (1755-1824) 
(Parkinson, 1817). He reported the features of the clinical syndrome of six cases as a 
“paralysis agitans”. Later in 19th century, Jean-Martin Charcot (1825-1893), also described 
the disease and named as “Parkinson’s disease” in 1872 in honour to James Parkinson 
(Charcot, 1872). In 1868, Theodor Hermann Meynert (1833-1892) suggested that PD was due 
to a defective function of the basal ganglia (Meynert et al., 1968). Friedrich Heinrich Lewy 
(1885-1950) described for the first time the presence of Lewy bodies, spherical inclusions in 
the nucleus substantia innominata and in the dorsal nucleus of the vagus of Parkinson patients 
(Lewy, 1912). The neurodegenerative mechanism leading to PD was proposed by the 
correlation between the clinical features and the nigrostriatal dopamine loss (Ehringer and 
Hornykiewicz, 1960). Indeed, these hypotheses were confirmed by the ability of levodopa (L-
Dopa, L-3,4-dihydroxyphenylalanine) to improve motor impairment of PD patients in 1961 
(Birkmayer and Hornykiewicz, 1962). During last decades, genetic mutations, abnormal 
misfolded proteins, oxidative stress and mitochondrial dysfunction have identified and 
investigated as potential factors leading to dopaminergic cells loss. However, the aetiology of 
PD remains poorly understood (Davie, 2008; Beitz, 2014; Kalia and Lang, 2015). 
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I. 2.  Epidemiology and cost burden for society 
PD is most common movement disorder affecting 1% in people over 60 years of age 
(de Lau and Breteler, 2006). The prevalence rates of PD vary between 18 and 418 per 100,000 
people worldwide and 102 and 190 per 100,000 people in western countries (Pagonabarraga 
and Kulisevsky, 2012). PD prevalence increases with age and it is estimated to around 17.4 
per 100,000 people between 50 to 59 years old and 93.1 per 100,000 people between 70 to 79 
years old (Bower et al., 1999). However, the prevalence is estimated to be around 13.4 per 
100,000 people per year and the average age of onset established at around 60 years old (Van 
Den Eeden et al., 2003). The annual incidence rates of PD range from 4.9 to 26 per 100,000 
people (Jankovic and Tolosa, 2015). The longitudinal epidemiological study in Rochester 
(Minnesota) reported an impact of age on the annual incidence rate, from 0.8 to 114.7 to 
304.8 per 100,000 people in age group from 0 to 29, 50 to 99 and 80 to 99 years old 
respectively (Bower et al., 1999). In total, approximately 4.1 and 4.5 million people are 
affected worldwide (Dorsey et al., 2007) and 177,095 people in France (Gustavsson et al., 
2011). Sometimes, epidemiological studies reported a male preponderance for PD. The PD is 
approximately twice more frequent in men than in age-matched women, which could suggest 
an X-linked genetic predisposition, influence of sex hormones or greater exposure to a 
causative environmental factor (de Lau and Breteler, 2006). 
 The mortality in PD patients was 2.9 times higher than in the general population (de 
Lau and Breteler, 2006; Morgan et al., 2014). But, since the introduction of L-Dopa, PD 
patients realized remarkable symptomatic benefits, which means that L-Dopa normalized the 
mortality rates to approximately 1.5 (de Lau and Breteler, 2006; Morgan et al., 2014). The 
long L-Dopa treatment over 12 years, the severity of Parkinson’s symptoms and the 
appearance of dementia increase mortality risk in PD (de Lau and Breteler, 2006; Morgan et 
al., 2014). 
In France, the economic burden is estimated at 1.26 billion of euros with an expense of 
7,128 euros by patient (Gustavsson et al., 2011). The total cost for United States is projected 
to be 23 billions of dollars annually with an expense of 10,349 dollars by patient (Huse et al., 
2005). The increase number of PD patients and their disability represents an important 
challenge for health care delivery systems worldwide. 
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I. 3.  Pathologic features and clinical diagnosis of 
Parkinson’s disease 
I. 3.1.  Motor symptoms 
PD produces severe motor impairments and a subsequent decline of the quality of life 
over time (Kalia and Lang, 2015). PD associated symptoms have been classified in two 
groups: the motor symptoms and non-motor symptoms. Motor disorders associated to PD are 
also named cardinal signs (Pápai and Pax, 1690; Koller and Montgomery, 1997). Cardinal 
signs include the four most common manifestations described in PD patients: tremor, 
bradykinesia (akinesia), rigidity, and postural instability.  
Akinesia or bradykinesia correspond respectively to a lack of movement and 
slowness of movement (Wilson, 1925). Bradykinesia is observed early after disease onset and 
corresponds to a deficit of planning, initiation and execution of movement with a reduction of 
its amplitude up to a complete cessation (Berardelli et al., 2001; Rodriguez-Oroz et al., 2009). 
A significant delay appears between the desire to realize the movement and its execution. The 
reductions of spontaneous movements, blinking rate, facial expressions and of arm swinging 
are typical manifestations of bradykinesia (Berardelli et al., 2001; Rodriguez-Oroz et al., 
2009). Bradykinesia/Akinesia is considered as one of the most disabling PD symptom, 
severely affecting daily activities such as writing, eating or washing. 
Rigidity is caused by an increased muscle tone leading to excessive and continuous 
contraction (Delwaide et al., 1986). The resistance to palpation at rest, reduced distension to 
passive movement, increase in the stretching-resistance and facilitation of the shortening 
reaction characterize this symptom. Rigidity may be associated with pain, and painful 
shoulder is one of the most frequent initial manifestations (Jankovic, 2008; Rodriguez-Oroz et 
al., 2009). 
Resting tremor is the easily recognized symptom of PD which is characterized by a 
4-6hz frequency at rest (Stanley-Jones, 1956). These tremors usually begin unilaterally with a 
predominant affection at the extremities of the upper limbs especially in the fingers, giving 
the known “pill-rolling” tremor.  
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Postural instability is due to a loss of postural reflexes and appears at the late stage of 
the disease (Bloem, 1992). It occurs after many years of disease progression and after onset of 
other clinical features. Postural instability is manifested by balance disorders which causes 
more and more frequent falls and contributes significantly to increase the risk of hip fractures 
(Jankovic, 2008; Rodriguez-Oroz et al., 2009). This is probably the most bothersome 
symptom because this can compromise the mobility and can become hazardous.  
These four cardinal symptoms are found in different proportions depending on the 
patients (Jankovic, 2008). The variation of intensity of these symptoms over time can be 
observable in patients and depends of the personal factors such as stress, emotion, hearing and 
visual stimulus (Jankovic, 2008; Rodriguez-Oroz et al., 2009). 
I. 3.2.  Non-motor symptoms 
Non-motor complications in PD represents a major source of deterioration in quality 
of life and contribute to severe disability (Chaudhuri et al., 2006). Non-motor symptoms 
become more evident with disease progression, but they could be already present years or 
decades before the apparition of motor symptoms (listed in Table 1) (Chaudhuri et al., 2006). 
Thus, the identification of non-motor symptoms such as rapid eye movement behaviour 
disorder, hyposmia, constipation, sleep disorders and depression could be useful for diagnosis 
at early stages of the disease (Jankovic, 2008; Massano and Bhatia, 2012). Mild cognitive 
impairment is apparent at early stages of the disease in many cases and recent data have 
shown that dementia will occur in 80% of patients after 20 years of disease progression 
(Meireles and Massano, 2012). The neurobiological basis of non-motor symptoms are not yet 
fully understood, however the loss of dopaminergic, noradrenergic and / or cholinergic 
stimulations appear to be involved in non-motor symptoms (Wishart and Macphee, 2011). 
Finally, some motor and non-motor symptoms occurring in PD such as dyskinesia and 
hallucinations are rather linked to the side effects of PD treatments such as L-Dopa (Foster 
and Hoffer, 2004).  
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Table 1. Non-motor symptoms in Parkinson’s disease 
Neuropsychiatric 
features 
Impairment to dementia (80% of the PD patients) 
Mood disorders, especially depression (45% of the PD patients, 
preclinical symptom) 
Hallucinations, illusions, delusions 
Cognitive deterioration, ranging from mild 
Apathy (preclinical symptom) 
Anxiety, panic attacks (preclinical symptom) 
Dysautonomia 
Orthostatic hypotension 
Constipation (80% of the PD patients, preclinical symptom) 
Urinary dysfunction  
Sexual dysfunction 
Excessive sweating 
Seborrhoea 
Sialorrhea (i.e., drooling, also attributable to decreased swallowing 
movements) 
Sleep disorders 
Insomnia 
Rapid eye movement (REM) behaviour disorder (30% of the PD patients, 
preclinical characteristic) 
Restless legs syndrome (preclinical characteristic) 
Periodic limb movements in sleep 
Excessive daytime sleepiness 
Sensory 
dysfunction 
Hyposmia (i.e., loss of sense of smell) (80% of the PD patients, 
preclinical characteristic) 
Decreased visual contrast and colour discrimination 
Decreased visual motion perception 
Abnormal sensations (paresthesias) 
Pain 
 
Fatigue (preclinical symptom) 
(Anderson, 2004; Chaudhuri et al., 2006; Bonnet et al., 2012) 
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I. 3.3.  Clinical diagnosis 
A diagnostic marker or test for idiopathic PD has not been developed yet (Chahine and 
Stern, 2011). In contrast, genetic tests allow to detect the mutated genes in the genetic forms 
of PD. The definitive diagnosis of PD is only achieved at the autopsy of the brain with the 
identification by histopathological detection of the nigrostriatal dopaminergic neurons loss 
and the presence of Lewy bodies or intra-neuronal inclusions. Intense research in the areas of 
imaging and biochemical analysis of body fluids may help to detect PD in early stages. Some 
exclusion and inclusion criteria (Table 2) as well as rating scales have been used for the 
clinimetric assessment of the motor and non-motor symptoms and disability in PD 
(Perlmutter, 2009) which may allow to differentiate PD from other parkinsonian disorders 
(Quinn, 1997; Perlmutter, 2009). Originally published in 1967, the Hoehn and Yars scale is 
universally accepted as a staging system measurement due to its reliability and convergent 
validity in assessment of PD diagnosis (Hoehn and Yahr, 1967; Goetz et al., 2004; Zhao et al., 
2010). This scale is intended to reflect the degree of disease progression, and combines 
features of motor impairment and disability (Table 3). However, the most well-established 
and used scale to follow the longitudinal course of PD progression in the clinical trial is the 
Unified Parkinson’s Disease Rating Scale (UPDRS), designed and improved by the 
Movement Disorder Society (Movement Disorder Society Task Force on Rating Scales for 
Parkinson’s Disease, 2003). It incorporates elements from the pre-existing scales to provide a 
reliable monitoring of PD-related disability and impairment. 
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Table 2. The UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria 
Parkinson's 
Disease Criteria  
Bradykinesia (slowness of initiation of voluntary movement with 
progressive reduction in speed and amplitude or repetitive actions) 
And at least one of the following: 
Muscular rigidity 
4–6 Hz rest tremor 
Postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction 
Parkinson's 
disease 
exclusion 
criteria 
Familiar parkinsonism 
Persisting strictly unilateral parkinsonism 
Sustained remission 
Levodopa-unresponsiveness 
Strokes with stepwise progressive parkinsonism 
Repeated head injuries 
Preceding neuroleptic treatment 
Supranuclear gaze palsy or oculogyric crises 
Early severe autonomic, cerebellar and/or pyramidal signs 
Early Alzheimer-type dementia 
Cerebral tumor, communicating hydrocephalus 
MPTP intoxication 
Supportive 
positive criteria 
of Parkinson’s 
Disease 
Unilateral onset 
Progressive disorder 
Clinical course > 10 years 
Persistent asymmetry affecting side of onset 
Excellent or persistent levodopa-responsiveness 
Levodopa-induced dyskinesias 
Rest tremor 
(Hughes et al., 1992) 
 
Table 3. Hoehn and Yahr scale 
A commonly used system for describing how the symptoms of Parkinson's disease 
progression. It was originally published in 1967 and later on modified with the addition of 
stages 1.5 and 2.5 to help describe the intermediate course of the disease 
(Hoehn and Yahr, 1967; Goetz et al., 2004; Zhao et al., 2010). 
Stage Hoehn and Yahr Scale modified 
1 Unilateral involvement only 
1.5 Unilateral and axial involvement 
2 Bilateral involvement without impairment of balance 
2.5 Mild lateral disease with recovery on pull test 
3 
Mild or moderate bilateral disease; some postural instability; physically 
independent 
4 Severe disability; still able to walk or stand unassisted 
5 Wheelchair bound or bedridden unless aided 
Parkinson’s disease 
Physiopathology and anatomo-functional dysregulation in Parkinson’s disease 
32 
I. 4.  Physiopathology and anatomo-functional 
dysregulation in Parkinson’s disease 
I. 4.1.  Anatomical pathways  
The main neurobiological characteristic of PD is the loss of dopaminergic neurons in 
the substantia nigra pars compacta clearly detectable by using immunohistochemical methods 
which evidence the loss of cell pigmentation due to the neuromelanin, a metabolite of 
dopamine (Kastner et al., 1992). The dopamine is widely distributed in the central nervous 
system while the dopaminergic neurons represent less than 1% of total number of neurons 
(Gaven et al., 2014). Several brain pathways use the dopaminergic neurotransmission. Indeed, 
the dopaminergic system is composed by four major pathways located in the midbrain: 
nigrostriatal pathway, tuberoinfundibular pathway and mesocorticolimbic projections with 
mesolimbic pathway and mesocortical pathway (Beaulieu and Gainetdinov, 2011).  
The most important pathway in the pathophysiology of PD is the nigrostriatal 
pathway, particularly involved in the production of movements (Fuxe et al., 2006). 
Nigrostriatal pathway involves two projection bundles from the substantia nigra pars 
compacta which innervate the basal ganglia including the caudate nucleus, the putamen and 
the specific regions of the striatum (Fuxe et al., 2006). The neurodegeneration of this pathway 
is clearly associated to the PD.  
The mesolimbic pathway involved in the addiction and reward processes includes the 
ventral tegmental area of the midbrain which is connected to the nucleus accumbens of the 
ventral striatum (Alcaro et al., 2007).  
The mesocortical pathway is implicated in cognitive control, motivation and emotional 
responses and involves the ventral tegmental area and its projections to the cortex (Adinoff, 
2004).  
The tuberoinfundibular pathway controls the hormonal secretion such as the prolactin 
of the pituitary glands which is activated by the dopaminergic transmission from the tuberal 
hypothalamus (Grattan, 2015). 
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I. 4.2.  Basal ganglia circuitry and Parkinson’s disease 
Normal voluntary movements have their origin in the activity of the motor cortex 
(Campbell et al., 1905; Rizzolatti and Luppino, 2001; Chouinard and Paus, 2006). Most of 
neurons in the motor cortex project their axons to the spinal cord, which controls the 
transmission of neural signals between the brain and the rest of the body. Motor cortex 
involves various regions such as the primary motor cortex, the premotor area, the 
supplementary motor area and the prefrontal and parietal associative cortex (Rizzolatti and 
Luppino, 2001; Chouinard and Paus, 2006). A set of cortico-subcortical loops of the basal 
ganglia regulates the activity of these cortical areas (Figure 1). The basal ganglia are a large 
group of subcortical nuclei in the forebrain and midbrain which control movements by their 
interconnection with motor cortex, but, also with the thalamus and the brainstem, as well as 
several other brain structures (e.g. limbic system) (Lanciego et al., 2012). Basal ganglia are 
composed by four main nuclei: the striatum (putamen, caudate and nucleus accumbens), 
pallidum (globus pallidus pars internalis and externalis), subthalamic nucleus and substantia 
nigra (pars compacta and reticulata) (Lanciego et al., 2012). The striatum is the central input 
structure of the basal ganglia which receives the massive excitatory glutamatergic afferents 
from the motor cortical regions but also from other brain regions (e.g. serotoninergic fibers 
from the raphe nuclei or cholinergic fibers from the pedunculopontine nucleus) (Tarsy et al., 
2003).  
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Figure 1. Representation of a simplified schematic diagram of basal ganglia circuitry 
Glutamatergic excitatory connections, GABAergic inhibitory connections and dopaminergic connections are 
indicated by blue, red and green arrows respectively; Enk, enkephalin; GABA, γ-aminobutyrique acid; DA, 
dopamine; Glu, glutamate; GPe, globus pallidus pars externalis; GPi, globus pallidus pars interna; SNc, 
substantia nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; 
 
The neurons of the striatum could be classified as interneurons and medium spiny 
neurons. The interneurons representing 5% of total striatal neurons have large size (up to 
60µm) and could be phenotypically grouped as cholinergic, GABAergic (γ-aminobutyrique 
acid), somatostatin and neuropeptide Y neurons (DiFiglia et al., 1976; Bennett and Bolam, 
1994; Kawaguchi et al., 1995). Medium spiny neurons represent 95% of striatal neurons 
having large and extensive dendritic trees with small spines receiving synaptic inputs (Ariano, 
1983; Bolam and Smith, 1990; Tepper and Bolam, 2004). They are the efferent neurons from 
striatum and express the GABA inhibitory neurotransmitter. We can distinguish two 
populations of medium spiny neuron. The first group expresses the substance P, the 
dynorphin, and the dopamine receptor D1 (D1R) (Alexander and Crutcher, 1990; Bolam and 
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Smith, 1990), whereas the second group expresses the enkephalin and the dopamine receptor 
D2 (D2R) (Gerfen et al., 1990; Surmeier et al., 1996). 
Dopamine released by neurons from the substantia nigra pars compacta acts on the 
D2R and D1R expressed in striatal medium spiny neurons (Dahlstroem and Fuxe, 1964). The 
activation of the D1R facilitates the postsynaptic activity of the neurons whereas the 
activation of the D2R inhibits the postsynaptic neurons (Steiner and Tseng, 2010). 
The striatal neurons with D1R are associated to the so-called direct pathway. The D1R 
activation inhibits the globus pallidus pars internalis and substantia nigra pars reticula that in 
turn reduce their GABAergic inhibition on the motor thalamus (Steiner and Tseng, 2010). The 
consequence of the inhibition triggered by the D1R activation leads to a stimulation of motor 
cortex due to the increase of glutamatergic activation from the thalamus. 
An important dopaminergic functional pathway so-called indirect pathway is 
associated to the D2R-expressing striatal neurons. This pathway is formed by multiple 
connexions between the globus pallidus pars externalis and the subthalamic nucleus (Steiner 
and Tseng, 2010). The activation of D2R striatal neurons reduces the GABAergic inhibition 
on the globus pallidus externalis, which in turn causes an activation of the GABAergic 
inhibitory signal on the subthalamic nucleus. Thus when D2R is activated, the subthalamic 
nucleus activity is downregulated, which reduces the glutamatergic stimulation activity on the 
globus pallidus pars internalis and the substantia nigra pars reticula (Steiner and Tseng, 2010). 
The consequence of this neuronal cascade is a reduction of inhibition of the thalamus by the 
globus pallidus pars internalis and the substantia nigra pars reticula.  
Both activation of D1R direct and D2R indirect pathways by the substantia nigra pars 
compacta reduce the inhibitory activity of the globus pallidus pars internalis on the thalamus. 
Subsequently, this reduction of inhibition facilitates the glutamatergic stimulation from the 
thalamus on the motor cortex, which triggers the motor action (Steiner and Tseng, 2010). 
The loss of neuron in the substantia nigra par compacta occurring in PD disrupts the 
dopamine homeostasis in the basal ganglia network (Albin et al., 1989; DeLong, 1990). In 
this context, the degeneration of nigrostriatal pathway results in a reduction of the D1R and 
D2R stimulation (Figure 2) (Blandini et al., 2000; Obeso et al., 2008). The consequence of 
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this degeneration is a hyperactivity of globus pallidus pars internalis because, in one hand, 
there is less inhibition of the globus pallidus pars internalis from striatal D2R neurons, and, on 
the other hand, there are more discharges from subthalamic nucleus on the globus pallidus 
pars internalis (Blandini et al., 2000; Obeso et al., 2008). Thus, the globus pallidus pars 
internalis hyperactivity reduces the thalamus activity on the motor cortex. In conclusion, the 
loss of dopaminergic neurons in PD reduces the activity of the direct pathway associated to a 
hyperactivation of the indirect pathway. Combined, they lead to a deficit of the initiation of 
voluntary movement. 
 
 
Figure 2. Representation of a simplified schematic diagram of basal ganglia circuitry in 
Parkinson’s disease 
Glutamatergic excitatory connections, GABAergic inhibitory connections and dopaminergic connections are 
indicated by blue, red and green arrows respectively; Enk, enkephalin; GABA, γ-aminobutyrique acid; DA, 
dopamine; Glu, glutamate; GPe, globus pallidus pars externalis; GPi, globus pallidus pars internalis; SNc, 
substantia nigra pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus (Smith et al., 
2012).  
Parkinson’s disease 
Physiopathology and anatomo-functional dysregulation in Parkinson’s disease 
37 
I. 4.3.  Alterations in other neurotransmitter systems 
Although the alteration of the dopaminergic system represents the hallmark in PD, 
other pathways and systems are also involved. Among others, serotoninergic, cholinergic, 
glutamatergic and adrenergic systems in different brain areas are also impacted. The 
degeneration of the norepinephrine-containing neurons from the locus coeruleus of PD 
patients may reach 80% of the normal system, this particularly in late stage of the disease 
(Cash et al., 1987; Zarow et al., 2003; Del Tredici and Braak, 2013). The serotonergic cell 
loss in the raphe nucleus can reach up to 40% (Halliday et al., 1990; Fox et al., 2009; Politis 
and Loane, 2011). Both noradrenergic and serotonergic depletions could contribute to the 
observed non-motor symptoms disorders such as depression. Loss of cholinergic neurons 
reaching 50% observed in the basal nucleus of Meynert and in pedunculopontine nucleus of 
PD patients may be involved in axial and postural disorders (Jellinger, 1991; Pahapill and 
Lozano, 2000; Müller and Bohnen, 2013). Moreover, cortical lesions have also been 
described in late stage of PD: they could participate in the pathophysiological process 
(Hanganu et al., 2013). 
I. 4.4.  Lewy bodies 
Lewy bodies are, together with the loss of dopaminergic neurons, an important 
histopathological hallmark of PD (Figure 3). Lewy bodies were firstly described by Friedrich 
Heinrich Lewy in 1942 which suggested that “pathological changes were widespread over the 
whole central nervous system” (Shults, 2006). They are neuronal inclusions composed of 
abnormal accumulation composed about 70 different proteins including α-synuclein 
(Leverenz et al., 2007). PD is described in the group of synucleinopathies which also includes 
multiple system atrophy and dementia with Lewy bodies (Sikorska et al., 2007). Lewy bodies 
appear as circular intracytoplasmic inclusions (a diameter of 5–25 μm) with a dense 
eosinophilic core and a clearer surrounding halo (Spillantini et al., 1998; Goedert, 1999). 
Ultrastructurally, the Lewy body core is composed by filamentous and granular material that 
is surrounded by radially oriented filaments. This observation suggests an alteration of the cell 
cytoskeleton and of the protein degradation, which could underlie an injury of the 
proteasomal and lysosomal systems (Spillantini et al., 1998; Goedert, 1999). Currently, it is 
unknown whether Lewy bodies sequestrate the toxic misfolded proteins for cell defence or 
they are directly involved in the neurodegenerative process (Wakabayashi et al., 2007). 
Typically, Lewy body distribution follows the monoaminergic systems in the brain but their 
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presence is also found in many brain structures from the medulla to motor and sensory cortex. 
This special distribution led to the proposal of various stages for PD progression (Table 4) 
(Braak et al., 2002, 2003; Wolters et al., 2014). The Braak’s theory is based on the 
observation of progressive accumulation of α-synuclein gradually extending to different brain 
regions. The topographic localization of Lewy bodies allowed distinguishing six stages of PD 
progression (Braak et al., 2002, 2003; Wolters et al., 2014).  
 
 
Figure 3. Microscopic images of substantia nigra Lewy bodies and Lewy neurites in a 
Parkinson's patient 
A and B: Intraneuronal inclusions with α-synuclein aggregated (60x). 
C and D: Lewy neurites and rounded Lewy bodies (20x).  
Counterstained with Mayer's haematoxylin.  
Free usage of images. Author: Suraj Rajan, Creative Commons Attribution-Share Alike 3.0 Unported license. 
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Table 4. Braak staging of Lewy pathology in Parkinson’s disease 
The Braak model proposes that Lewy pathology progresses temporally and spatially through the following stages 
(Braak et al., 2002, 2003; Wolters et al., 2014) 
Braak 
stages 
Equivalent 
Hoehn and 
Yahrs scale 
Disease 
progression 
Clinical features General brain region Specific brain region 
Age 
(Years) 
1 - Preclinical 
stages: 
appearance of 
Lewy bodies  
Olfactory dysfunction 
Gastrointestinal symptom 
Autonomic dysfunction 
Medulla oblongata 
Olfactory bulb  
Dorsal nucleus of vagus nerve  
Anterior olfactory nucleus 
50 
2 - 
REM sleep disorder 
Depression 
Anxiety 
Medulla oblongata 
Pontine tegmentum (Brain stem) 
Magnocellular portions,  
Locus coeruleus Raphe nuclei 
55 
3 1 
Clinical stages: 
diagnosis 
Unilateral cardinal motor signs 
Pain 
Perception and emotions disorders 
Midbrain 
Substantia nigra pars compacta 
Pedunculopontine nucleus 
Raphe nuclie  
Basal nucleus of Meynert 
Amygdala  
Hypothalamus 
60 
4 2 
Bilateral cardinal motor signs 
Psychiatric symptoms 
Basal prosencephalon  
Mesocortex 
Hypothalamus 
Thalamus  
Mesocortex  
Hippocampus 
Limbic system 
65 
5 3 Advanced 
Stages: 
maximum 
spreading 
Cognitive decline Neocortex 
Striatum  
Neocortex 
70 
6 4 - 5 Dementia Hospitalisation Neocortex 
Premotor  
Motor and sensory fields 
80 
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I. 5.  Etiology 
I. 5.1.  Genetic factors and familial Parkinsonism 
Many genetic and environmental factors have been investigated and associated to the 
initiation and progression of PD. A general consensus has been reached suggesting that PD is 
likely caused by a combination of genetic and environmental factors and not by one single 
factor (Tanner et al., 1999; de Lau and Breteler, 2006). The genetic forms of PD only explain 
a small proportion (10%) of all PD cases that are in vast majority idiopathic forms (Massano 
and Bhatia, 2012). Familial Parkinsonism has been described and linked to 21 loci classified 
as PARK and several additional gene mutations are considered as risk factors (Table 5). For 
most of them, the mutation effects leading to the neurodegenerative process are not fully 
understood and still under evaluation. Indeed, the significance of a few PARKs in PD 
(PARK11, 12 and 13) remains controversial or sometimes without confirmation (replication 
study) (Wolters et al., 2014). However taking in account the potential cell dysfunctions 
associated to above mutated proteins, PD related loci could be classified in four subgroups: 
1. Protein misfolding: PARK1 and PARK4 are caused by the mutated gene of α-
synuclein protein (Polymeropoulos et al., 1996, 1997). Mutated α-synucleins may contribute 
to PD pathogenesis because they form a native unfolded protein and because they have the 
capacity to self-aggregate, which disrupts the cellular homeostasis and subsequently leads to 
cell death (Chauhan and Jeans, 2015). 
 
2. Dysfunction of ubiquitin proteasome system: E3 ubiquitin-protein ligase (parkin, 
PARK2) and ubiquitin carboxyl-terminal esterase L1 (UCHL-1, PARK5) are both 
ubiquitously expressed in brain and involved in the ubiquitin proteasome system (Leroy et al., 
1998; Paisán-Ruíz et al., 2004; Lim and Tan, 2007; Li et al., 2014). They trigger signalling 
cascades for the recycling and degradation of proteins. Leucine-rich repeat kinase 2 (LRRK2, 
PARK8) is widely expressed in human tissue and its mutation is the most common form of 
inherited autosomal dominant PD mutation. LRRK2 is involved in the phosphorylation 
cascades of the several cellular signalling pathways and more specifically in the cytoskeletal 
dynamic, macroautophagy and chaperone-mediated autophagy.  
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3. Lysosomal dysfunction: ATPase type 13A2 mutation (ATP13A2, PARK 9) and 
glucocerebrosidase (GBA) have been proposed to be involved in the dysfunction of lysosomal 
autophagy which plays a role in the biomolecule degradation via the intralysosomal 
hydrolytic enzymes (Goker-Alpan et al., 2004; Ramirez et al., 2006; Manzoni and Lewis, 
2013). The impairment of autophagy-lysosomal pathways is increasingly regarded as a major 
pathogenic event in PD. 
 
4. Dysfunction of mitochondria and mitophagy: PTEN-induced putative kinase 1 
(PINK1, PARK6) and protein deglycase (DJ-1, PARK7) could play a role in the integrity and 
mitophagy process of the mitochondria (Valente et al., 2001; van Duijn et al., 2001; Ryan et 
al., 2015). The mitophagy is involved in the turnover and the maintenance of a healthy pool of 
mitochondria, which contributes to reduce oxidative stress. Additionally, DJ-1 modulates the 
gene transcription and has chaperone-like function in mitochondria. The impairment of 
mitochondrial function increases the oxidative stress, which leads to cell damage and cell 
death (Ryan et al., 2015). F-box protein 7 (FBXO7, PARK15) and its interactions with parkin 
(PARK2) and PINK (PARK6) were suggested for the regulation of the mitophagy (Shojaee et 
al., 2008; Burchell et al., 2013). 
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Table 5. Clinicogenetics – Genes and loci related to Parkinson’s disease 
Locus 
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PARK1 EOPD 4q22.1 Rare 1% 
Point mutations: A53T, A30P 
E46K, A18T, etc.  
SNCA α-synuclein 
 Unknown protein function 
α-synuclein misfolding and aggregation 
AD + + + 
PARK2 EOPD 6q26 
Most common AR 
form: 1.4-8.2% 
More than 200 mutations PRKN 
E3 ubiquitin protein ligase 
(Parkin) 
Ubiquitin-protein ligase 
Involved in UPS for protein degradation 
AR + +/- + 
PARK3 LOPD 2p13 Rare Point mutations SPR n/d n/d AD + + + 
PARK4 EOPD 4q22.1 Rare 1% Duplication/ Triplication SNCA α-synuclein 
 Unknown protein function 
α-synuclein misfolding and aggregation 
AD + + + 
PARK5 LOPD 4p14 Extremely rare Deletion or point mutations UCHL1 
Ubiquitin carboxyl-
terminal esterase L1 
Hydrolyse small C-terminal adducts of ubiquitin 
Involved in UPS for protein degradation 
AD + - 
 
PARK6 EOPD 1p36.12 Rare: 3.7% More than 40 mutations  PINK1 
PTEN-induced putative 
kinase 1 
Mitochondrial kinase serine/threonine AR + +/- + 
PARK7 EOPD 1p36 Rare: 2-8% More than 10 mutations DJ-1 Protein deglycase DJ-1 Oxidative stress protection AR + - + 
PARK8 LOPD 12p12 
Most common AD 
form : 5 -10% 
Point mutations: most common 
G2019S + 6 other mutations 
LRRK2 
Leucine-rich repeat kinase 
2 /dardarin 
Phosphorylation 
Cytoskeletal dynamics 
Chaperone-mediated autophagy 
Kinase and GTPase function 
AD + +/- + 
PARK9 JOPD 1p36 Rare 
Point mutations and 
duplication 
ATP13A2 ATPase type 13A2 
Lysosomal protein 
Putative transport substrate function in lysosome 
AR + - + 
PARK10 LOPD 1p32 Rare Point mutations n/d n/d n/d - + + 
 
PARK11 LOPD 2q37.1 Rare Point mutations GIGYF2 
GRB10 interacting GYF 
protein 2 
Regulate tyrosine kinase receptor, Regulation 
insulin signalling  
Putative regulation of autophagy 
AD + + + 
PARK12 LOPD Xq21-q25 Rare Point mutations n/d n/d n/d 
X-
linked 
+ - 
 
PARK13 LOPD 2p12 Rare Point mutations 
OMI/ 
HTRA2 
High temperature 
requirement A2 
mitochondrial protein 
Serine protease stimulates apoptosis by caspase 
activity 
AR + + 
 
PARK14 EOPD 22q13.1 Rare Point mutations PLA2G6 Phospholipase A2  
Catalyze hydrolysis of phospholipid 
 Release of arachidonic acid and fatty acids 
AR + + + 
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PARK15 EOPD 22q12.3 Rare Point mutations FBXO7 F-box protein 7 
Phosphorylation dependent-ubiquitination 
Regulation of mitophagy  
AR + + + 
PARK16 LOPD 1q32 Rare Point mutations n/d n/d n/d AR + - 
 
PARK17 LOPD 16q11.2 
Extremely rare: 
0.08–0.14% 
Point mutation:  
Asp620Asn, Gly51Ser, 
Leu774Met 
VPS35 Vacuolar protein sorting 35 
Transport between endosomes and trans-golgi 
network 
AD + - + 
PARK18 LOPD 3q27.1 
Extremely rare: 
0.02–0.2% 
Point mutation:  
Gly686Cys, Ser1164Arg 
EIF4G1 
Eukaryotic translation 
initiation factor 4-gamma  
Recruitment of mRNA to the ribosome AD + + 
 
PARK19 JOPD 1p31.3 Extremely rare 
Point mutation  
 p.Q734X 
DNAJC6 
DnaJ (Hsp40) Homolog, 
Subfamily C, Member 6 
(Auxilin) 
Regulates the molecular chaperone activity by 
stimulating ATPase activity 
AR - + + 
PARK20 EOPD 21q22.11 Extremely rare 
Point mutation: Arg258Gln, 
Ala551Val 
SYNJ1 Synaptojanin 1 Synaptic transmission and membrane trafficking AR + + + 
PARK21 LOPD 3q22 Extremely rare 
Point mutation:  
Asn855Ser 
DNAJC13 
DnaJ (Hsp40) Homolog, 
Subfamily C, Member 13 
(RME8) 
Regulates the dynamics of clathrin coats in early 
endosomes 
AD + + 
 
Gaucher 
locus 
LOPD 1q21 Extremely rare More than 200  GBA Glucocerebrosidase  Lysosomal enzyme RF 
 
+ + 
FTDP-17 LOPD 17q21 Extremely rare 3 point mutations MAPT Tau Stabilizes microtubules RF 
   
SCA2 LOPD 12q12 Extremely rare 
Point mutations and 
trinucleotide repeats 
ATXN2 Ataxin-2 Transcriptional regulation and RNA processing RF + 
  
SCA3 LOPD 14q32 Extremely rare 
Point mutations and 
trinucleotide repeats 
ATXN3 Ataxin-3 
Involved in ubiquitin-proteasome system, 
deubiquitinating enzyme 
RF + 
  
 
JOPD 5p15.33 Extremely rare Point mutations SLC6A3 Dopamine transporter Extracellular dopamine reuptake AR - 
  
 
LOPD 2q24.1 Extremely rare Point mutations 
NURR1 
(NR4A2) 
Nuclear receptor subfamily 
4, goup A, member 2 
Nuclear receptor involves in maintenance of 
dopaminergic system 
AD + + 
 
 
JOPD 11p15,5 Extremely rare Point mutations TH Tyrosine hydroxylase Metabolism of dopamine AR + 
  
EOPD, early-onset Parkinson’s disease; LOPD, late-onset Parkinson’s disease; juvenile-onset Parkinson’s disease; +, positive; -, negative; AD, autosomal dominant; AR, autosomal recessive; n/d, 
not determine; RF, risk factor. 
(Belin and Westerlund, 2008; Chartier-Harlin et al., 2011; Cheon et al., 2012; Edvardson et al., 2012; Fujioka and Wszolek, 2012; Houlden and Singleton, 2012; Klein and Westenberger, 2012; 
Massano and Bhatia, 2012; Fujioka et al., 2013; Köroğlu et al., 2013; Bin-Umer et al., 2014; Olgiati et al., 2014; Tsika et al., 2014; Vilariño-Güell et al., 2014; Winkler et al., 2014; Wolters et al., 
2014; Beilina and Cookson, 2015; Chen et al., 2015; Deng et al., 2015; De Rosa et al., 2015; Erro, 2015; Ruiz-Martinez et al., 2015) 
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I. 5.2.  Potential mechanisms of dopaminergic cell death 
The causes of dopaminergic cell death occurring in PD remain unknown. However, 
different mechanisms have been proposed in order to explain the loss of those neurons in 
idiopathic and genetic PD. Protein misfolding and mitochondrial dysfunction leading to 
protein aggregation and oxidative stress respectively may constitute the molecular 
mechanisms at the basis of dopaminergic cell death. Inflammation is also a feature of PD 
neuropathology, and mounting evidence supports its contribution in neurodegeneration. 
These mechanisms have been found altered in PD and they could be interrelated, however 
there is no indication about the starting point.  
I. 5.2.1.  Aggregation of misfolded proteins and dysfunction of the 
ubiquitin-proteasome/autophagy-lysosome systems  
The abnormal deposition of proteinaceous materials in aggregate forms such as the 
Lewy bodies in PD, is a common feature of many age-related neurodegenerative diseases, 
including PD (Cook et al., 2012). In sporadic PD and more especially in PD patients with α-
synuclein mutations, these aggregates from misfolded protein such as α-synuclein could be 
the initiation factor of the dopaminergic cell damage and death due to the impairment of 
intracellular trafficking, cell deformation and sequestration of proteins necessary for cell 
survival (Klein and Westenberger, 2012; Jankovic and Tolosa, 2015). This hypothesis is 
supported by the observation in aged brains of the high levels of oxidized proteins (e.g. α-
synuclein), impairment of chaperone proteins involved in protein folding, ubiquitin-
containing protein aggregates and the loss of functional proteasomal/autophagy-lysosomal 
system necessary for the protein degradation (Keller et al., 2002). All these impairments can 
induce a vicious cycle, where each damage or insult reinforces the proteins misfolding 
leading to cell death. Recently, a new hypothesis proposes for α-synuclein aggregation a 
prion-like spreading mechanism (Masuda-Suzukake et al., 2013; Chauhan and Jeans, 2015). 
This hypothesis suggests a neighbouring cell-to-cell spreading from abnormal α-synuclein 
structure to the “normal” α-synuclein, which leads to the aggregation of the “normal” α-
synuclein and cell death.  
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I. 5.2.2.  Mitochondrial dysfunction and oxidative stress 
Brain constitutes about 2% of total body but the brain mitochondrial consumption 
represents 20% of oxygen of the total body. Therefore, brain is highly exposed to the reactive 
oxygen species (ROS) metabolites produced by the mitochondrial respiratory chain (Uttara et 
al., 2009). Numerous studies in PD have reported a dysfunction of mitochondrial complex I 
with a higher level of ROS and a lower level of antioxidant glutathione in substantia nigra 
pars compacta (Ciccone et al., 2013). Inhibition of complex I induces an increase of oxidative 
metabolites, peroxynitrites and ROS leading to the damage of proteins, nucleic acids and 
lipids that in turn affect the mitochondrial activity and starts a cycle of ROS generation (Dias 
et al., 2013). In addition, the dopamine synthesis itself and the dopamine auto-oxidation 
occurring in dopaminergic neurons generates oxidative metabolites and ROS which are 
strongly linked to the damages of the neighbourhood proteins (see chapter: II. 5.1. Dopamine 
oxidation and oxidative stress in Parkinson’s disease) (Meiser et al., 2013). 
I. 5.2.3.  Inflammation 
Anatomo-pathological studies have reported that brains from PD patients present a 
proinflammatory activation of the resident immune cells such as microglia and astrocyte 
(glial cells), but peripheral leukocytes are also involved in the inflammation process (Hunot 
and Hirsch, 2003; Whitton, 2007; Hirsch and Hunot, 2009; Hirsch et al., 2012). These 
leukocytes come from the blood vessel and infiltrate the brain though blood-brain barrier. 
These immune cells acquire phagocytic properties and the capacity to produce inflammatory 
mediators. In PD brain, various proinflammatory cytokines are detected in the CSF, in serum 
and in the affected brain regions such as tumor necrosis factor α (TNF-α), interleukin-1β (IL-
1β), IL-2, IL-6 and interferon-γ (IFN-γ) (Boka et al., 1994; Bessler et al., 1999; Hunot et al., 
1999; Rocha et al., 2015). Cytokines activate the production of nitric oxide and ROS through 
the increase of the expression of nicotinamide adenine dinucleotide phosphate (NADPH)-
oxidase, inducible nitric oxide synthase (iNOS) and cyclo-oxygenase 2 (COX2), which 
contributes to inflammation process (Boje and Arora, 1992; Hunot et al., 1996; Knott et al., 
2000). The activation nuclear factor–κB (NF-κB) is detected in the substantia nigra in PD and 
is required for the transcription of proinflammatory molecules (Hunot et al., 1997). Cytokines 
are able to potentiate the activation of the glial cells and subsequently potentiate the 
inflammation (Jankovic and Tolosa, 2015). They also act directly on dopaminergic neurons 
by the activation of their receptive receptors. For instance, the activation of the TNF receptor 
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triggers an intracellular signalling cascade, which leads to cell death (Boka et al., 1994; 
Hunot et al., 1999). However, inflammation seems to be a secondary event in PD pathology 
and it is not a primary pathogenic event, which suggests a signal arising from injured neurons 
or from an alteration in the microenvironment (Jankovic and Tolosa, 2015). Based on this 
information, it is supposed that neuroinflammation does not initiate PD neurodegeneration 
but can amplify PD progression. 
I. 5.3.  Environmental factors 
The research of environmental factors potentially involved in PD has been 
significantly slower. Indeed, conducting clinical and experimental studies which investigate 
the role of environmental factors is more difficult for several reasons. Exposure to a toxic 
environment factor may occur before the onset of clinical manifestation and remains 
undetected (Di Monte et al., 2002; Goldman, 2014). Moreover, the complexity of these 
studies can also come from possible additive or synergistic effects of multiple exposures and 
from the interactions between environmental factors and genes (Di Monte et al., 2002). 
Despite these complexities, the studies on environmental factors may have far-reaching 
implications, including the development of preventive strategies and policies. 
Pesticides: Organochloride insecticides (dichlorodiphenyltrichloroethane, DDT, for 
mosquito and dieldrin for termites) commercialized in 1940s and 1950s then banned in 1970s 
are the most commonly pesticides associated to PD. They double the risk to develop PD 
(Goldman, 2014). Organochlorides lead to the activation of ROS production and 
neuroinflammation as well as they induce the aggregation of α-synuclein and impairment of 
the ubiquitin-proteasome system (Goldman, 2014). Several other families of pesticides such 
as hexachlorohexanes, organophosphates (insecticide), 2,4-dichlorophenoxyacetic acid 
(herbicide), dithiocarbamates (fungicides) are also suggested to increase the risk for PD. 
Nicotine: Despite the numerous adverse health effects of cigarette smoking, many 
studies have consistently found that smokers have a lower incidence of PD, which could 
related to the protective effect of nicotinic receptors activation (Thiriez et al., 2011; Quik et 
al., 2012).  
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 Coffee: The consumption of coffee is also consistently associated to a reduction of 
the PD risk, probably due to the caffeine effect which is antagonist of adenosine A2A 
receptor (Kempster and Wahlqvist, 1994; Costa et al., 2010; Quik et al., 2012). 
Metal: The iron plays a role in neurodegeneration process but it is still unclear 
whether it occurs prior the neurodegeneration or it is the consequence of the 
neurodegeneration (Dusek et al., 2015). High levels of redox-active irons could initiate the 
ROS production by the mitochondria, α-synuclein aggregation and neuroinflammation 
(Goldman, 2014; Dusek et al., 2015). The copper, lead, manganese, zinc and mercury are also 
suspected to be involved in PD (Stelmashook et al., 2014). 
Head injuries: Demonstrated over the years, the traumatic brain injuries were 
associated with an increase in PD risk, probably by the involvement of inflammation, 
disruption of the blood-brain barrier, oxidative stress and genetic PD link with α-synuclein 
(Goldman et al., 2012; Surgucheva et al., 2014; Lee et al., 2015).  
Air pollution: Currently, there is not clear evidence of the influence of air pollution 
on PD risk (Goldman, 2014). Nevertheless, recent data suggest that the long-term exposure to 
air pollution that can disrupt the blood-brain barrier and induce neuroinflammation and α-
synuclein accumulation (Calderón-Garcidueñas et al., 2008). 
I. 5.4.  Neurotoxins producing Parkinson disease’s-like symptoms 
I. 5.4.1.  MPTP 
In 1982, several drug abusers in Northern California developed severe Parkinson-like 
symptoms because of an accidental intoxication from an even limited exposure of a 
contaminant in the synthetic heroin named 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) (Langston et al., 1983). This discovery gave the first indication that exogenous 
toxins may be involved in the PD pathophysiology (Langston et al., 1984). The clinical 
neurological features of MPTP intoxication are the same than observed in PD and respond to 
L-Dopa. Patients showed damage in the substantia nigra, but unlike PD, Lewy bodies were 
not present. MPTP is a lipophilic molecule that freely cross the blood-brain barrier (Riachi et 
al., 1989) and is readily metabolized by the glial monoamine oxidase type B (MAO-B) in 
toxic form, the 1-methyl-4-phenylpyridinium (MPP
+
) (Rainbow et al., 1985). MPP
+
 is 
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extruded via the organic cation transporter-3 (OCT3) into the extracellular compartments 
(Wu et al., 1998) and is taken up by the dopamine transporter (DAT) into dopaminergic 
neurons (Gessner et al., 1985; Javitch et al., 1985). The accumulation of MPP
+
 inhibits the 
electron transport chain complex I of mitochondria (Ramsay and Singer, 1986; Klaidman et 
al., 1993), which induces ROS production and nigral toxic damages (Cohen, 1984). 
Currently, mice and monkeys treated with MPTP are reliable and widely used models for PD 
research (Tieu, 2011). 
I. 5.4.2.  6-OHDA  
6-Hydroxydopamine (6-OHDA) was the first dopaminergic neurotoxin discovered 
and extensively used to generate PD models since 30 years (Ungerstedt, 1968; Schwarting 
and Huston, 1996; Tolwani et al., 1999). Like dopamine, 6-OHDA does not cross the blood-
brain barrier that is why it is administered by a stereological injection into brain (Simola et 
al., 2007). 6-OHDA is a structural analogue of dopamine which can be taken up by DAT into 
dopaminergic neurons where it is oxidized, which leads to generate oxidative dopamine 
metabolites, free radicals and ROS and the subsequent cell damages and cell death (Simola et 
al., 2007). 
I. 5.4.3.  Paraquat and rotenone 
Paraquat (1,1’-dimethyl-4,4-bipyridinium) is a cationic herbicide widely used in 
agriculture fields during the 20
th 
century and discontinued in 2006 in France because its long-
term exposure induces the development of PD (Goldman, 2014). This herbicide has structural 
similarities with MPP
+
 and crosses the blood-brain barrier, probably through the neutral 
amino acid transporter (Corasaniti et al., 1991). Paraquat is also taken up by DAT into 
dopaminergic neurons (Rappold et al., 2011). Within neurons, paraquat produces hydroxyl 
free radicals and ROS leading to dopaminergic cell death. 
Rotenone was originally extracted from Fabaceae plant and used by the indigenous 
people as a poison to catch fish (Goldman, 2014). Around the world, rotenone was commonly 
used as an organic unselective pesticide for vegetable gardens. Now, it is restricted to 
eradicate invasive fish species as a piscicide in lakes (Goldman, 2014). The advantage of 
rotenone is that it is easily degraded by exposure to sunlight and water, therefore, the 
likelihood of rotenone exposure is very low. Rotenone is very lipophilic and crosses easily 
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the blood-brain barrier to be distribute evenly throughout the brain (Cannon et al., 2009). 
Rotenone impairs mitochondrial function, reduces ATP production, generates ROS, and 
activates microglia (Cannon et al., 2009). Thus, these cellular dysfunctions induce the 
dopaminergic neuronal degeneration, which leads to mimics pathological hallmarks of PD 
including formation of Lewy bodies. 
I. 6.  Parkinson’s disease treatments 
I. 6.1.  Pharmacologic treatments for restoration of dopamine 
depletion 
The research on the PD pathophysiology and the development of PD animal models 
allowed the optimization of several therapeutic drugs. The first pharmacological approaches 
in PD consist to compensate the depletion of dopamine to alleviate motor dysfunction and to 
improve the patient’s quality of life. Two strategies are used to rescue the dopamine depletion 
(Jankovic and Aguilar, 2008). Firstly, administration of a dopamine precursor or 
dopaminergic agonist receptors can compensate the loss dopamine. Secondly, the inhibitors 
of enzymes involved dopamine degradation can help to sustain the level of dopamine. 
I. 6.1.1.  Levodopa (L-Dopa) 
Discovered in 1960, L-Dopa is a precursor of the dopamine widely used in the 
management of PD symptoms (Carlsson et al., 1958; Birkmayer and Hornykiewicz, 1961; 
Cotzias et al., 1967, 1969). Unlike to the dopamine, L-Dopa crosses the blood-brain barrier 
and then it is converted into dopamine to restore the level of dopamine. The effectiveness of 
L-Dopa treatment on motor symptom in PD can be divided into three periods (Hauser, 2009; 
Nagatsua and Sawadab, 2009).  
1. The first period of treatment corresponds to the 3 to 6 years with a dramatic beneficial 
improvement and an almost normal quality of life, described as the “honeymoon”.  
2. Then, this period is followed by a fluctuation on motor efficacy named wearing off. 
This second period corresponds to a loss of L-Dopa treatment effectiveness with the 
reappearance of motor symptoms. This effect is clearly associated to the treatment 
duration and is found in 90% of patients after 10 years of treatment. New symptoms 
are observed such as freezing and involuntary movements named dyskinesia. This 
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dyskinesia appears when the L-dopa plasma level is too high. Conversely, when the 
plasma level is low, akinesia and bradykinesia are present.  
3. Finally, patients become non-responsive to L-Dopa. This is the most disabling period. 
I. 6.1.2.  Dopamine agonists 
Dopamine agonists generate less syndrome effect and motor fluctuation than the L-
Dopa, essentially due to the longer plasmatic elimination (Wolters et al., 2014). They are 
frequently used as monotherapy or in combination with L-Dopa to retard its dosage and the 
wearing-off symptoms (Clarke and Guttman, 2002). Developed in the 1980s, the first 
dopamine agonists are derivatives from ergot including bromocriptine, pergolide, carbergolin, 
apomorphine and lisuride (Horowski, 2007). However, their use is discouraged because of 
the important side-effects such as neuropsychiatric and cardiovascular disorders (Brooks, 
2000). Only the apomorphine is still available in a self-injectable form essentially used as a 
rescue drug for people with severe freezing or off episodes (Wolters et al., 2014). Currently, 
the most widely used dopamine agonists are the pramipexole, ropinirole and rotigotine in 
prolonged formulation and in transdermal patch (Wolters et al., 2014). 
I. 6.1.3.  Inhibitors of dopamine degradation  
Three therapeutic classes are used to block the degradation of dopamine or L-Dopa: 
the inhibitors of: 1) aromatic L-amino acid decarboxylase (DOPA decarboxylase, ADCC); 2) 
catechol-O-methyl transferase (COMT); 3) MAO-B.  
ADCC inhibitors (DDCI), such as carbidopa and benzerzide, help to avoid the 
peripheral ADCC conversion of L-Dopa into dopamine (Pinder et al., 1976; Lieberman et al., 
1984; Gershanik, 2015). These compounds do not cross the blood-brain barrier, which does 
not block the brain ADCC, essential for the brain conversion of L-Dopa into dopamine 
(Pinder et al., 1976; Lieberman et al., 1984; Gershanik, 2015). 
COMT inhibitors, such as entacapone and tolcapone, block peripheral COMT 
metabolization of L-Dopa, which helps to increase its half-life up to 50% (Bonifácio et al., 
2007; Leegwater-Kim and Waters, 2007; Marsala et al., 2012). Entacapone acts only 
peripherally whereas tolcapone also acts in the central nervous system, that is why tolcapone 
is probably more effective than entacapone (Bonifácio et al., 2007; Leegwater-Kim and 
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Waters, 2007; Marsala et al., 2012). However, due to the hepatoxicity side effect of 
tolcapone, it is mostly used as a second-line of COMT inhibitors. 
The dopamine is also degraded by the monoamine oxidase B (MAO-B) (Marconi and 
Zwingers, 2014). Its inhibition by the selegiline and rasagiline helps to reduce the dose of L-
dopa (Marconi and Zwingers, 2014).  
I. 6.2.  Non-dopaminergic agents 
The amantadine, an antagonist of N-methyl-D-aspartate-type (NMDA) glutamate 
receptor, is used in monotherapy or with L-Dopa to regulate the excess of glutamatergic 
activity and thus improves the motor symptoms of PD such as dyskinesia (Rajput et al., 1998; 
Connolly and Lang, 2014).  
Anticholinergic drugs (trihexyphenidyl, biperiden, orphenadrine, procyclidine, 
ethopropazine, diphenhydramine) are used to reduce the hyperactivity induced by the striatal 
cholinergic tone (Katzenschlager et al., 2003). However, these drugs have important 
peripheral (dry mouth, blurred vision, constipation) and central nervous system (confusion 
and memory impairment) side effects. 
The non-motor symptoms such as depression are treated with drugs commonly used 
in non-parkinsonian depression such as tricyclic antidepressants and serotoninergic and 
noradrenergic reuptake inhibitors (Paumier et al., 2012; Connolly and Lang, 2014). 
I. 6.3.  Surgical treatment: deep brain stimulation 
The deep brain stimulation of the subthalamic nucleus or globus pallidus internalis is 
a useful surgical procedure to improve locomotor symptoms in PD (Benazzouz et al., 1993; 
Pollak et al., 1993; Limousin et al., 1995). The aim of the stimulation is to changes brain 
activity in a controlled manner by the inhibition of the neuronal hyperactivity on the 
thalamus. Functionally, a pacemaker placed under the clavicle triggers the brain stimulation 
through two electrodes implanted bilaterally. This implantation improves the motor function 
that is preserved after 5 years and allows to stop or to reduce the L-Dopa treatment. Deep 
brain stimulation is rather reserved for patients refractory to pharmacologic therapy with 
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idiopathic PD and under 70 years of age (Volkmann, 2004; Perlmutter and Mink, 2006; 
Moldovan et al., 2015). 
I. 6.4.  New strategies, targets and drugs to cure Parkinson’s 
disease 
Most of the current pharmacotherapeutic approaches in PD presented before aim to 
treat the symptomatic motor disorders by the principle of dopamine replenishment. Moreover 
these drugs provide symptomatic relief because many patients develop motor complications 
with long-term treatment (Mandel et al., 2003; Stayte and Vissel, 2014). Unfortunately, there 
is no available curative or disease-modifying treatment for neurodegenerative process so far 
(Jankovic and Aguilar, 2008). However, in last decade, many new strategies of treatment are 
currently being evaluated in preclinical research and for some have reached the clinical trials. 
Indeed, several new potential therapeutic targets have been proposed to restore motor 
functions, to reduce non-motors symptoms and drug side effects as well as for their 
neuroprotective and/or neurorestorative effects (listed in Table 6) (Mandel et al., 2003; Stayte 
and Vissel, 2014).  
Great advance was also made in the field of gene therapy (Coune et al., 2012; Douglas, 
2013; O’Connor and Boulis, 2015). It consists in an intraputaminal bilateral injection of a 
viral vector to overexpress an enzyme(s) involved in the synthesis of dopamine or GABA 
(listed in Table 6). These viral injections (ProSavin and AAV2-GAD) have already 
demonstrated an improvement in UPDRS scores in PD patients (LeWitt et al., 2011; Palfi et 
al., 2014). 
The replacement of lost dopaminergic cell by neural transplantation was also already 
tested in human (listed in Table 6). For example, the transplantation of human embryonic 
stem cells was tried into the striatum of patients (Brundin et al., 2010; Freed et al., 2011; 
Barker et al., 2013). Despite good performance on motor symptoms, patients developed 
involuntary movement side effects, so called graft-induced dyskinesias. Additionally, an 
accumulation of α-synuclein was also observed, probably due to a contamination from the 
host tissue.  
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Table 6. New strategies, targets and drugs to cure Parkinson’s disease 
Reduction of 
motor deficit 
and dyskinesia 
Antagonists of AMPA receptor: perampanel, talampanel, topiramate 
Agonists of 5-HT1A, 5-HT1B receptor: sarizotan, buspirone, 
mirtazapine, eltoprazine 
Antagonists of adrenergic receptor α2 
Negative allosteric modulators of mGluR5 receptor: ADX48621-201 
Antagonist of NMDA receptor and agonist of sigma 1: AVP-923 
Neuroprotective  
/  
Neurorestorative 
therapies  
Antagonists of A2A receptor: istradefylline, preladenant, caffeine 
Antagonists of mGluRI: dipraglurant, AFQ056 
Calcium channel blockers (Cav1.3): isradipine 
Agonist of GLP1R: exandin-4  
Iron chelators 
Anti-inflammatory drugs: PPAR-γ activator (pioglitazone) 
Antioxidants: inosine, glutathione, coenzyme Q10, N-acetylcysteine 
Neurotrophic factors: GDNF, neurturin, PYM50028 (cogane), CERE-120 
ROCK inhibitors, statins, nicotinic agonists, GM1 ganglioside, NURR1 
agonists, LXR agonists 
Strategies based 
on PD mutation 
Blockers of the α-synuclein accumulation 
Increase the clearance of α-synuclein: phenylbutyrate 
Active α-synuclein immunization: epitope based therapy PD01A, affitope 
and PD03A 
Passive α-synuclein immunization: antibody based therapy, PRX002 
Inhibitors of LRRK2  
Other drugs related PD mutations 
Gene therapies - 
 overexpression 
Combination of AADC, GCH1 and TH (Prosavin, lentiviral vector)  
AAV2-GAD  
Neurotrophic factors (AAV2-GDNF, AAV2-NTN: CERE-120) 
Dopaminergic 
neural grafting 
 
Fetal ventral mesencephalon grafting cell from abortion 
Blastocyst-derived embryonic stem cell line differentiated into 
dopaminergic neurons (hESCs) 
Somatic cells reprogrammed and differentiated into dopaminergic 
neurons (iPS cells) 
5HT, 5-hydroxytryptamine (serotonine); A2A, adenosine 2A; AADC, aromatic L-amino acid decarboxylase 
(catalyses L-Dopa in dopamine); AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ; GAD, 
glutamate decarboxylase (catalyses the decarboxylation of glutamate into GABA); GCH1, GTP cyclohydrolase 
1 (synthetizes the tetrahydrobiopterin, a co-factor of the tyrosine hydroxylase); GDNF, glial derived 
neurotrophic factor; GLP1R, glucagon-like peptide 1 receptor; hECSs, human embryonic stem cells; iPS, 
induced pluripotent stem cell; LXR, liver X receptors; mGluR, metabotropic glutamate receptor; NMDA, N-
methyl-D-aspartate; NTN, neuturin; NURR1, nuclear receptor related 1 protein; PPAR, peroxisome 
proliferator-activated receptors; ROCK, rho-associated protein kinase ; 
(Mandel et al., 2003; Brundin et al., 2010; Freed et al., 2011; Coune et al., 2012; Barker et al., 2013; Douglas, 
2013; Stayte and Vissel, 2014; Kalia et al., 2015; O’Connor and Boulis, 2015) The Michael J. Fox Foundation 
for Parkinson's Research: https://www.michaeljfox.org/ 
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II.  Dopaminergic synapse 
Dopamine was synthesized for the first time by Barger and Ewens in 1910 (Fahn, 
2008). In 1938, Holtz discovered the ADCC enzyme responsible to converting L-Dopa in 
dopamine (Holtz et al., 1938). The catecholaminergic pathway (L-Dopa, dopamine, 
norepinephrine and epinephrine) was proposed by end of the 1940s (Blaschko, 1939) and a 
decade later the link between the dopamine and brain function in the context of the 
pathophysiology of PD. Two studies identified the striatum as the area with the most 
important concentration of dopamine in the brain (Bertler and Rosengren, 1959; Sano et al., 
1959).  
II. 1.  Dopamine biosynthesis  
The pathways for catecholamine synthesis are well known (Figure 4) (Elsworth and 
Roth, 1997; Daubner et al., 2011; Meiser et al., 2013). The amino acid L-tyrosine from the 
blood is the common precursor of all catecholamines. In synaptic terminal, the tyrosine 
hydroxylase (TH) catalyses the hydroxylation reaction of L-tyrosine to L-Dopa (Bayer and 
Pickel, 1990; Meiser et al., 2013). This rate-limiting step in the synthesis of dopamine 
(Nagatsu et al., 1964) is possible by the phosphorylated TH form which activity is dependent 
on calcium, cyclic adenosine monophosphate (cAMP) and tetrahydrobiopterin (BH4) 
(Musacchio et al., 1971; Nakashima et al., 1971; Gutman and Segal, 1972; Nagatsu, 1995). 
At this point, the resulting molecule is L-Dopa, also used as a pharmacological treatment in 
PD. Then, DOPA decarboxylase enzyme synthetizes the L-Dopa in dopamine (Burkhard et 
al., 2001). 
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Figure 4. Dopamine biosynthesis, degradation and oxidation products 
AADC, aromatic L-amino acid decarboxylase; ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; 
Asc, ascorbate; COMT, catechol-O-methyl transferase; DBH, dopamine-β-hydroxylase; DHA, dehydroascorbic 
acid; MAO, monoamine oxidase; PAH, phenylalanine hydroxylase; PNMT, phenylethanolamine N-
methyltransferase; ROS, reactive oxygen species; SAM, S-adenosyl-l-methionine; SAH, S-adenosyl-l-
homocysteine; TH, tyrosine hydroxylase; O2
·−
, superoxide; OH
·
, hydroxyl radical; OH
-
, hydroxide ion. 
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II. 2.  Dopaminergic synaptic vesicles and exo-
endocytosis 
The synaptic vesicle consists of spherical lipid bilayers with an external diameter of 
40 nm (Figure 5) (Floor et al., 1988). Vesicles are formed in the Golgi apparatus, then, they 
are transported along microtubules using kinesin and dynein motors to go until presynaptic 
terminals (Oster et al., 1989). Plenty of proteins participate in the synaptic vesicles function 
(Morciano et al., 2005; Takamori et al., 2006; Burré and Volknandt, 2007; Volknandt and 
Karas, 2012). More than 80 proteins with transmembrane domains identified by proteomic 
studies are present in the vesicles (Boyken et al., 2013). Most of these vesicular proteins such 
as rabs, synaptotagmin and synaptobrevin are involved in the intracellular transport and 
exocytosis docking plasma membrane (Stein et al., 2003; Takamori et al., 2006; Schlager and 
Hoogenraad, 2009). Only a small fraction of proteins (approximately 10 copies per vesicles) 
plays the critical role to refill the vesicles with the neurotransmitters. Among these, we could 
find the vesicular glutamate transporter (VGluT), vesicular GABA transporter (VGAT), 
vesicular acetylcholine transporter (VAchT) and vesicular monoamine transporter (see 
chapter II. 4.3. Vesicular monoamine transporter) (Fei et al., 2008). The synthesized 
dopamine is packaged into the synaptic vesicles through the vesicular monoamine transporter 
(VMAT) (Nirenberg et al., 1996). Synaptic vesicles are also highly enriched in a putative 
transporter named synaptic vesicle glycoprotein 2 (SV2) (Floor and Feist, 1989; Takamori et 
al., 2006). Three isoforms have been characterized: SV2A, SV2B and SV2C (Bajjalieh et al., 
1993; Janz et al., 1998). They belong to major facilitator superfamily (MFS) and possess 12 
transmembrane domains highly glycosylated, but their substrates have not been clearly 
identified. SV2A and SV2B exhibit broad expression in the central nervous system (Bajjalieh 
et al., 1994). Besides its potential transport function, SV2A seems involved in the formation 
of exocytosis complex through the interaction with the synaptotagmins and thus it could be 
critical for release of vesicles (Janz et al., 1999; Crèvecœur et al., 2013). SV2C, the third 
member of the synaptic vesicles protein family, has a restricted distribution with a high level 
found in the basal ganglia, midbrain and brainstem, a pattern very similar to VMAT2-
containing vesicles (Janz and Südhof, 1999). SV2C has been suggested to be a modulator of 
dopamine vesicle storage (Janz and Südhof, 1999; Dardou et al., 2011, 2013). Recently, two 
SV2C SNPs (single nucleotide polymorphism) have been identified to be protective factor 
against PD when they are associated to the cigarette-smoking (Hill-Burns et al., 2013). Two 
types of dopaminergic vesicles containing VMAT2 has been identified: the large dense core 
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vesicles (LDCVs) and the small synaptic vesicles (SSVs) with a diameter of 120-160 nm and 
45-50 nm respectively (Liu et al., 1994; Erickson et al., 1996; Nirenberg et al., 1996, 1997a; 
Elsworth and Roth, 1997). The dopaminergic system of substantia nigra uses the SSVs for 
dopamine release and they are localized in axon terminals but also in the trans-Golgi network 
of neuronal perikarya, the tubulovesicles of smooth endoplasmic reticulum, and in the 
potential sites of vesicular membrane recycling (Nirenberg et al., 1995). 
The release of synaptic vesicles is initiated by action potentials from the neuronal 
body (Neher and Sakaba, 2008) but only 10-20% of action potentials have an effect on 
exocytosis. Release of the vesicles takes place in specialized and structured areas in the 
presynaptic compartment named “active zone” which is a zone of the membrane associated to 
a macromolecular network and located on direct opposed side to the postsynaptic density 
(Harris et al., 1992; Spacek and Harris, 1998). A fraction of 6 to 8 vesicles is associated to the 
membrane in the active zone as a pool named “readily releasable pool” (Rizzoli and Betz, 
2005; Denker and Rizzoli, 2010; Denker et al., 2011). Two other pools of vesicles are present 
in the terminal but not in the active zone: a reserve pool with 17 to 20 vesicles and a larger 
resting pool with more than 180 vesicles (Rizzoli and Betz, 2005; Denker and Rizzoli, 2010; 
Denker et al., 2011; Alabi and Tsien, 2012; Rizzoli, 2014). Both pools are essentially 
involved in the prolonged stimulation of action potentials which opens the Ca
2+
 channels 
inducing an elevation level of Ca
2+
 into the cytosol. This Ca
2+
 increase is crucial for the 
fusion of the membrane vesicles and plasma membrane (Chen and Scheller, 2001; Jahn and 
Fasshauer, 2012). Indeed, many soluble N-ethylmaleimide-sensitive factor activating protein 
receptor of the vesicles (v-SNARE) and of the plasma membrane (target-SNARE, t-SNARE) 
such as synaptotagmin and syntaxin are calcium sensors. The Ca
2+
 binding to SNARE 
proteins induces theirs conformational structural changes, which triggers the interaction 
between v-SNARE and t-SNARE. This interaction brings closer the vesicles to plasma 
membrane and allows their fusion, a mechanism named zipping (Jackson, 2010; Risselada 
and Grubmüller, 2012). Then, after the exocytosis, the vesicles are recycled back into the 
pool of vesicles (Harris and Weinberg, 2012; Rizzoli, 2014). 
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Figure 5. Schematic of striatal dopaminergic synapse and mechanisms involved in 
Parkinson’s disease neurodegeneration 
ADCC, aromatic L-amino acid decarboxylase; cAMP, cyclic adenosine monophosphate; ADP, adenosine 
diphosphate; ATP, adenosine triphosphate; CREB, cAMP response element-binding protein; DA, dopamine; 
DAT, dopamine transporter; DARPP-32, dopamine- and cAMP-regulated neuronal phosphoprotein; DR1, 
dopamine receptor D1; DR2, dopamine receptor D2; DJ1, protein deglycase; LDCV, large dense-core vesicle; 
LRRK2, leucine-rich repeat kinase 2; PINK1, PTEN-induced putative kinase 1; PKA, protein kinase A; PKC, 
protein kinase C; MAO, monoamine oxidase; MB-COMT, membrane-bound catechol-O-methyl transferase; 
ROS, reactive oxygen species; S-COMT, soluble catechol-O-methyl transferase; SSV, small synaptic vesicle; 
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VMAT2, vesicular monoamine transporter 2; SNARE, soluble N-ethylmaleimide-sensitive factor activating 
protein receptor; SV2, synaptic vesicle glycoprotein 2; SYNGR3, synaptogyrin 3; TH, tyrosine hydroxylase; 
UCHL-1, ubiquitin carboxy-terminal hydrolase L1; V-ATPase, vesicular ATPase; 
II. 3.  Postsynaptic activation of dopamine receptors 
 Two families of dopamine receptors exist, D1 and D2. D1 family encompasses D1 
and D5 receptors and D2 family encompasses D2, D3 and D4 receptors (Beaulieu et al., 
2015). The most abundantly expressed receptor in the brain is the D1R and widespread in the 
caudate-putamen, nucleus accumbens, olfactory bulb, amygdala and frontal cortex (Cadet et 
al., 2010). D2R which is found in the caudate-putamen and nucleus accumbens is the second 
most abundantly expressed dopamine receptor (Meador-Woodruff and Mansour, 1991). D3, 
D4 and D5 receptors are less abundant and have restricted brain distribution.  
All dopaminergic receptors are part to the large family G protein–coupled receptor 
(GPCR) (Sidhu and Niznik, 2000). GPCRs are composed of a central core domain consisting 
of seven-transmembrane domain for ligand binding and three subunits α, β and γ in 
heterotrimeric complex. Under the inactive state, α subunit is bound to the guanosine 
diphosphate (GDP). Once the ligand (dopamine) activates the GPCR, it leads to a 
conformational change of the receptor, which dissociates the GDP from the α subunit 
(Kobilka, 2007). Then, guanosine triphosphate (GTP) can take the empty place of the GDP, 
which dissociates the heterotrimeric G protein from the receptor and splits it into two active 
signalling elements: the α subunit and βγ complex. These subunits modulate various 
downstream specific effectors. 
 The classification of G proteins is based on the nature of the α subunit. D1R is 
coupled to αs subunit which activates the adenylate cyclase whereas D2R is coupled to αi 
which inhibits the adenylate cyclase (Figure 5) (Sidhu and Niznik, 2000). The adenylate 
cyclase produces the cAMP for the activation of the protein kinase A (PKA) which 
phosphorylates the potassium channels and DARPP-32 (dopamine- and cAMP-regulated 
neuronal phosphoprotein). Potassium channel phosphorylation reduces the potassium 
conductance and DARPP-32 phosphorylation can regulate neuronal electrical activity 
(Svenningsson et al., 2004). Both regulations induce a depolarization of the membrane which 
triggers the action potentials (Jaber et al., 1996; Missale et al., 1998; Beaulieu and 
Gainetdinov, 2011). Therefore, D1R activation provokes a stimulation of the postsynaptic 
neurons whereas D2R activation lowers the postsynaptic activity. Many other mechanisms 
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are modulated by dopamine receptor activation such as the calcium channel activity (Bigornia 
et al., 1990) and the transcriptional activity of the nuclear factor cAMP response element-
binding protein (CREB) (Carlezon et al., 2005). 
II. 4.  Dopamine recycling and transport into the 
synapse 
II. 4.1.  Dopamine reuse and degradation 
The reuse of dopamine requires a cycle of the reuptake dopamine in the presynaptic 
terminal through DAT followed by refilling of synaptic vesicles via VMAT2 (Figure 5) (Qi et 
al., 2008; Meiser et al., 2013; Schmitt et al., 2013). However, the dopamine can be degraded 
via a series of enzymes either by the dopaminergic neurons or by glial cells (Meiser et al., 
2013). The neuronal cytosolic excess of dopamine is degraded by the MAO-B (Figure 4). 
MAO-B proceeds to oxidative deamination of dopamine into the 3,4-
dihydroxyphenylacetaldehyde (DOPAL) and hydrogen peroxide (Edmondson et al., 2004). 
Then, alcohol dehydrogenase (ADH) or aldehyde dehydrogenase (ALDH) reduces or 
oxidizes DOPAL into 3,4-dihydroxyphenylethanol (DOPET) or 3,4-dihydroxyphenylacetic 
acid (DOPAC) respectively (Meiser et al., 2013) 
  The second pathway involved in the dopamine degradation is mediated through the 
glial cells using both MAO-B and soluble COMT (S-COMT) enzymes (Napolitano et al., 
1995; Siderowf and Kurlan, 1999). S-COMT converts the DOPAC into homovanillic acid 
(HVA): the major metabolite of dopamine degradation. Finally, a membrane COMT (MB-
COMT) anchored in the postsynaptic membrane can degrade the dopamine directly into the 
synaptic cleft (Roth, 1992; Myöhänen et al., 2010; Chen et al., 2011a). Both DOPAC and 
HVA reach the systemic circulation to be excreted in urine (Siirtola et al., 1975). 
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II. 4.2.  Dopamine transporter (DAT) 
II. 4.2.1.  Structure and function of DAT 
The amount of dopamine dictates the endurance of synaptic transmission and it seems 
critical to regulate the level of dopamine in the synaptic cleft. To this end, DAT regulates the 
level of dopamine by the reuptake of dopamine from the synaptic cleft to the synaptic 
terminal cytosol (Uhl, 2003; Leviel, 2011; Schmitt et al., 2013). The DAT function is crucial 
in terminal dopaminergic neurons because it provides 95% of dopamine of the intracellular 
stores (Jones et al., 1998). DAT is mainly localized in the plasma membrane close to the 
exocytosis site (active zones) of dopaminergic vesicles in the perisynaptic areas (Nirenberg et 
al., 1997a, 1997b). DAT mRNA is located in the dopaminergic cell bodies and nerve 
terminals including the basal ganglia and substantia nigra pars compacta (Ciliax et al., 1995; 
Freed et al., 1995; Haber, 2014). 
DAT (69 kDa for human) forms a dimer or a tretramer (Hastrup et al., 2001, 2003) 
and contains 12 transmembrane domains, an intracellular C- and N-terminals and 
glycosylation sites at the N-terminus and within the intracellular loop between 
transmembrane domains 3 and 4 (Patel et al., 1993; Vaughan et al., 1996). It is a Na
+
/CL
-
 
dependent transporter belonging to the family of solute carrier 6 (SLC6A3), closely related to 
the two other monoamine transporters: the norepinephrine transporter (NET, SLC6A2) and 
the serotonin transporter (SERT, SLC6A4) (Chen and Reith, 2000; Vallone et al., 2000; 
Kristensen et al., 2011). DAT uses the transmembrane Na
+
 gradient between the extracellular 
space and the cytosol as a driving force to transport dopamine across the plasma membrane. 
Two Na
+
 and one Cl
-
 ions are co-transported with one dopamine molecule. Thus, dopamine 
transport depends on the gradient essentially established by the ubiquitous plasma membrane 
Na
+
/K
+
-ATPase.  
II. 4.2.2.  DAT regulation 
DAT is highly regulated in the plasma membrane and subsequently it modulates the 
dopaminergic signalling due to either attenuation or intensification of the dopamine reuptake 
(Mortensen and Amara, 2003; Torres et al., 2003b; Torres, 2006; Eriksen et al., 2010). It has 
been shown that the activation of PKC with phorbol 12-myristate 13-acetate (PMA) 
downregulates the DAT transport activity (Copeland et al., 1996; Vaughan et al., 1997; Zhu 
et al., 1997; Daniels and Amara, 1999; Melikian and Buckley, 1999; Chi and Reith, 2003; 
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Sorkina et al., 2005). Indeed, PKC activation induces the internalization of DAT through a 
rapid clathrin-dependent endocytosis process of the plasma membrane and then DAT is either 
degraded or recycled back to the plasma membrane (Sorkina et al., 2005). The molecular 
mechanism involved in the PKC-induced DAT internalization remains unclear. It seems to be 
related to the phosphorylation activity of PKC on DAT but it is also probably due to an 
activity of ubiquitination on the N-terminus domain of DAT. Studies using DAT-specific 
mutations of lysine positions (Lys19, Lys27, Lys35) demonstrated a clear absence of DAT 
ubiquitination and of PMA-induced DAT internalization (Miranda et al., 2007). Several other 
partners have been described in the mechanism of internalization such as phosphoinositide 3-
kinase (PI3K)/Akt, protein kinase A (PKA) and neural precursor cell expressed 
developmentally downregulated gene 4-like (NEDD-4-2) (Sorkina et al., 2006). It has been 
shown that inhibition of Akt or the expression of a dominant negative mutant of Akt reduces 
the DAT cell surface in human embryonic kidney 293 (HEK293) transfected cell with DAT 
(Carvelli et al., 2002; Lin et al., 2003; Garcia et al., 2005). 
The synaptic vesicles could regulate the DAT uptake by several SNARE proteins such 
as the synthaxin 1A and the synaptogyrin 3 (SYNGR3). DAT interacts with syntaxin 1A in 
the plasma membrane which in turn interacts with the vesicular synaptotagmin 1 (Lee et al., 
2004; Binda et al., 2008; Carvelli et al., 2008). The overexpression of syntaxin 1A in 
LLCPK1 cells reduces the maximal rate velocity (Vmax) of dopamine uptake, probably due to 
DAT internalization, but, which is independent to PKC activity (Cervinski et al., 2010). The 
synaptic vesicle protein SYNGR3, it is a specific protein of dopaminergic systems expressed 
in the basal ganglia and substantia nigra (Belizaire et al., 2004) which seems to regulate 
positively the dopamine uptake of DAT (Egana et al., 2009). The co-immunoprecipitation 
studies using striatal mouse tissue and co-transfected cells with SYNGR3 and DAT showed 
an interaction between the N-terminus of DAT and the cytoplasmic N-terminus of SYNGR3. 
SYNGR3 overexpression increases the DAT activity whereas SYNGR3 downregulation with 
siRNA reduces the DAT activity. These data suggest a possible interaction mechanism 
between DAT and the vesicles in order to have an efficient dopamine uptake through both 
DAT and VMAT2 directly into the synaptic vesicles what may avoid an increase in cytosolic 
dopamine (Egana et al., 2009). Several in-vitro and in-vivo studies have demonstrated a 
positive effect on the dopamine uptake through an increase of the DAT surface expression 
induced by D2R expression (Lee et al., 2009).  
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II. 4.2.3.  DAT inhibitors 
DAT is the target of several psychostimulants such as cocaine and amphetamine. 
Potent and selective compounds inhibiting DAT have been identified. Among others, WIN 
35,428, 3-CPMT and GBR-12935 are the most potent compounds blocking the reuptake of 
dopamine and subsequently increasing the extracellular concentration of dopamine 
(Kintscher, 2012; Huot et al., 2015). Nevertheless, they display an activity also in other 
neurotransmitter transporters such as NET and SERT. Several numerous radiolabeled DAT 
inhibitors (WIN 35,428, RTI-121 or 55) are available for positron emission tomography 
(PET)- or single-photon emission computed tomography (SPECT)-ligands allowing to 
determine DAT binding in nigro-striatal system and thus to evaluate PD neurodegenerative 
progression (Marshall and Grosset, 2003; Brooks, 2004). 
II. 4.3.  Vesicular monoamine transporter 2 (VMAT2) 
II. 4.3.1.  Structure and function of VMAT2 
VMATs are responsible for the efficient reuptake and storage of monoamines from 
the cytosol to the synaptic vesicles, which is crucial for proper monoaminergic 
neurotransmission in dopaminergic system (Carlsson et al., 1962; Kirshner, 1962; 
Wimalasena, 2011). VMATs contain 12 transmembrane domains and a cytosolic C- and N-
terminals (Wimalasena, 2011). The intravesicular loop between 1 and 2 transmembrane 
domains contains three or four glycosylated sites (Yao and Hersh, 2007; Cruz-Muros et al., 
2008). Indeed, VMATs are acidic glycoproteins with an apparent higher molecular weight of 
70 kDa, but the native form of VMATs is also present with a relative molecular weight of 55 
kDa. In addition, immunoblot detection also revealed a third VMATs band at low molecular 
weight (40 kDa) which correspond to a truncated form (Jassen et al., 2005; Tong et al., 2011). 
Yet, its function remains unclear. 
 Two VMAT isoforms (VMAT1 and VMAT2) with high homology have been 
identified (Erickson et al., 1996). VMATs belong to SLC18 transporter family and the MFS. 
VMAT2 (SLC18A2) is expressed in the central nervous system expression and in the 
endocrine and neuroendocrine system (Weihe et al., 1994; Peter et al., 1995; Schütz et al., 
1998). Not only dopamine, but also norepinephrine, epinephrine, histamine, and serotonin 
can be transported by VMAT2. VMAT1 (SLC18A1) is exclusively expressed in 
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neuroendocrine system including chromaffin and enterochromaffin cells and it transports the 
same neurotransmitters as VMAT2 except histamine.  
The VMAT-mediated dopamine transport into vesicles is powered by a 
transmembrane electrochemical H
+
 gradient. This gradient helps to counteract the high 
concentration gradient of dopamine between the outside and the inside of the vesicles (Knoth 
et al., 1981; Nguyen et al., 1998; Beyenbach and Wieczorek, 2006). Vacuolar-type H
+
-
ATPase (V-ATPase) generates the H
+
 gradient, which maintains a low intravesicular pH of 
5.5. VMAT2 effluxes two protons out from the vesicle and reversely transports one molecule 
of dopamine as an antiport (Phillips and Apps, 1980; Eiden et al., 2004). First, one proton is 
extruded from the vesicle in order to generate a high-affinity binding site for dopamine on the 
cytosolic face. Then, VMAT ejects a second proton, which induces a VMAT2 
conformational change for the incorporation of the dopamine molecule into the vesicle.  
VMAT2 presents a low Km (affinity of the transporter for the substrate) in the 
micromolar range compared to other transporter such as VGluT, VGaT and VAchT 
(millimolar range) (Liu and Edwards, 1997; Blakely and Edwards, 2012). This low Km 
indicates a robust efficacy of VMAT2 in the dopamine uptake, which helps to reduce 
dopamine accumulation into the cytosol. It is important to note that the dopamine contained 
into the synaptic vesicles is concentrated to approximately at 100 µM, which is 10–1000 
times higher than the cytosolic level (Elsworth and Roth, 1997).  
II. 4.3.2.  VMAT2 regulation 
 The VMAT2 regulation remains poorly understood. It has been shown that 
Ca
2+
/calmodulin-dependent protein kinase II (CaMKII) and PKA phosphorylate the acid 
patch motif at the extreme C-terminus of VMAT2 without modifying dopamine uptake 
(Krantz et al., 1997; Yao et al., 2004; Chen et al., 2011b). It has been suggested that the 
phosphorylation could play a role in VMAT2 trafficking and subsequently influences its 
subcellular localization (Waites et al., 2001). Moreover, several studies have reported that the 
heterotrimeric G protein Gαo2 and Gαq are able to downregulate the expression of VMATs in 
PC12 cells and in primary cultures, which leads to the monoamine uptake reduction (Ahnert-
Hilger et al., 1998; Höltje et al., 2003; Winter et al., 2005; Brunk et al., 2006). A recent report 
suggests a coupled interaction complex with TH and ADCC enzymes and VMAT2, which 
helps to avoid the accumulation of dopamine into the cytosol (Cartier et al., 2010). D2R 
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activation with quinpirol agonist showed an upregulation of the vesicular dopamine uptake in 
purified striatal vesicles (Truong et al., 2004). This effect has been proposed as subsequent 
redistribution of VMAT2 in the membrane protein of the cytoplasmic non-membrane 
associated vesicles towards the plasmalemmal membrane-associated vesicles (Fleckenstein et 
al., 2007). 
II. 4.3.3.  VMAT2 inhibitors 
Reserpine and tetrabenazine are the most important identified inhibitors of VMAT2 
(Rudnick et al., 1990; Schuldiner et al., 1993; Erickson and Varoqui, 2000; Chaudhry et al., 
2008; Wimalasena, 2011). Amphetamine-like psychostimulants are also known to bind 
VMAT2 but they promote the release of monoamine vesicular stores (Floor and Meng, 
1996). 
 Reserpine, an alkaloid historically used to treat high blood pressure (Slim et al., 
2011), is a high-affinity competitive inhibitor of VMAT2 blocking irreversibly the transport 
(Parti et al., 1987) and the quantal release of dopamine (Colliver et al., 2000). The binding 
site of reserpine is the same as dopamine, which prevents the conformational change of 
VMAT2, the efflux of the second proton and the return to initial state (Zallakian et al., 1982). 
This binding mechanism explains the modulation of the transmembrane pH gradient and the 
irreversibility component of reserpine (Zallakian et al., 1982). The reserpine-treated rodent 
was an acute transitory PD models employed in research (Roos and Steg, 1964; Duty and 
Jenner, 2011). Reserpine induces a loss of storage capacity and a depletion of monoamine in 
the brain, which reproduces some symptoms associated to PD. However, reserpine-treated 
rodents are not accurate models due to the lack of selectivity for the inhibition of 
intravesicular dopamine reuptake, it also depletes the storage of the noradrenaline and 
serotonin.  
 TBZ is a high-affinity non-competitive inhibitor of VMAT2 with short action 
duration. Although not yet identified, the TBZ-sensitive binding site seems to be different 
from the reserpine-sensitive one (Ugolev et al., 2013). Indeed, studies reported a binding site 
independent of the pH gradient (Scherman and Henry, 1982) and non-inhibited by the 
reserpine or by the high concentration of dopamine (>100 fold to TBZ affinity binding) 
(Ugolev et al., 2013). Derivative radiolabeled dihydrotetrabenazine is used in image studies 
for measuring its binding level on VMAT2 for the assessment of PD neurodegeneration 
Dopaminergic synapse 
Dopamine toxicity and transport dysregulation in Parkinson’s disease 
66 
(Martin et al., 2008). Moreover, TBZ is used for treatment of abnormal hyperkinetic 
involuntary movements in Huntington’s chorea (Ondo et al., 2002) 
II. 5.  Dopamine toxicity and transport dysregulation 
in Parkinson’s disease 
Compelling evidence suggests that degeneration of dopaminergic neurons in PD 
begins at synaptic terminals and axons (Morales et al., 2015). At the onset of motor 
disturbance in PD, 70% of dopamine and 50% of proteins involved in metabolism of 
dopamine such as TH, DAT and VMAT2 are lost in the striatum, whereas only 50% of 
dopaminergic neurons in substantia nigra is lost at this time. This observation suggest an 
initiation of pathogenesis in the synapse of nigral neurons (Coleman, 2005; Stephenson et al., 
2007; Cheng et al., 2010; Tian et al., 2012). 
II. 5.1.  Dopamine oxidation and oxidative stress in Parkinson’s 
disease 
The dopamine catechol ring is unstable under the neutral cell physiological conditions 
(pH 7.4), which results in a spontaneous oxidation due to the dissociation of the proton to the 
oxygen in the hydroxyl groups (Cabbat et al., 1985; Pham et al., 2009). This oxidation 
process produces the many toxic metabolites such as dopamine-o-quinone, cysteinyl-
catechol, neuromelanin (ultimate product of dopamine oxidation) and ROS such as hydrogen 
peroxide and superoxide) (Meiser et al., 2013). Additionally, the dopamine degradation via 
the MAO-B enzyme produces hydrogen peroxide which is converted by Fenton reaction to 
the hydroxyl radicals in presence of ferrous iron (Youdim and Bakhle, 2006).  
Several studies demonstrated that the accumulation of these dopamine metabolites 
results in a neurotoxicity and oxidative stress in PD (Jenner and Olanow, 1996). The post-
mortem studies on PD brain patients showed the presence of the high level of oxidized 
proteins, lipids, and nucleic acids (Kumar et al., 2012). The neuromelanin (Spencer et al., 
1998; Zecca et al., 2001, 2003) and cysteinyl-catechol were also found in the nigral region of 
PD brains (Miyazaki and Asanuma, 2008). Moreover despite a lake of neurotoxic effect of 
dopamine in one study (Santiago et al., 2000), typically the stereotaxic injection of dopamine 
in rat striatum provokes a dopaminergic cells loss which can be rescued by the antioxidant 
agents (Hastings et al., 1996a, 1996b; Rabinovic et al., 2000). The neurotoxic effects of 
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dopamine were confirmed in the midbrain neuron cultures and neuronal-like cells (Graham et 
al., 1978; Masserano et al., 1996; Koshimura et al., 2000; Zhang et al., 2000). Dopamine 
metabolites impair several crucial mechanisms and structures of the cells such as 
mitochondria, lysosome and proteasome system (Asanuma et al., 2004; Muñoz et al., 2012 
p.20012; Dias et al., 2013; Segura-Aguilar et al., 2014; Blesa et al., 2015). Additionally, 
oxidative dopamine induces the α-synuclein misfolding and its aggregation (Maguire-Zeiss et 
al., 2005; Mosharov et al., 2009; Chan et al., 2012). All these data strengthen the evidence of 
the involvement of the dopamine oxidative stress in dopaminergic cell death.  
II. 5.2.  DAT in Parkinson’s disease 
In agreement with the degeneration observed in the substantia nigra, imaging studies 
using radiolabeled markers have shown a decrease of DAT expression in PD in correlation to 
the stage disease severity (Bannon and Whitty, 1997; Nutt et al., 2004; Bannon, 2005; 
González-Hernández et al., 2010; Vaughan and Foster, 2013; Politis, 2014). In human PD, 
the loss of dopaminergic neurons correlates with the level of DAT expression. More the level 
of DAT is high, more dopaminergic neurons are vulnerable and match with a robust 
preferential neuron degeneration especially in the midbrain observed with topographic pattern 
of DAT protein expression (Cerruti et al., 1993; Uhl et al., 1994; González-Hernández et al., 
2004). The glycosylated DAT is predominant in terminals of nigrostriatal neurons compared 
to other dopaminergic neurons (e.g. mesolimbic) and displays a higher dopamine uptake 
(Torres et al., 2003a; Li et al., 2004). The authors suggest that glycosylation level can explain 
the higher dopamine uptake and vulnerability of nigrostriatal neurons in PD (Afonso-Oramas 
et al., 2009). Regarding DAT mutation, only one DAT SNP has been detected in infantile 
patients with severe parkinsonism-dystonia, probably due to the DAT inactivation 
(Blackstone, 2009; Kurian et al., 2011). 
Animal and in in-vitro studies have shown that DAT overexpression increases 
neurodegeneration. High sensitivity of dopaminergic cells were observed after treatment with 
neurotoxic agents (e.g. MPP
+
, MPTP, paraquat and rotenone) in DAT ectopic expression 
(Donovan et al., 1999; Rappold et al., 2011; Masoud et al., 2015). These data have been 
confirmed in in-vitro neuroblastoma SK-N-MC cells and non-neuronal HEK293 and COS 
cells (Pifl et al., 1993; Kitayama et al., 1998; Storch et al., 1999, 2002). In contrast, DAT
 
knockout animals and treatment with DAT inhibitors led to a higher resistance to neurotoxic 
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agents (Gainetdinov et al., 1997; Martins et al., 2013). Therefore, DAT seems the principal 
gateway for neurotoxicity and its dysregulation may contribute to disease initiation and/or 
progression (Bougria et al., 1995; Miller et al., 1999; Kurosaki et al., 2003; Hirata et al., 
2008; Vaughan and Foster, 2013).  
α-synuclein and parkin have been shown to impact DAT, suggesting a role in PD 
(Sidhu et al., 2004a). α-synuclein binds to CaMKII site at C-terminus of DAT and stimulates 
the ion current mediated by the DAT (Swant et al., 2011), which has been confirmed by the 
formation of a DAT and α-synuclein heteromeric complex in the cells co-transfected and in 
the rat mesencephalic neurons (Lee et al., 2001; Wersinger and Sidhu, 2003; Wersinger et al., 
2003). It has been shown that the co-expression of α-synuclein and DAT in Lkt-mouse 
fibroblasts decreases the dopamine uptake (Vmax reduction of 30-50%) compared to DAT 
transfection alone (Wersinger and Sidhu, 2003; Wersinger et al., 2003). α-synuclein 
downregulation with siRNA induced a reduction of DAT Vmax dopamine uptake and of DAT 
inhibitor binding (WIN35-428) (Fountaine and Wade-Martins, 2007). Moreover, α-synuclein 
mutation A30P and A53T increase the sensitivity of HEK293-DAT transfected cells to the 
neurotoxins (6-OHDA, MPP
+
 and rotenone) (Lehmensiek et al., 2002, 2006). 
The E3 ubiquitin ligase (parkin) also regulates the DAT by its ubiquitination and 
degradation. Parkin induces a stabilization of the DAT at the cell surface which is associated 
to an increase dopamine uptake (Jiang et al., 2004). However, this result is inconsistent with 
the data which show that parkin disrupts the interaction between DAT and α-synuclein 
leading to a decrease of dopamine uptake neurotoxicity (Moszczynska et al., 2007).  
Several studies have been reported the therapeutic potential of DAT inhibitors in PD. 
The increase of the extracellular dopamine for the potentiation of postsynaptic activity and 
the blockage of the entry of neurotoxic agents in the presynaptic terminal induced by the 
DAT inhibitors could be beneficial in PD (Nutt et al., 2004; Huot et al., 2015). Data in 
rodents and non-human primates PD models suggest that DAT inhibitors such as modafinil, 
amineptine, methylphenidate, SEP-228,791 or vanorexine may have neuroprotective effects 
against MPTP intoxication, although they have demonstrated no clear effectiveness on motor 
symptoms in the clinical trials in PD (Nutt et al., 2004; Huot et al., 2015). 
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II. 5.3.  VMAT2 in Parkinson’s disease 
Numerous studies suggest the potential role of VMAT2 function in human 
Parkinsonism (Liu and Edwards, 1997; Lotharius and Brundin, 2002; Alter et al., 2013; Lohr 
and Miller, 2014). Post-mortem PD brains display a severe reduction of VMAT2 greater than 
what could be explained by dopaminergic terminal loss (Pifl et al., 2014). In recent study in 
Italy, two SNP polymorphisms within the VMAT2 gene promoter are inversely associated to 
PD, presumably due to the increase in VMAT2 expression leading to a higher vesicular 
dopamine reuptake (Brighina et al., 2013). A lower incidence of PD in women was also 
found due to SNP gain-of-function in the VMAT2 promoter, thus conferring a 
neuroprotective effect selective for females (Glatt et al., 2006; Lin et al., 2010b). In contrast, 
a SNP in the coding exon of VMAT2 was identified in a Saudi Arabian family causing an 
infantile parkinsonian with profound motor and cognitive impairments, probably due to a 
reduction of monoamine transport (Rilstone et al., 2013). VMAT2 polymorphism and its 
expression level could also be associated to a variety of neuropsychiatric illness linked to a 
dopamine disorder such as schizophrenia, depression, Tourette’s syndrome and bipolar 
disorder (Lajtha and Mikoshiba, 2009). 
In in-vivo models, VMAT2 knockdown in mice induces a high oxidative stress, α-
synuclein accumulation and progressive degeneration of the nigrostriatal neurons as well as a 
reduction of dopamine storage, transport and quantal release (Fon et al., 1997; Takahashi et 
al., 1997; Wang et al., 1997; Gainetdinov et al., 1998; Miller et al., 2001; Caudle et al., 2007; 
Taylor et al., 2011; Lohr et al., 2015). These mice display a high sensitivity of dopaminergic 
neurons to neurotoxic agents whereas mice overexpressing VMAT2 are less sensitive to 
neurotoxic MPTP insult (Lohr et al., 2014). In agreement, cultured midbrain neurons and cell 
lines overexpressing VMAT2 showed a protective effect against neuronal damage associated 
to an increase of storage capacity and dopamine release (Chen et al., 2005a; Vergo et al., 
2007; Muñoz et al., 2012; Choi et al., 2015b). Interestingly, it has been suggested that 
increased VMAT2 Vmax uptake of dopamine and MPP
+
 (2-fold elevation) observed in rat 
dopaminergic neurons may confer the resistance to MPTP-induced neurotoxicity compared to 
other species such as mice, primate and human (Staal and Sonsalla, 2000; Staal et al., 2000). 
VMAT2 inhibition induced by Ro 4-1284 and reserpine enhances the MPP
+
 or MPTP 
neurotoxicity by a reduced sequestration into the vesicles (Staal and Sonsalla, 2000). It was 
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demonstrated that VMAT2 reduction in MPTP primate PD model is the key pathogenic event 
that precedes nigro-striatal dopaminergic neurons loss(Chen et al., 2008).  
Strong evidence shows a direct link between α-synuclein and VMAT2. α-synuclein 
protofibrils may permeabilize the vesicles by its binding to VMAT2. This interaction induces 
the formation of an annular pore-like in the vesicular membrane, which may lead to a leakage 
of monoamines into the cytosol (Lashuel et al., 2002; Lotharius and Brundin, 2002; Volles 
and Lansbury, 2002, 2003; Zhu et al., 2003; Sidhu et al., 2004b; Guo et al., 2008). Moreover, 
in-vitro overexpression of α-synuclein in the SH-SY5Y cells causes a downregulation of the 
expression of VMAT2 proteins which is associated to a decrease of vesicular dopamine 
uptake and an increase in cytosolic dopamine and ROS (Mosharov et al., 2006; Guo et al., 
2008). 
II. 5.4.  VMAT2, a potential therapeutic target 
All these data support the interest of VMAT2 as a potential therapeutic target for PD 
through the prevention of dopaminergic cytosolic oxidative stress by several mechanisms 
(Figure 6) (Zheng et al., 2006; Bernstein et al., 2014; Lohr and Miller, 2014; Yulug et al., 
2015): 
1. Reduction of dopamine oxidation into cytosol through the uptake of dopamine into 
the vesicles. 
2. Blockage of dopamine oxidation into vesicles due to the low intravesicular pH 
(strong bond of the dopamine proton to the oxygen in the hydroxyl groups). 
3. Sequestration of neurotoxic agents into the vesicles.  
Today no VMAT2 activator has been identified, however some studies have proposed 
potential neuroprotective effects related to VMAT2 activation. Methylphenidate, a DAT 
inhibitor, is widely used in attention deficit hyperactivity disorder (ADHD) (Sandoval et al., 
2002; Volz, 2008; Volz et al., 2009; Nandhagopal et al., 2011). Additionally to increase the 
brain dopamine level, methylphenidate also increases dopamine storage into synaptic vesicles 
and dopamine release from vesicles after potassium stimulation. It was suggested that the 
effects could be due to an increase in VMAT2 expression level. Subsequently, 
methylphenidate could improve the motor deficits in PD. Similarly to methylphenidate, 
pramipexole, which is a D2/D3 receptor agonist used in treatment of PD, is associated to a 
potential neuroprotective effect involving VMAT2 (Zou et al., 1999). Indeed, synaptic 
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vesicles from rat striatum treated pramipexole display a higher VMAT2 dopamine uptake 
activity. In In-vitro experiments, pramipexole treatment of the SH-SY5Y cells showed a time 
and dose-dependent increase in mRNAs and proteins of nuclear receptor related 1 protein 
(NURR1), DAT and VMAT2 (Pan et al., 2005). 
However, the regulation of dopamine in neuronal terminal is a delicate balance. The 
aim is to keep the dopamine at the right place and time. When there is too much dopamine 
outside the vesicle, the dopamine becomes toxic. Reciprocally, too much dopamine packaged 
induses a less effective postsynaptic stimulation. And to make things even more complicated, 
a recent hypothesis suggests an interaction between DAT and VMAT2 leading to a mutual 
modulation of the dopamine reuptake, a fairly logical idea in order to have a fine regulation 
of dopamine into the cells (Egana et al., 2009).  
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Figure 6. Hypothetical neuroprotective and neurodegenerative mechanisms of dopamine transporter and vesicular monoamine 
transporter 2 involved in Parkinson’s disease 
A. Cartoon of hypothetical transport mechanisms involved in the detoxification of oxidized dopamine and neurotoxic agents. This cartoon present also the neuroprotective 
and neurodegenerative components in Parkinson’s disease  
B. Schematic diagram of hypothetical neuroprotective and neurodegenerative mechanisms involving the activities of the dopamine transporter and vesicular monoamine 
transporter 2. 
DA, dopamine; DAT, dopamine transporter; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; VMAT2, vesicular monoamine transporter 2; 
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II. 6.  Dopaminegic neurodegeneration in Parkinson’s 
disease and the therapeutic potential of 
dopaminergic differentiation, neurogenesis and 
neurorestoration 
Current therapies of PD target motor symptoms and do not cure, prevent or slow 
down the progression of dopaminergic cell loss. In this context, the neurorestoration and 
neuroregenerative therapies aim to fill a huge unmet medical need and represent a major 
challenge for human societies. Although some PD symptoms may appear before the complete 
dopaminergic cell loss, at the time of diagnosis about 70% decrease of dopamine level and 
about 50% of dopaminergic neurons are lost (Bernheimer et al., 1973; Kish et al., 1988; 
McGeer et al., 1988). Moreover, axonal projections to the striatum from the substantia nigra 
disappear by retrograde degeneration called dying-back phenomenon (Jellinger, 1999; Cheng 
et al., 2010). These observations suggest the possibility of a therapeutic intervention for 
reversing this degeneration.  
II. 6.1.  Axonal and dendritic degeneration in Parkinson’s disease 
Several mechanisms were described in the dysregulation and degeneration of 
dopaminergic axons and dentrites in PD. The main factors triggering above mechanisms are 
neurotoxic agents (Spencer, 2000; O’Malley, 2010) as well as α-synuclein (Waxman and 
Giasson, 2009; Bellucci et al., 2012) and LRRK2 mutations (Santpere and Ferrer, 2009; 
Berwick and Harvey, 2013). Studies using 6-OHDA and MPTP PD models confirmed the 
dying-back phenomenon observed in PD. A retrograde degeneration of the nigrostriatal 
system was observed prior to the loss of nigral cell bodies in 6-OHDA rat model (Sauer and 
Oertel, 1994; Przedborski et al., 1995; Serra et al., 2002; Li et al., 2009a) and MPTP non-
human primate (Herkenham et al., 1991; Meissner et al., 2003).  
MPTP and MPP
+
 treatments can induce a dysfunction and fragmentation of axonal 
microtubules (Cappelletti et al., 2005; Ren et al., 2005; Morfini et al., 2007). Midbrain mice 
culture treated with 6-OHDA showed the same pattern of fragmentation, in addition to a 
retrograde degeneration and the impairment of axonal transport (Lu et al., 2014). Neurotoxic 
agents directly bind to tubulin, which affects the tubulin polymerisation and microtubule 
transport leading to a axonal degeneration (Cappelletti et al., 1999, 2005).  
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About PD mutations such as α-synuclein mutation A30P and A53T in 
phosphorylation state have been shown to impair axonal transport and neurite outgrowth in 
rat primary midbrain and cortical neurons (Saha et al., 2004; Lee et al., 2006; Sousa et al., 
2009; Prots et al., 2013; Tönges et al., 2014; Koch et al., 2015). The wild-type and mutated α-
synuclein overexpression impairs microtubule polymerization and actin stability. Actin 
polymerization is regulated by Rho-associated protein kinase (ROCK) and its activation by α-
synuclein mutations could block the neurite sprouting and induce a neurite retraction (see 
chapter: II. 6.2.3. RhoA pathway and ROCK inhibition) (Tönges et al., 2014).  
Bacterial artificial chromosomes (BAC) transgenic LRRK2 mouse model of human 
mutated form (R1441G) shows a motor impairment but without loss of dopaminergic neurons 
(Li et al., 2009b). However, TH immunostaining of projection highlighted the dystrophic 
neurites and fragmented axons containing spheroid-like structures (Li et al., 2009b). LRRK2 
mutation G2019S overexpressed in animals (rats, mice and drosophila) also induces neurite 
retraction, microtubule fragmentation, neurite inclusions and mislocalization of axonal 
protein tau (Lin et al., 2010a; Winner et al., 2011; Kawakami et al., 2012; Tsika et al., 2015). 
In agreement, studies in the SH-SY5Y neuroblastoma cells (Plowey et al., 2008; Chan et al., 
2011) and primary hippocampal and midbrain cultures from mutant mice overexpressing the 
mutated G2019S form of LRRK2 (MacLeod et al., 2006; Dächsel et al., 2010; Ramonet et al., 
2011; Sepulveda et al., 2013) showed a reduction of the neurite length and branching 
complexity. In contrast, these pathological changes were not observed after overexpression of 
wild-type LRRK2, whereas the LRRK2 downregulation increases the neurite length 
(MacLeod et al., 2006; Dächsel et al., 2010; Heo et al., 2010; Paus et al., 2013; Sepulveda et 
al., 2013). Mechanism leading to retraction induced LRRK2 mutations is not well understood 
but it seems closely related to phosphorylation status of the LRRK2 (Parisiadou and Cai, 
2010; Greggio, 2012). The phosphorylated LRRK2 may in turn phosphorylate other proteins 
directly involved in neurite growth such as tau and β-tubulin as well as proteins involved in 
the signalling pathway of the polymerisation of microtubule and actin such as Rac1 
(Parisiadou et al., 2009; Chan et al., 2011; Kawakami et al., 2012). Recent data showing the 
impact of LRRK2 on actin cytoskeleton guidance further support the interest of this protein in 
the dynamics and stability of the growth cone: crucial element for axon sprouting (Parisiadou 
et al., 2009; Häbig et al., 2013). The growth cone is a highly dynamic neuritic structure and 
essentially supported by a bundle of actin filament. It promotes for the generation of new 
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axonal and dendritic projection for the creation of the new synapses (Goodman, 1996; 
Lowery and Van Vactor, 2009; Kerstein et al., 2015). 
II. 6.2.  Induction of dopaminergic differentiation and 
neurogenesis by transcription factors and its potential for 
the treatment of PD 
Neurorestorative strategies for PD represents a large field of basic and pharmaceutical 
research. A huge number of promising targets have been proposed aiming the 
neurorestorative mechanisms including the activation of neurodifferentiation pathways 
towards the dopaminergic phenotype (Kalia et al., 2015). Among those attracting significant 
interests are the nuclear factors and the ras homolog gene family, member A (RhoA) 
downstream cell-signalling pathway because of their action on neuronal phenotype and the 
morphological neurodifferentiation respectively. Several transcription factors have been 
proposed as potential targets not only because of their potential restoration of dopaminergic 
phenotypes but also because of their subsequent neuroprotective component due to 
stabilization of neurotransmitter-specific synaptic elements. Nuclear factors such as retinoic 
acid receptor (RAR), liver X receptor (LXR), peroxisome proliferator-activated receptor 
(PPAR) and NURR1 are the more important targets, which, in most cases, act as heterodimer 
complexes with retinoic X receptor (RXR) binding to DNA sequences and inducing gene 
transcription (Skerrett et al., 2014).  
II. 6.2.1.  Retinoic acid and RAR activation 
Retinoic acid (RA), a metabolite of vitamin A, is major activator of RAR, potentially 
involved in the dopaminergic differentiation (Kitamura et al., 2002; Friling et al., 2009; 
Skerrett et al., 2014). RAR activation by RA plays an important role in the development of 
central nervous system and is mostly involved for midbrain dopaminergic neurons (Maden, 
2007; Jacobs et al., 2011; Rhinn and Dollé, 2012; Allodi and Hedlund, 2014). Indeed, 
knockout mice of RAR have locomotor impairments and a reduction of D1R and D2R 
(Krezel et al., 1998). Moreover, a high expression level of RA synthesis enzyme is observed 
in the dopaminergic neurons (McCaffery and Dräger, 1994).  
RA has been proposed as therapeutic option in PD due to its specific role in midbrain 
development, and its neuroprotective effect in several models of PD. RA reduces hydrogen 
peroxide-induced apoptosis (Moreno-Manzano et al., 1999; Kitamura et al., 2002). It has 
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been demonstrated that RA confers a higher resistance to MPP
+
 and 6-OHDA treatment in 
SH-SY5Y cells and in rat primary ventro-mesencephalic cultures by upregulation of cell 
survival via activation of the Akt pathway (Cheung et al., 2009). RA also potentiates the 
synthesis of the nerve growth factor (NGF) and the expression receptor of neurotrophin trkA 
involved in the survival and development of neuronal cells, which could explain its protective 
effect (von Holst et al., 1995; Plum and Clagett-Dame, 1996; Arrieta et al., 2005). In PD 
models, RA has been shown to reverse the impairment of locomotor function and 
dopaminergic neuron degeneration induced by the 6-OHDA, MPTP and rotenone (Ulusoy et 
al., 2011; Yin et al., 2012; Esteves et al., 2015). Interestingly, pituitary homeobox 3 (PITX3) 
or NURR1 activation is proposed to participate to this neuroprotective effect of RA 
(Sacchetti et al., 2002; Jacobs et al., 2011; Hong et al., 2014). These transcriptional factors 
may act in cooperation and are crucial for the maturation and survival of the dopaminergic 
neurons (Jacobs et al., 2009, 2011; Hong et al., 2014). The deficient mice for PITX3 fail to 
develop dopaminergic neurons specifically in the substantia nigra and display a low level of 
dopamine and an impairment of locomotor function (Nunes et al., 2003; van den Munckhof et 
al., 2003; Smidt et al., 2004; Luk et al., 2013; Kim et al., 2014; Le et al., 2015). More 
interestingly, PITX3 directly activates the transcription of VMAT2 and DAT genes (Hwang 
et al., 2009). 
The interest of NURR1 in PD has been strengthen by the proof-of-principle using 
genetic approaches (Zetterström et al., 1996; Wallen-Mackenzie et al., 2003; Hermanson et 
al., 2006; Park et al., 2006; Bae et al., 2009; Bensinger and Tontonoz, 2009; Decressac et al., 
2013). NURR1 also up-regulates the expression of the TH, VMAT2 and DAT expression 
(Castillo et al., 1998; Hermanson et al., 2003; Kim et al., 2003; Smits et al., 2003). The 
NURR1-deficient mice display a reduction of striatal dopamine and of dopaminergic neuron 
markers in ventral midbrain and striatum, and a impairment of the locomotor function (Le et 
al., 1999; Jiang et al., 2005; Kadkhodaei et al., 2009). Histological analyses revealed a loss of 
dopaminergic neurons and an increased sensitivity to oxidative stress and to MPTP. A very 
recent study using bexarotene, an agonist of NURR1, reported a dopaminergic neuron 
protection and a reversion of the behavioural deficits in 6-OHDA PD model (McFarland et 
al., 2013). Authors suggested that the upregulation of DAT and VMAT2 expression 
modulated by NURR1 was probably implicated in the protective effect of bexarotene. These 
findings are also supported by reported data in rat embryonic stem cells and ventral midbrain 
cultures showing that XCT0139508, a NURR1 ligand, increases the dopamine cell survival 
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against 6-OHDA insult (Friling et al., 2009). Moreover, NURR1 transfection promotes 
neurogenesis in neuronal precursors from rat foetal cortices (Hermanson et al., 2006; Park et 
al., 2006; Bae et al., 2009; Jacobs et al., 2011; Hong et al., 2014).  
RA induces neurogenesis and differentiation, an effect well characterized in-vitro 
models proposed for axonal regeneration (Puttagunta and Di Giovanni, 2011). RA-induced 
neurite growth and development of the growth cones have been observed in neuronal cell 
lines (SH-SY5Y) and in primary cultures from adult or embryonic rodent brains (Corcoran et 
al., 2000; Encinas et al., 2000; Presgraves et al., 2004; Dmetrichuk et al., 2006; Cheung et al., 
2009; Farrar et al., 2009; Dwane et al., 2013; Korecka et al., 2013). RA-mediated 
differentiation in SH-SY5Y cells leads to a higher level of dopamine storage and expression 
level of dopaminergic markers such as TH or DAT (Hashemi et al., 2003; Presgraves et al., 
2004; Constantinescu et al., 2007; Korecka et al., 2013). Overall results demonstrated the cell 
differentiation toward the dopaminergic phenotype. Currently, specific co-treatment with RA 
and other compounds has been used in embryonic stem cells to induce dopaminergic 
differentiation for grafting purposes in 6-OHDA PD model and also in PD patients (Fathi et 
al., 2010).  
II. 6.2.2.  LXR nuclear factor  
Nuclear receptor LXR regulates the level of cholesterol, fatty acid and glucose 
homeostasis (Wang et al., 2002; Skerrett et al., 2014). Besides this main role, LXR activation 
promotes neuron and midbrain neurogenesis (Wang et al., 2002; Andersson et al., 2005; Xu 
et al., 2014). The activation of LXR by oxysterol differentiates the embryonic ventral 
midbrain and mouse embryonic stem cells inducing higher levels of TH, VMAT2, PITX3, 
DAT and NURR1(Sacchetti et al., 2009; Theofilopoulos et al., 2013). LXR knockout mice 
present a higher sensibility to MPTP-induced degeneration of neuronal cells in substantia 
nigra (Dai et al., 2012). Moreover, T0901317 and GW3965, agonists of LXR, are able to 
recover motor function and to protect dopaminergic neurons against MPTP (Dai et al., 2012; 
Campolo et al., 2014). LXR upregulates another important transcription factor for regulation 
of the dopaminergic proteins called forkhead box protein A2 (FOXA2) (Arenas, 2008; 
Domanskyi et al., 2014). Suppression of FOXA2 gene triggers spontaneous parkinsonism 
with predominant loss of dopamine neurons of substantia nigra in mice (Kittappa et al., 
2007). In a recent study, the injection of NURR1- and FOXA2-adenovirus markedly protects 
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the dopaminergic neurons and restores motor impairment in MPTP mice model (Oh et al., 
2015).  
II. 6.2.3.  RhoA pathway and ROCK inhibition  
ROCK inhibition has been proposed as a potential target for PD (Tönges et al., 2011; 
Fujita and Yamashita, 2014; Labandeira-Garcia et al., 2014). ROCK is a kinase involved in 
the axonal growth and regeneration signalling. Two ROCK isoforms with a high homology 
have been identified: ROCK1 expressed in the periphery of the brain whereas ROCK2 
expressed in central nervous system and in muscle (Tönges et al., 2011; Labandeira-Garcia et 
al., 2014). The direct endogenous activator of ROCK is the GTPase RhoA which is activated 
by signalling cascades coming from extracellular ligands such as Nogo, oligodendrocyte 
myelin glycoprotein (OMgp) or myelin associated glycoprotein (MAG) (Figure 7) (Cao et al., 
2010; Saha et al., 2014; Seiler et al., 2015). These extracellular molecules are known to be 
synthetized by the oligodendrocytes, myelin, and scar tissue and represent a stopping signal 
for axonal growth though activation of complexes of Nogo receptor 1 (NgR1), LINGO-1 
orp75NTR (Cao et al., 2010; Saha et al., 2014; Seiler et al., 2015). The RhoA activates the 
ROCK kinase activity by the disruption of the interaction between C- and N-terminal regions 
of ROCK and subsequently releases the auto-inhibition of ROCK (Tönges et al., 2011; 
Labandeira-Garcia et al., 2014). LIM domain kinase (LIMK) is the principal downstream 
effector of ROCK is (Yang et al., 1998; Bernard, 2007) and four other effectors were also 
described such myosin light chain (MLC), collapsing response mediator protein-2 (CRMP-2), 
ezrin, radixin and moesin (ERM) and adducin (Arimura et al., 2004; Kim and Chang, 2004). 
The activation of these downstream effectors leads to a stabilization and retraction of neurite, 
whereas its inhibition promotes neurite growth. Indeed, ROCK inhibition with fasudil and Y-
27632 reduces the neurite growth in PC12, SH-SY5Y and primary neuronal neurons (Zhang 
et al., 2006; Ichikawa et al., 2008; Racchetti et al., 2010a; Tonges et al., 2012). 
 Phosphatase and tensin homolog (PTEN) has been identified as a downstream 
effector of ROCK (Li et al., 2005). PTEN is a phosphatase which negatively regulates 
PI3K/Akt pathway by the dephosphorylation of phosphatidylinositol(3,4,5)trisphosphate 
(PIP3) in phosphatidylinositol 4,5-bisphosphate (PIP2) (Gupta and Dey, 2012). PI3K/Akt has 
been identified as canonical pathway for the neuronal survival, the upregulation of protein 
synthesis and for the cell growth. Indeed, the activation of PI3K/Akt pathway through PTEN 
inactivation induced by ROCK inhibition protects against apoptotic cell death (Street and 
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Bryan, 2011). For exemplee, ROCK inhibitor Y-27632 is widely used for survival promotion 
in differentiation step of embryonic stem cell (Watanabe et al., 2007; Kamishibahara et al., 
2014).  
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Figure 7. ROCK signalling pathway involved in the regulation of neurite growth and cell 
survival. 
CRMP2, collapsin response mediator protein; ERM, ezrin, radixin and moesin; LIMK, LIM domain kinase; 
PTEN, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase; p75NTR, p75 neurotrophin receptor; MAG, 
myelin-associated glycoprotein ; Nogo, reticulon-4; MLC, myosin light chain phosphatase; MLCP, myosin light 
chain protein; NgR, nogo Receptor; Omgp, oligodendrocyte-myelin glycoprotein; PI3K, phosphoinositide 3-
kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; ROCK, 
Rho-associated protein kinase; 
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ROCK inhibitors in PD may represent interesting disease-modifying principles for the 
treatment in PD due to the induction of neurite outgrowth and cell survival (Tönges et al., 
2011; Labandeira-Garcia et al., 2014). Supporting this hypothesis, treatment of cells (SH-
SY5Y, MES 23.5, rat primary midbrain and mesencephalic cultures) with Y-27632, fasudil or 
MBPTA reduce both death of TH positive dopaminergic neurons and axonal retractions 
induced by MPP
+
 (Tonges et al., 2012; Borrajo et al., 2014). Animal studies also reported 
neuroprotective effects of fasudil or Y-27632 against dopaminergic neurons loss as well as 
restoration of the motor function in MPTP mice model (Tonges et al., 2012; Rodriguez-Perez 
et al., 2013; Zhao et al., 2015). The reported effect was associated to a reduction of 
proinflammatory activity (IL-1β, TNF-α, NF-κB-p65 and TLR-2) and oxidative stress (iNOS 
and gp91Phox). Moreover, downregulation of ROCK2 by viral small hairpin RNA (shRNA) 
transfection in primary midbrain neurons showed a strongest resistance to MPP
+
 toxicity 
(Saal et al., 2015). The injection of this virus in mice treated with 6-OHDA leads to a 
decrease of loss of dopaminergic cells in substantia nigra, restoration of striatal TH fibers and 
motor improvement after 4 weeks. 
Neurorestoration and differentiation could be mechanisms with therapeutic disease-
modifying potential for the treatment of PD. The induction of neurorestoration by promoting 
both a dopaminergic phenotype and a growth of neurite and axons has been largely 
demonstrated for above mentioned pathways (Airavaara et al., 2012; Marxreiter et al., 2013; 
Hegarty et al., 2014). The phenotype induction could help to compensate the loss of 
dopaminergic neuron by a higher dopaminergic function of the remaining neurons and by the 
reduction of oxidative stress, while the growth of synaptic elements could regenerate 
dopaminergic terminals (Lingor et al., 2012; Burke and O’Malley, 2013; Lamm et al., 2014).  
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III.  Cholesterol, brain and statins 
The inhibition of cholesterol biosynthesis has been proposed to have neuroprotective 
and neurorestorative effects. The following chapters outline how the statins, cholesterol-
lowering drugs, acting at 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) may have a 
beneficial effect on neurological disorders including PD, and represent a potential disease-
modifying principles for restoration of the dopaminergic terminals.  
III. 1.  Cholesterol 
Cholesterol is a hydrophobic molecule of the sterol family with intrinsic structural 
rigidity that plays an important role in the structure and function of cells (Yeagle, 1991, 1991; 
Krause and Regen, 2014). Cholesterol is essential for the growth and cell viability and 
represents 30% of total lipids of the human body (Krause and Regen, 2014). The cholesterol 
structure contains four carbon rings with an amphipathic component due to hydrophilic 
hydroxyl group on the carbon 3 and to the lipophilic hydrocarbon tail (Figure 8). 
 
Figure 8. The structure of cholesterol 
The cholesterol of mammalian cells is provided by dietary uptake (30%) while de 
novo cholesterol (70%) is mainly synthetized in the liver (Wilson and Lindsey, 1965; Wilson, 
1972; Wilson and Rudel, 1994). Endogenous cholesterol is synthesized from glucose and 
fructose in the liver and extrahepatic tissues via the glycolysis and the mevalonate pathways 
(Popjak, 1958; Chang et al., 1997). Every cell has the capacity to synthesize the needed 
cholesterol and the body has various homeostatic mechanisms to regulate its levels (Phillips 
and Johnson, 1998). 
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The dietary cholesterol is transported to the liver by the lipoprotein chylomicrons 
while the synthesized cholesterol also uses the lipoprotein named VLDL (Figure 9) (very 
low-density lipoproteins). The lipoprotein particles are complexes of lipids and proteins that 
are more soluble in blood and lymph than free cholesterol due to amphipathic component of 
the cholesterol (Figure 10) (Myant, 1982; Lestavel and Fruchart, 1994; Goldstein and Brown, 
2009). These lipoproteins represent the source of cholesterol for the muscles and fat cells. 
LDL (low-density lipoproteins) supply with cholesterol all other tissues (Myant, 1982; 
Lestavel and Fruchart, 1994; Goldstein and Brown, 2009). The transport of tissue cholesterol 
back to the liver happens by participation of HDL (high-density lipoproteins). The 
lipoproteins are trapped by the LDL receptor (LDLR), which leads to its endocytosis and 
digestion in several components including amino acids, cholesterol esters and free cholesterol 
by cell lysosomes (Myant, 1982; Lestavel and Fruchart, 1994; Goldstein and Brown, 2009). 
 
 
Figure 9. Simplified cartoon of cholesterol lipoprotein particle transports between the 
intestine, liver and extrahepatic tissues 
VLDL, very low density lipoprotein; LDL, low density lipoprotein; HDL, high density liprotein. 
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Figure 10. Structure of the lipoproteins and the chylomicrons 
Free of usage: Author: OpenStax College, licensed under the Creative Commons Attribution 3.0 Unported 
license. 
Cholesterol is abundant in both endosomes and Golgi apparatus, especially in the 
trans-Golgi zone while the endoplasmic reticulum contains only about 1% of cellular 
cholesterol (Ikonen, 2008). Cholesterol affects several cellular processes via its interaction 
with other membrane lipids and specific proteins and its structure increases the cohesion and 
the consolidation of the neighbouring lipids in the lipidic bilayer (Needham and Nunn, 1990) 
and subsequently a decrease in the fluidity and permeability (Cooper, 1978). Cholesterol 
orchestrates the formation of specialized areas (lipid rafts) in the plasma membrane by its 
lateral organization in the lipidic bilayer (Chong et al., 2009). Lipid raft containing the 
cholesterol with sphingolipids which has an affinity for proteins would be implicated in the 
signal transduction, membrane proteins and trafficking and cell adhesion (Simons and 
Ikonen, 1997; Simons and Ehehalt, 2002; Korade and Kenworthy, 2008; Pike, 2009). The 
biochemical organization of cholesterol allows to increase the mechanical strength of the 
lipid bilayer, which reduces the passive permeability of water, small molecules and gases 
(Róg et al., 2009). Cholesterol may also serve as precursor for steroid hormones and regulates 
the function of signalling molecules like hedgehog (Porter et al., 1996; Payne and Hales, 
2004). 
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III. 2.  Brain cholesterol  
The brain comprises 23% of the total body cholesterol at a concentration of 15-20 
g/kg of brain tissue, essentially in a unesterified free form (99%) (Dietschy and Turley, 2001; 
Zhang and Liu, 2015). It is important to note that central nervous system represents only 
2.1% of the body total weight, thus the brain is highly enriched in cholesterol compared to the 
rest of the body. All brain cholesterol is basically synthetized locally. In adult brain neurons 
are mostly dependent on astrocytes for its source of cholesterol via the lipoproteins 
containing the apolipoprotein E (ApoE) (Edmond et al., 1991; Dietschy, 2009; Pfrieger and 
Ungerer, 2011). However during embryogenesis, all cells produce a large amount of 
cholesterol needed for neurogenesis processes such as cell division and neurite formation 
(Dietschy and Turley, 2001; Dietschy, 2009). Brain cholesterol has a slow turnover rate 
unlike other tissues. However, brain astrocytes have a higher turnover rate of cholesterol 
synthesis allowing the transfer of a cholesterol amount for the neurons. The synthesis rate of 
brain cholesterol is only 0.9% of whole body, which translates into a half-life of 4-6 months 
in the rat and up to 5 years in a human brain (Björkhem et al., 1998; Dietschy and Turley, 
2004; Vaya and Schipper, 2007). It also is important to highlight cholesterol from 
oligodendrocytes which represents 70% of total cholesterol in the brain (Björkhem and 
Meaney, 2004; Saher et al., 2005). These cells ensure neuronal transmission by formation of 
cholesterol-enriched myelin sheaths to wrap neuronal axon. Myelin sheaths reduce the 
permeability to ions, and therefore allow the propagation of the electrical impulse along the 
axon. Numerous other brain processes such as conformation of neurotransmitter receptors 
and transporters, synaptic vesicle microtubular transport and exocytosis fusion, cell adherent 
junctions, appropriate membrane curvature and assembly of vesicle-specific proteins and 
lipids are also dependent on the cholesterol (Yeagle, 1991; Koudinov and Koudinova, 2003; 
Pfrieger, 2003; Segatto et al., 2014). Today, it remains unclear what is role and how 
cholesterol level could affect the function, stability and biogenesis of the synaptic vesicles. 
However, cholesterol represents 40% of total lipids in synaptic vesicles (Takamori et al., 
2006) and its interactions with the synaptic proteins (e.g. synaptophysin and synaptotagmin) 
have been reported (Thiele et al., 2000; He et al., 2006; Lv et al., 2008).  
Brain cholesterol levels are tightly regulated because the cholesterol does not pass 
through the blood-brain barrier (Orth and Bellosta, 2012). This mechanism protects the brain 
of a too high level of plasma cholesterol and the subsequent deleterious effect of toxic free 
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cholesterol accumulation because of its amphipathic component (Björkhem and Meaney, 
2004; Dietschy, 2009; Fantini and Yahi, 2015). Unlike other tissue, the cholesterol cannot be 
extruded of the brain and thus it is converted by the cholesterol 24-hydroxylase (Cyp46A1) in 
a form with polar component allowing its passage through the blood-brain barrier such as 
24(S)-hydroxycholesterol and transport to the liver for degradation (Björkhem et al., 1998; 
Björkhem, 2006; Leoni and Caccia, 2013). Cholesterol 24-hydroxylase enzyme is highly 
expressed into brain and especially in the neuron in comparison to the rest of the body 
(Russell et al., 2009). 24(S)-hydroxycholesterol is able to regulate the cholesterol 
homeostasis of neurons and plays a critical role in cholesterol synthesis by the activation of 
LXR (see chapter: III. 3.2. SREBP regulation and cholesterol) (Björkhem, 2006; Cartagena et 
al., 2010; Gabbi et al., 2014). 
III. 3.  Cholesterol synthesis and mevalonate pathway  
The cholesterol synthesis involves the mevalonate pathway with a quite complex 
series of more than 25 separate enzymatic reactions. These reactions produce a range of 
different metabolites that regulate the mevalonate pathway (Buhaescu and Izzedine, 2007; 
Goldstein and Brown, 1990). The most critical steps of this pathway are summarized below 
(Figure 11). 
The first step of the mevalonate pathway is the synthesis of HMG-CoA from three 
molecules of acetyl-CoA via two enzymatic reactions of acetoacetyl-CoA thiolase and HMG-
CoA synthase (Massy et al., 1996; Buhaescu and Izzedine, 2007; Goldstein and Brown, 
1990). Acetyl-CoA molecules are directly provided by oxidative conversion of pyruvate from 
the glycolysis pathway (Berg et al., 2002). Then, 3-hydroxy-3-methylglutaryl-CoA reductase 
(HMGCR) tightly regulates the conversion of HMG-CoA into mevalonate (Jo and Debose-
Boyd, 2010). HMGCR is located in endoplasmic reticulum membrane and is the rate-limiting 
step enzyme of cholesterol synthesis (Friesen and Rodwell, 2004). In the absence of sterol 
into cells, HMGCR gene transcription is highly upregulated by the transcription factor sterol 
regulatory element-binding protein (SREBP) (Espenshade, 2006) (see chapter: III. 3.2. 
SREBP regulation and cholesterol). Following mevalonate synthesis, five subsequent 
reactions convert mevalonate into farnesyl pyrophosphate (FPP). The FPP is a pivotal 
substrate for two distinct pathways named prenylations (see chapter: III. 3.1. Prenylation 
pathway) (Miziorko, 2011; Holstein and Hohl, 2004). Two molecules of FPP are condensed 
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in squalene molecule by squalene synthase (Nes, 2011). This product is the first committed 
step of the specific cholesterol biosynthesis. Then, squalene is cyclized in two-step into 
lanosterol, which is in turn converted to cholesterol in a series of 19 reactions (Nes, 2011).  
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Figure 11. Mevalonate pathway, regulation factors, isoprenoids, and cholesterol 
Insig, insulin-induced gene 1 protein; LXR, liver X receptor; ROCK, rho-associated protein kinase; RXR, 
retinoid X receptor; PI3K, phosphoinositide 3-kinase; S1P, site-1 protease; S2P, site-2 metalloprotease; SCAP, 
SREBP cleavage-activating protein; SRE, sterol regulatory element; SREBP, sterol regulatory element-binding 
protein; 
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III. 3.1.  Prenylation pathways 
The mevalonate pathway provides the essential isoprenoids lipids for the cells which 
are produced by the prenylation downstream pathways. Prenylation process is an important 
mechanism of post-translational modification of proteins and is required for proper 
subcellular localization and biological function of the proteins (Miziorko, 2011; McTaggart, 
2006; Zhang and Casey, 1996). Farnesyltransferase (FTase) and geranylgeranyltransferase 
(GGTase) are the two enzymes that carry out the process of prenylation (Miziorko, 2011; 
McTaggart, 2006; Zhang and Casey, 1996). This process involves the covalent attachment of 
hydrophobic molecules to the cysteine motif CAAX (C, Cys; A, aliphatic amino acid; X, any 
amino acid) at the C-terminus of the proteins (Casey, 1992; Holstein and Hohl, 2004). A 
short-chain C-15 farnesyl pyrophosphate (FPP) or C-20 geranylgeranyl pyrophosphate 
(GGPP) are attached to the proteins by the enzymes GGTase and FTase respectively (Casey, 
1992; Holstein and Hohl, 2004). Both enzymes preferentially attach isoprenoids to the small 
GTPases such as Ras, RhoA, and Rac families, which enables the protein anchorage into lipid 
membrane. This anchorage in membrane of the small GTPases acts as molecular switches for 
the regulation of their respective signalling pathway such as cell proliferation, inflammation 
and oxidative stress (Park et al., 2014; Li et al., 2012; Hooff et al., 2010; Palsuledesai and 
Distefano, 2015; Schafer and Rine, 1992).  
III. 3.2.  SREBP regulation and cholesterol 
The major feedback control of cholesterol synthesis is performed by the family of 
SREBP transcriptional factors (Espenshade, 2006; Shao and Espenshade, 2012). SREBPs 
enhance the transcription of more than 30 genes including proteins for uptake and synthesis 
of cholesterol, fatty acids, triglycerides, and phospholipids (Espenshade, 2006; Ye and 
DeBose-Boyd, 2011; Shao and Espenshade, 2012). Two genes encode three SREBP 
isoforms: SREBP-1a, SREBP-1c and SREBP-2. SREBP-1a is a potent activator of all 
SREBP-responsive genes, including the gene transcriptions for the synthesis enzymes of fatty 
acids and cholesterol (Horton et al., 2002; Ferré and Foufelle, 2007). SREBP-1c 
preferentially enhances the transcription of genes encoding for enzyme of the fatty acid 
synthesis, whereas SREBP-1a essentially increases the transcription of genes involved in the 
cholesterol synthesis (Horton et al., 2002; Ferré and Foufelle, 2007). SREBP-1c is 
predominant within the liver and other tissues but the transcriptional activity of this isoform 
is weaker than SREBP-1a. SREBP2 is ubiquitous with the same amount as the total amount 
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of SREBP-1a and -1c. SREBPs are anchored in the endoplasmic reticulum (ER) (Figure 12) 
(Bengoechea-Alonso and Ericsson, 2007; Sato, 2009; Eberlé et al., 2004). The high cytosolic 
cholesterol level sequesters SREBPs in the ER, while low cholesterol level leads to the 
transcriptional activity of SREBPs. SREBPs contain two distinct regulatory domains, the C-
terminus forming a complex with SREBP-cleavage-activating protein (SCAP) and the N-
terminus, a basic helix-loop-helix leucine zipper transcription domain necessary for 
transcription activation (Gasic, 1994; Yokoyama et al., 1993). SCAP is able to detect the 
cholesterol level via its “sterol-sensing” domain. Low cholesterol level leads to a 
conformational change of SCAP that promotes the release of the protein Insig (Sato, 2010; 
Shimano, 2001; Brown and Goldstein, 1997) and allows the transport of this complex in 
COPII-coated vesicles to the Golgi (Edwards et al., 2000; Wang et al., 1994; Xiao and Song, 
2013). In the Golgi, SREBP is processed by two sequential proteolytic cleavages, which 
releases the N-terminus transcription factor domain (Bengoechea-Alonso and Ericsson, 2007; 
Sato, 2009; Eberlé et al., 2004). First, the site-1 protease (S1P) cleaves the consensus 
sequence RxxL (Arg-X-X-Leu) in the luminal loop, then site-2 metalloprotease (S2P) cleaves 
the intramembrane sequence of SREBPs in the lipid bilayer releasing the N-terminus 
(Espenshade, 2006). A dimer of the cleaved N-terminus domain of SREBP is formed into the 
cytosol and then it is transported into the nucleus by importin-β (Lee et al., 2003). The 
transcription of lipid metabolic genes is activated by binding to the sterol regulatory element 
(SRE) promoter (Espenshade, 2006).  
The SREBP-1c gene is regulated by the nuclear transcription factor LXR. (see chapter: 
II. 6.2.2. LXR nuclear factor) (Repa et al., 2000; Yoshikawa et al., 2001). Oxysterol, 
hydrocholesterol and demosterol families are identified as potential activator ligands such as 
25-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(S),25-Epoxycholesterol, etc. (Schultz et 
al., 2000; Xiao and Song, 2013). The activation of LXR leads the regulation of LXRE 
promoter upstream to SRE promoter and also activates the genes of lipid metabolism specific 
of SREBP-1c (Yoshikawa et al., 2001). 
Recently, studies showed a link between the PD and SREBP. A genome-wide 
association study on PD cohort has identified a SNP for SREBP1 gene and more especially 
for gene coding for SBREP-1c splicing form (Do et al., 2011). The genome-wide RNAi 
screen study demonstrated that SREBP1 gene plays a conserved role in mitophagy. SREBP-1 
could stabilize PINK1 (PARK6) during the initiation of mitophagy (Ivatt et al., 2014). 
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Genistein, a blocker of SREBP activation by S1P inhibition, blocks the mitochondrial 
translocation of the E3 ubiquitin-protein ligase (PARK2, parkin). This effect is also observed 
with SREBP1 downregulation with siRNA (Ivatt and Whitworth, 2014).  
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Figure 12. The pathway of SREBP activation in the cholesterol metabolism 
Insig, insulin-induced gene 1 protein; LXR, liver X receptor; RXR, retinoid X receptor; S1P, site-1 protease; 
S2P, site-2 metalloprotease; SCAP, SREBP cleavage-activating protein; SRE, sterol regulatory element; 
SREBP, sterol regulatory element-binding protein; 
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III. 3.3.  Statins in diseases 
Statins are the main pharmaceutical drugs used for cholesterol. Mevastatin was the 
first statin identified by Endo and colleagues in 1976 and extracted from Penicillium 
Citrinium fungi (Figure 13) (Endo et al., 1976; Alberts, 1988). Later in 1980s and 1990s, 
several other statins were either extracted from other fungi or they were chemically modified 
such as lovastatin, simvastatin, atorvastatin, fluvastatin, pravastatin and cerivastatin. These 
new drug entities display a higher selectivity, affinity, lipophilicity and efficacy in patients 
and they are less hepatotoxic than mevastatin (Alberts et al., 1980; Alberts, 1990; Illingworth 
and Tobert, 1994; Jones, 2003). Statins are widely used to diminish the risk of occurrence 
(primary prevention) and recurrence (secondary prevention) of cardiovascular diseases 
resulting from the accumulation of cholesterol such myocardial infarction, angina pectoris, 
peripheral artery disease, stroke. They prevent artery narrowing and occlusion by 
atherosclerotic plaque rupture (Fuster et al., 1990; Palinski and Napoli, 2002; Taylor et al., 
2013). Thus, cardiovascular morbidity and mortality are strongly reduced with statins (Taylor 
et al., 2013; Mihos et al., 2014; Prasad, 2014). The target of statins is the competitive 
inhibition of the conversion of HMG-CoA to mevalonate by HMGCR (Goldstein and Brown, 
1990). Statins block a portion of the HMG-CoA catalytic binding site of the HMGCR (Istvan 
and Deisenhofer, 2001; Tabernero et al., 2003). Statins act principally by the inhibition of the 
HMGCR cholesterol production but also by an increase in the expression of cell surface 
LDLR via the SREBP activation (Tobert, 2003; Sirtori, 2014). The LDLR overexpression 
increases the clearance of LDL cholesterol from the blood flow ranging of 30% to 50% (Ma 
et al., 1986). In addition, based on recent preclinical and clinical researches, many beneficial 
pleiotropic effects in cardiovascular diseases are attributed to the statins which are 
independent of the cholesterol reduction (Liao and Laufs, 2005; Satoh et al., 2015; Profumo 
et al., 2014; Takemoto and Liao, 2001). Indeed, by inhibition of mevalonate synthesis, statins 
also inhibit the prenylation pathways and subsequently modulates the activity of the small 
GTPases involved in anti-inflammation, anti-oxidant and anti-thrombotic effects (see chapter: 
III. 3.1. Prenylation pathway). To summarize, statins reduce the inflammation and oxidative 
stress and activate the angiogenesis, endothelial nitric oxide synthase (eNOS) expression and 
circulating endothelial progenitor cells (EPCs). Thus, endothelial blood cells increase their 
capacity of nitric oxide production, which results in a reduction of atherogenic process due to 
an inhibition of the platelet aggregation in the thrombus, smooth muscle contraction and 
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endothelial-leukocyte interactions (Liao and Laufs, 2005; Satoh et al., 2015; Profumo et al., 
2014; Takemoto and Liao, 2001).  
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Figure 13. Chemical structures of the statins 
During the last two decades, statins have been extensively studied in other diseases 
such as autoimmune diseases (e.g. rheumatoid arthritis) and in the neurological disorders 
such as stroke, multiple sclerosis, dementia, Alzheimer’s disease and PD (Willey and Elkind, 
2010; Silva et al., 2013; McFarland et al., 2014; Roy and Pahan, 2011; Wood et al., 2014; 
Reiss and Wirkowski, 2007; van der Most et al., 2009; Wang et al., 2011; Malfitano et al., 
2014). The inhibition of prenylation pathways are proposed to mediate the pleiotropic 
neuroprotective effects in PD as proposed for the additional protective effect in 
cardiovascular diseases. In addition to the inhibition of prenylation, the activation of 
PI3K/Akt pathway by statins is commonly accepted by the research community and could 
contribute to the pleiotropic effects. However, the exact pharmacologic mechanisms leading 
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to neuroprotective remains poorly studied and could be related to the pleiotropic effects, but 
no consensus was found for neuroprotective effect of statins in PD. 
III. 3.4.  Statins and phosphoinositide 3-kinase/AKT pathway 
Many studies suggest that statins activate PI3K/Akt pathway while the mechanism is 
not identified. Indeed, statins promote rapidly and effectively the activation and 
phosphorylation of PI3K and Akt in in-vitro and in-vivo experimental models (Zhang et al., 
2007; Wu et al., 2008; Jin et al., 2012; Yang et al., 2012). PI3K mediates the activation of 
serine/threonine protein kinase AKT and involves at least three subunits Akt1/PKBa, 
Akt2/PKBb and Akt3/PKBg (Manning and Cantley, 2007; Jha et al., 2015; Hemmings and 
Restuccia, 2012; Cantley, 2002). This PI3K/Akt signalling pathway is usually activated by 
neurotrophic factors such as platelet derived growth factor receptor (PDGF-R), insulin, 
epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and insulin-like 
growth factor I (IGF-I). PI3K is a family of intracellular lipid kinases classified in groups 
(class I, II, III) and class according to signalling receptor and the substrate specificity for 
phosphatidylinositols (Manning and Cantley, 2007; Jha et al., 2015; Hemmings and 
Restuccia, 2012; Cantley, 2002). To summarize, most of phosphatidylinositols (PI and PIP2) 
are converted by PI3K to PIP3 at the plasma membrane. The PIP3 recruits and activates the 
Akt in multistep process with the coupling of 3-phosphoinositide-dependent kinase 1 or 2 
(PDK1 or PDK2) (Manning and Cantley, 2007). The activation of Akt activates or inhibits, 
by phosphorylation, potentially thousands of cellular substrates, more than 50 of them have 
been characterized so far (Manning and Cantley, 2007). Obviously, here, it is difficult to 
present all of them, but they are involved multiple cellular processes such as the regulation of 
cell survival, proliferation and insulin-dependent metabolic cell responses (Wang et al., 2012; 
Yang et al., 2004; Matsuda et al., 2013; Song et al., 2005; Shanware et al., 2013; Carracedo 
and Pandolfi, 2008). It has also been demonstrated that this pathway is implicated in the 
survival of neurons and in the reduction of neurological disorders (Jha et al., 2015; Kitagishi 
et al., 2012; Uranga et al., 2013; Brunet et al., 2001; Datta et al., 1999). 
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III. 4.  Statins in Parkinson’s disease 
III. 4.1.  Cholesterol and statins in epidemiological Parkinson’s 
disease studies 
Epidemiological studies highlighted the potential association between plasma 
cholesterol levels and the risk of PD. Higher occurrence of PD is associated with low LDL 
concentrations in a case-control study (LDL-C ≥ 138 mg/dL, OR 2.2 vs LDL-C to 115 to 137 
mg/dL, OR 3.5 vs LDL-C of 92, OR 2.6) (Huang et al., 2007). Four prospective and 
retrospective population-based studies also found a statistically signiﬁcant relationship 
between lower VLDL, LDL, HDL and triglyceride levels and an increased risk of PD (de Lau 
and Breteler, 2006; Huang et al., 2008; Wei et al., 2013; Guo et al., 2014). Reciprocally, large 
prospective study (121,046 women; 50,833 men) reported an association between a self-
reported history of hypercholesterolemia and a lower PD risk (OR 0.86) (Simon et al., 2007). 
In addition, a large prospective population-based Rotterdam study based on primary care 
database with 6,465 subjects demonstrated a link between high levels of cholesterol and a 
decreased risk of PD (OR 0.77) (de Lau and Breteler, 2006; Becker and Meier, 2009). In 
contrast, high total cholesterol is associated with an increased risk of PD in a large Finnish 
population-based prospective (total cholesterol < 5, 5–5.9, 6–6.9, and ≥ 7 mmol/L, respective 
OR 1.00, 1.42, 1.56 and 1.86) (Hu et al., 2008). Overall, an association between cholesterol 
levels and PD risk might still be inconclusive due to contradictory finding.  
Retrospective epidemiological study (312 PD patients and 342 controls) showed an 
inverse association between the use of statins and the risk of PD in a dose-response 
relationship (OR 0.37) (Wahner et al., 2008). The prospective epidemiological data analysis 
of register-based from 4.5 million of United-State veterans demonstrated a significant inverse 
association between the use of simvastatin and the risk of PD (OR 0.46) whereas atorvastatin 
is associated to a modest reduction of PD (OR 0.91) (Wolozin et al., 2007). More recently, a 
large study among 43,810 users of statins also showed a decreased of the risk of PD with 
lipophilic statins treatment such as simvastatin (lipophilic statins: OR 0.42 and simvastatin: 
OR 0.23), especially in female users (OR 0.11). But, atorvastatin had a lower significant 
effect (OR 0.42) (Lee et al., 2013). During 12 years of a follow-up study of 38,192 men and 
90,874 women, the risk of PD was lower among current statin users compared to the control 
group (OR 0.74) but only in patients aged less than 60 years (< 60 years: OR 0.31 vs > 60 
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years: OR 0.83) (Gao et al., 2012). Finally, the meta-analysis of eight studies support the 
hypothesis that statin use reduces the risk of PD (OR 0.77) (Undela et al., 2013). 
Different results have been found in epidemiological studies, certainly due to the 
study-related factors such as metholody, population sizes, PD diagnosis, type and dose of 
statins (Table 7) (Reiss and Wirkowski, 2007; Willey and Elkind, 2010; Dolga et al., 2011; 
Roy and Pahan, 2011; Wang et al., 2011; Malfitano et al., 2014).  
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Table 7. Statins - general and clinical pharmacology - Parameters related to blood-brain barrier penetration and lipophilicity 
 
Pharmacodynamics - pharmacokinetics 
pharmacology parameters 
Brain pharmacokinetics - permeability 
Statins 
IC
5
0
 H
M
G
-C
o
A
 
re
d
u
ct
a
se
 (
n
M
) 
O
ra
l 
a
b
so
rp
ti
o
n
 (
%
) 
B
io
a
v
a
il
a
b
il
it
y
 (
%
) 
L
iv
er
 e
x
tr
a
ct
io
n
 (
%
) 
P
ro
te
in
 b
in
d
in
g
 (
%
) 
H
a
lf
-l
if
e 
(t
1
/2
) 
(h
) 
M
et
a
b
o
li
sm
 C
Y
P
4
5
0
 
S
ta
ti
n
s 
tr
a
n
sp
o
rt
er
 
in
v
o
lv
ed
 
S
ta
n
d
a
rd
 d
a
il
y
 d
o
se
 
(m
g
) 
L
o
g
P
 
P
A
M
P
A
 a
ss
a
y
  
(%
 c
ro
ss
in
g
) 
Cholesterol levels after 1µM 
statins treatment  
(% related untreated cells) 
Rat blood-brain-barrier 
permeability (µL/min/cm²) 
[14C]-statins 
LogD 
coefficients 
Neuron 
cells  
(SK-N-
MC) 
Glial cells 
(U87MG) 
Hepatic 
cells 
(Hep-
G2) 
Lactone 
form 
Acid 
form 
Lactone 
form 
Acid 
form 
Lactone 
form 
Acid 
form 
Pravastatin 4 35 18 45 50 1-3 3A4 
OATPB1 / 
MRP2 
10-40 3.06 0 89 103 107 0.178 0.0755 2.42 -0.47 
Lovastatin 3 30 5 70 >98 2-5 3A4 OATP1B1 10-40 4.09 10.8 73 100 88 57.9 0.653 8.32 0.193 3.91 1.51 
Simvastatin 1.2 72 5 80 >95 2-5 3A4 MRP2 10-40 4.63 33 47 72 91 27.7 0.442 4.76 0.42 4.4 1.88 
Fluvastatin 6.5 98 30 70 >98 1-3 2C9 OATP1B1 80 4.18 28 55 92 91 
n/d 
3.65 1.75 
Atorvastatin 1.16 30 12 70 >98 7-20 3A4 OATP1B1 10-80 5.55 4.9 59 103 90 4.4 1.53 
Rosuvastatin 0.16 50 20 63 90 20 2C9 OATP1B1 5-40 2.29 0.1 63 91 87 
n/d 
Pitavastatin 0.1 80 60 n/d 96 10-13 2C9 
OATPB1 / 
MRP2 
1-4 4.58 12.7 60 92 87 
LogP, partition-coefficient and LogD: distribution-coefficient (D): ratio of concentrations of statin in a mixture of two immiscible phases at equilibrium (octanol/eau). 
These coefficients are a measure of the difference in solubility and lipophilicity. LogD take into account the pKa of the compound 
PAMPA: parallel artificial membrane permeability assay, determines the permeability of substances from a donor compartment through lipid-infused artificial 
membrane into an acceptor compartment 
Adapted from (Hsiang et al., 1999; van der Most et al., 2009; Sierra et al., 2011; Wood et al., 2014). n/d, not determine. 
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III. 4.2.  Statins and their effects in Parkinson’s disease models 
III. 4.2.1.  Neuroprotective effects of statins 
III. 4.2.1.1.  Inhibition of proinflammatory process 
Statins could modulate the proinflammation process though the PI3K/Akt and 
prenylation pathways (Greenwood et al., 2006; Kitagishi et al., 2012). In PC12 cells, 
simvastatin treatment protects cells against 6-OHDA toxicity and downregulates the 
proinflammatory factors such as TNF-α, IL-6 and COX-2, probably though the activation of 
PI3K/Akt pathway (Xu et al., 2013). Moreover, this reduction of proinflammatory activation 
as well as the protective effect are confirmed in two other studies by measuring the mRNA 
reduction of the TNF-α, IL-1β, and IL-6 and MMP9 in PC12 treated with 6-OHDA (Yan et 
al., 2014a, 2014b). In lipopolysaccharide (LPS)–stimulated rat primary astrocytes, lovastatin 
is able to inhibit the activation of NF-κB, the expression of iNOS and proinflammatory 
cytokines (TNF-α, IL-1β, and IL-6) (Pahan et al., 1997). In addition, simvastatin inhibits the 
production of TNF-α and nitric oxide in cultured rat microglia stimulated with the LPS 
(Selley, 2005). The reduction of iNOS and the inhibition of NF-κB triggered by statins can be 
reverted with the addition of mevalonate or FPP, whereas the proinflammation inhibition 
effect with lovastatin remains unchanged with the cholesterol treatment (Pahan et al., 1997). 
Overall, these results suggest the involvement of prenylation pathway rather than cholesterol 
pathway in the reduction of proinflammatory response by the statins. Moreover to support 
previous data, the FTase inhibitors suppress also the activation of NF-κB and expression of 
iNOS induced by the LPS treatment in glial cells (Pahan et al., 1998, 2000). In addition, 
simvastatin can block the activation NF-κB and p21Ras (a apoptotic and proinflammatory 
factor) induced with MPP
+
 in microglia (Ghosh et al., 2009). In MPTP treated mice, 
simvastatin is able to strongly inhibit the synthesis of proinflammatory components and the 
activation of p21
Ras
 the substantia nigra (Ghosh et al., 2009). Moreover, TNF-α and IL-6 is 
reduced by simvastatin and atorvastatin treatments in the 6-OHDA PD model (Kumar et al., 
2012). Together, these studies suggest that statins are capable to suppress the expression of 
proinflammatory cytokines, chemokines, adhesion molecules in glial cells and PD models via 
attenuation of prenylation and/or PI3K/Akt pathways. Thus, the anti-inflammatory effect of 
statins may be beneficial for neuroprotection in PD patients (van der Most et al., 2009) 
. 
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III. 4.2.1.2.  Reduction of oxidative stress 
Some evidence suggests that statins induce a reduction of oxidative stress. 
Simvastatin inhibits the formation of ROS such as 3-nitrotyrosine in MPTP-treated mice. 
Statins inhibit geranylgeranylation of Rac and thereby can attenuate the NADPH oxidase-
mediated generation of ROS (Di-Poï et al., 2001; Miyano and Sumimoto, 2012). In 6-OHDA 
treated rat, atorvastatin and simvastatin are able to decrease the glutathione which is an 
antioxidant produced in ROS oxidative stress conditions (Kumar et al., 2012). Thus, the 
decreased of glutathione suggests a reduction of oxidative stress induced by the ROS. 
Supporting this data, lipid peroxidation referring to the oxidative degradation of lipids is 
reduced by atorvastatin. Therefore, statins may provide neuroprotection in PD by inhibiting 
NADPH oxidase, lipid peroxidation and ROS (Zacco et al., 2003; Reiss and Wirkowski, 
2009; Ramirez et al., 2011).  
III. 4.2.1.3.  Protection against neurotoxic agents 
In MPTP treated mice, simvastatin restores the level of biogenic amines (dopamine, 
DOPAC and HVA) in the striatum, independently of the brain cholesterol level. Moreover, 
high dose of simvastatin is able to produce more biogenic amines than the control (Selley, 
2005). In MPTP-intoxicated mice, simvastatin and pravastatin improve motor functions 
(Ghosh et al., 2009). In contrast, other studies fail to demonstrate a neuroprotective effect of 
simvastatin against MPTP-induced death of dopaminergic neurons (Santiago et al., 2009). 
Moreover, ﬂuvastatin or pitavastatin treatments display no significant changes in the 
neuroprotection in the MPTP model (Yokoyama et al., 2008). However, in 6-OHDA rat 
model, atorvastatin and simvastatin enhance mitochondrial complex I and III activity and 
restore locomotor activity, which increases the cell survival (Kumar et al., 2012). The 
protective effect of simvastatin in 6-OHDA model has been confirmed by the observation of 
a higher proportion of TH positive cells in the substantia nigra and by the restoration of 
expression level of NMDA receptor measured by the autoradiography binding of [
3
H]MK-
801 (Yan et al., 2011a). Lovastatin also protects against glutamate-induced toxicity in primary 
cortical neurons by activating the TNF receptor 2 (TNFR2) signalling pathway which is 
involved in the activation of PI3K/Akt pathway (Zacco et al., 2003; Dolga et al., 2008). In 
addition, lovastatin rescues cholinergic neuron and projection fibers after NMDA infusion 
injury in rodents. The PI3K/Akt pathway is proposed to mediates this protective effect (Dolga 
et al., 2009).  
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III. 4.2.1.4.  Inhibition α-synuclein aggregation 
 Statins induce a redistribution of α-synuclein in caveolar fractions (a special type of 
lipid raft) in primary neuronal culture and decrease the α-synuclein accumulation and 
oxidation (Bar-On et al., 2008). In contrast, cholesterol supplementation promotes α-
synuclein aggregation and reduces the neuronal outgrowth (Fortin et al., 2004). More 
importantly, lovastatin has also been investigated in-vivo mice overexpressing α-synuclein 
(Koob et al., 2010). A high lovastatin dose in these mice reduces significantly the oxidized 
cholesterol metabolites involved in the aggregations of α-synuclein. Thus, lovastatin reduces 
the neuronal degeneration and restores the locomotor dysfunction in mice overexpressing α-
synuclein. Moreover, the reduction of oxidative stress by statin could also help to reduce α-
synuclein aggregation (Esteves et al., 2009). Bosco and colleagues suggest that the oxidized 
cholesterol accelerates α-synuclein fibrillization and it is accumulated in the Lewy bodies, 
thus, it could contribute negatively to α-synucleinopathy (Bosco et al., 2006). 
III. 4.2.1.5.  Endothelial nitric oxide synthase (eNOS) activation 
eNOS activation could be beneficial for PD by the capacity of eNOS to produce 
endothelium-derived nitric oxide (Tieu et al., 2003). It increase blood flow and endothelium 
relaxation in the brain (Dimmeler et al., 1999). The eNOS knockout mice are more sensitive 
to MPTP intoxication than the wild-type mice. However, currently, no data are available on 
the relationship between eNOS and PD. As mentioned before, statins reduce the expression 
of iNOS, while the opposite effect is found for eNOS associated to higher production of NO 
(Hernández-Perera et al., 2000). GGPP but not FPP is able to abolish the induction of eNOS 
by the statins suggesting a RhoA involvement in statin-induced eNOS (Hernández-Perera et 
al., 1998). However, Fulton and colleagues demonstrated that the PI3K phosphorylates eNOS 
and increases the production of nitric oxide (Fulton et al., 1999). Thus, statins may upregulate 
eNOS via the RhoA or PI3K/Akt pathways, which could have beneficial effect in PD 
patients. 
III. 4.2.1.6.  Modulation of synaptic proteins  
The treatment of 6-OHDA deregulates the expression and function of D1R and D2R 
in the striatum (Qin et al., 1994). In this context, simvastatin increase the level of D1R and 
D2R in normal condition but also restores the level both receptors in 6-OHDA-induced PD 
rats (Wang et al., 2005). In the same condition, brain tissue from striatum treated with 
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simvastatin presents higher-level of dopamine content up to 110%. However, dopamine 
uptake remains unchanged in the synaptosomal preparation (Wang et al., 2006). Regarding 
other synaptic markers, the reduction TH and DAT expressions induced 6-OHDA treatment 
levels are partially reverted by simvastatin in PC12 cells (Xu et al., 2013). Besides the 
activation of lipidic and metabolic gene expressions, the chronic administration of lovastatin, 
pravastatin and simvastatin can upregulate the gene expressions of many other cellular 
processes (Johnson-Anuna et al., 2005; Dong et al., 2009). Interestingly, lovastatin treatment 
enhances the expression of SV2A more than 10 fold in non-neuronal HepG2 cells. This result 
correlates with the transcriptional upregulation of SV2A up to 40 fold induced by SREBP-1 
overexpression in HepG2 and human fibroblast AG01518 cells transfected (Kallin et al., 
2007). In addition, downregulation of SREBP-2 with shRNA lentivirus infection reduces the 
intensity of the postsynaptic density 95 (PSD95) and synaptobrevin expression levels in 
dendrites of hippocampal neurons (Suzuki et al., 2010).  
III. 4.2.2.  Neurorestoration effects of statins 
Statins are also investigated for their disease-modifying potential in several 
neurological disorders such as epilepsy, multiple sclerosis and Alzheimer’s disease 
(Dimmeler et al., 2001; McGuinness et al., 2014; Malfitano et al., 2014). In stroke model, 
statins are associated to a potential dual effect of neuroprotection and neurorestoration during 
and after ischemic injury respectively. It has been suggested that statins may improve 
neurological function in a rat model of stroke by an action on neurogenesis promotion, 
angiogenesis and synaptic plasticity (Chen et al., 2003, 2005c; Chen and Chopp, 2006). 
Besides a possible beneficial effect due to proinflammatory reduction and eNOS activation in 
stroke model, statin treatments increase the secretion of beneficial various growth factors 
such as vascular endothelial growth factor (VEGF), brain derived neurotrophic factor 
(BDNF) and tissue plasminogen activator (tPA) (Chen et al., 2005c). In an in-vitro model, 
statins protected cortical neurons from excitotoxicity and increase the neurite outgrowth and 
synaptogenesis (Zacco et al., 2003; Pooler et al., 2006). Several studies have recently shown 
the capacity of statins to promote neurogenesis and to improve spatial learning after traumatic 
brain injury of the dentate gyrus (C3) in the hippocampus (Robin et al., 2014). Although the 
mechanism leading to neurorestoration is not fully understood, PI3K/Akt activation and 
prenylation inhibition of signalling molecules such as the RhoA and neurotrophic factor 
synthesis may be responsible of these improvements (Zheng and Chen, 2007; Wu et al., 
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2008; Lu et al., 2007). These preclinical data of statin treatment in stroke model are in line 
with the epidemiological studies. Statins diminish the severity and apparition of stroke but 
also help to recover after an acute ischemic stroke (Choi et al., 2015a). 
Neurogenesis and growth of neurites induced by statin treatments have been also 
observed in in-vitro using different cell lines. Neuronal cells treated with statins showed an 
enhancement of neurite sprouting in SH-SY5Y cells (Hughes et al., 2010; Raina et al., 2013), 
PC12 (Fernández-Hernando et al., 2005), neuro2A (Evangelopoulos et al., 2009; Watanabe et 
al., 2012), B35 rat neuroblastoma cells (Samuel et al., 2014) and primary culture s(Pooler et 
al., 2006; Jin et al., 2012).  
Moreover, mevalonate, GPP and FPP blocks the neurite growth induced by 
atorvastatin and pravastatin in neuro-2A and PC12 cells (Fernández-Hernando et al., 2005; 
Evangelopoulos et al., 2009; Watanabe et al., 2012). All these substrates are the upstream 
activators of RhoA pathway and ROCK, which leads to neurite stabilization. Statins, but not 
GPP, reduces the activated form RhoA-GTP and cofilin in hippocampal primary neuron 
culture, PC12 and B35 cells (Schulz et al., 2004; Fernández-Hernando et al., 2005; Pooler et 
al., 2006; Samuel et al., 2014). Interestingly a recent study using various cholesterol-blocker 
agents such as cholesterol scavenger (mβCD), inhibitor of cholesterol transport (U18666A), 
cholesterol intercalater (α-lysophosphatidylcholine) and cholesterol binding probe (filipinIII) 
have suggested that cholesterol is necessary for neurite growth (Raina et al., 2013). In 
addition, atorvastatin-induced neurite growth in cortical primary culture can be reduced by 
the PIK3 inhibitor (LY294002) and downstream inhibitors of PI3K pathway such as MEK 
(U0126 and PD98059), mTOR (rapamycin), Akt (triciribine) and GSK3β (SB415286) 
inhibitors (Jin et al., 2012a). 
All these data suggest that modulation of RhoA and PI3K/Akt pathways by statins 
may be involved in the growth and stabilization of neurites. Although there is no consensus, 
these complex modulations suggest a potential disease-modifying therapies for PD involving 
neuroprotection and neurorestoration mechanisms (Figure 14) (Paul et al., 2015; Roy and 
Pahan, 2011; Reiss and Wirkowski, 2007; Ramirez et al., 2011). 
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Figure 14. Hypothetical schematic overview of some pleiotropic mechanisms depicting 
the neuroprotection of statins in Parkinson’s disease. 
COX2, cyclooxygenase 2; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; IL, 
interleulin; NF-κB, nuclear factor-kappa B; NO, nitric oxide ; P21ras, proto-oncogene Proteins p21(ras); PI3K, 
phosphoinositide 3-kinase; RhoA, ras homolog gene family, member A; ROCK, rho-associated protein kinase; 
TNF, tumor necrosis factor; 
Principal objectives 
103 
Principal objectives  
The treatment of motors symptoms in PD has been successfully achieved by the 
therapies addressing the substitution of dopamine deficits such as L-Dopa and dopamine 
receptor agonists. However, the progressive neurodegeneration taking place during the course 
of the disease as well as side effects of drug treatments represent a major unmet medical 
need. Last decade a major effort has been focused in finding a treatment to slow down 
neurodegenerative mechanisms or to restore lost neuronal systems. Unfortunately, no disease-
modifying treatment is available for PD patients so far. Recent epidemiological and 
preclinical studies on statins have highlighted a potential neuroprotective effect in PD, 
however the understanding of the neuroprotective mechanism/s triggered by these molecules 
remain undisclosed.  
Although a few studies have demonstrated a modulation of the dopaminergic system 
and synaptic markers, there is no result on a neurorestorative component of the statin as 
proposed for other neurological disease (e.g. stroke, spinal cord injury). The cholesterol 
metabolism is the primary action of statin, however several downstream pathways have been 
recently identified and suggest a complex action on mechanism involved in neuroprotection 
and neuroregeneration. It has been found that statins impact biological pathways (e.g. RhoA 
and PI3K/Akt) controlling the formation and integrity of cytoskeleton and the induction 
neurite growth. Moreover, statins affect the cholesterol-dependent SREBP-1 pathway that 
controls gene transcription. While above studies indicate that statins may be involved in 
neuroregeneration, the specificity of these actions as well as their role in controlling neuronal 
phenotype remains poorly understood. Few studies have demonstrated a statin-induced 
modulation of the dopaminergic system, however the impact in the expression of presynaptic 
dopaminergic markers and their function remain rather unknown. This knowledge represents 
an important element of validation of the therapeutic potential of statin for the treatment of 
PD.  
In this context, present project aimed to investigate the effects of statins in the 
presynaptic dopaminergic system as well as the downstream pathways potentially involved in 
neuroprotection and neuroregeneration. The objective of the studies was also to determine the 
potential functional impact of statins in the dopamine transport system, a key element of the 
neuropathological process-taking place in PD. Using SH-SY5Y neuroblastoma cells, a 
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neuronal cell line with a mild dopaminergic phenotype, we have investigated the statin effects 
in the expression of presynaptic dopaminergic markers, the genesis of synaptic elements, the 
functional changes of dopamine transport.  
1. Study of statin-induced neurite growth, identification of downstream pathways 
and potential specific effects compared to other modulators of this 
neuroregenerative mechanism including RhoA- and PI3K/Akt-pathway inhibitors. 
2. Determination of the effect of statins on the phenotypic differentiation towards the 
dopaminergic pathways. The study aimed to analyse the protein levels and gene 
transcriptions of dopaminergic presynaptic markers including DAT, VMAT2, 
SYNGR3, SV2A, SV2C and TH.  
3. Investigation of the impact of statin treatments in the functionality of the cellular 
dopamine transport system with particular focus on the changes in dopamine 
transport capacity associated to DAT and VMAT2 activities.  
4. Study of statin-induced modulation of SREBP-1 in SH-SY5Y neuroblastoma 
cells. This part aimed to determine the potential role of this cholesterol-dependent 
pathway in the actions of statins in the dopaminergic system of the SH-SY5Y 
cells. 
Overall, present project aimed to contribute to the validation of the therapeutic 
potential of statins for the treatment of PD by investigating cellular and molecular effects of 
these compounds and the downstream mechanism modulating the dopaminergic presynaptic 
system. 
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Results and discussion 
IV.  Harnessing the trophic and modulatory potential of 
statins in a dopaminergic cell line 
IV. 1.  Abstract 
The identification of an effective disease-modifying treatment for the 
neurodegenerative progression in Parkinson's disease (PD) remains a major challenge. 
Epidemiological studies have reported that intake of statins, cholesterol lowering drugs, could 
be associated to a reduced risk of developing PD. In-vivo studies suggest that statins may 
reduce the severity of dopaminergic neurodegeneration. We have investigated the trophic 
potential of statins and their impact on the expression of dopaminergic synaptic markers and 
dopamine (DA) transport function in SH-SY5Y cells. Our findings show that statin treatment 
induces neurite outgrowth involving a specific effect on the complexity of the neurite 
branching pattern. Statins increased the levels of presynaptic dopaminergic biomarkers such 
as vesicular monoamine transporter 2 (VMAT2), synaptic vesicle glycoproteins 2A and 2C 
(SV2C) and synaptogyrin-3 (SYNGR3). Gene expression analysis confirmed a rapid statin-
induced upregulation of VMAT2-, SV2C- and SYNGR3-mRNA levels. Assessment of 
[
3
H]DA transport in statin-treated cells showed a reduction in DA uptake concomitant to a 
modification of VMAT2 pharmacological properties. We also observed a nuclear 
translocation of the sterol regulatory element-binding protein 1 (SREBP-1). Our results 
suggest that statins induce phenotypic changes in dopaminergic cells characterized by an 
increase in growth, complexity of structural synaptic elements and expression of key 
presynaptic proteins with functional impact on the DA transport capacity. Statin-induced 
changes are likely the result of a downstream modulation of SREBP-1 pathway. Overall, these 
mechanisms may contribute to the neuroprotective or neurorestorative effects observed in the 
dopaminergic system and strengthen the therapeutic potential of statins for PD. 
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IV. 2.  Introduction 
Epidemiological studies have identified an association between the use of statins and a 
diminished risk for developing Parkinson's disease (PD) (Wolozin et al., 2007; Wahner et al., 
2008; Gao et al., 2012; Lee et al., 2013) or Alzheimer's disease (Li et al., 2012), thereby 
suggesting the therapeutic potential of statins in neurodegenerative diseases. The precise 
molecular mechanism by which statins may decrease the risk of PD is however not yet 
understood. 
Statins might have neuroprotective effects through different molecular pathways. 
Several studies demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase partially prevented neuronal degeneration in-vitro and in animal 
models of PD. Compelling data showed that statins are able to prevent the neurodegenerative 
effects induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Ghosh et al., 2009; 
Castro et al., 2013) and 6-hydroxydopamine (6-OHDA) (Yan et al., 2011a; Xu et al., 2013) 
treatment and to dampen α-synuclein-induced toxicity (Bar-On et al., 2008; Koob et al., 
2010). Statins have been reported to induce restoration of mitochondrial enzyme complex and 
upregulation of endothelial nitric oxide synthase as well as reduction of proinflammatory 
responses such as cytokine releases, nuclear factor kappa-B activation and inducible nitric 
oxide synthase expression (Ghosh et al., 2009; Roy and Pahan, 2011; Kumar et al., 2012; Xu 
et al., 2013). 
In addition to the neuroprotective potential, statins might also stimulate 
neurorestoration by promoting neurogenesis in rat dentate gyrus (Lu et al., 2007; Robin et al., 
2014) and neurite growth in rat cortical and hippocampal primary neuronal cultures (Pooler et 
al., 2006; Jin et al., 2012) and also in different neuronal cell lines such as PC12 (Sato-Suzuki 
and Murota, 1996; Schulz et al., 2004), SH-SY5Y (Raina et al., 2013) and neuro-2A 
(Evangelopoulos et al., 2009; Watanabe et al., 2012). The precise molecular mechanisms for 
these statin-induced actions remain unclear but it has been suggested that Phosphoinositide 3-
kinase (PI3K)/Akt and ras homolog gene family, member A (RhoA) signaling pathways 
might play a role in statin-induced neurite growth (Schulz et al., 2004; Evangelopoulos et al., 
2009; Jin et al., 2012; Raina et al., 2013; Samuel et al., 2014). Inhibition of HMG-CoA 
reductase by statins leads to inhibition of the mevalonate pathway and cholesterol synthesis. 
Subsequently, decreasing cholesterol levels will induce the maturation of the transcription 
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factor sterol regulatory element-binding protein (SREBP) and its nuclear translocation (Kallin 
et al., 2007; Shao and Espenshade, 2012). Although the transcription activity of SREBP up-
regulates expression of multiple genes involved in fatty acid and cholesterol metabolism (Kim 
and Spiegelman, 1996; Shimano et al., 1999; Shao and Espenshade, 2012), SREBP is also 
able alter the regulation of expression of neuronal markers (Kallin et al., 2007; Suzuki et al., 
2010). For example, ectopic overexpression of SREBP-1 induced a clear mRNA increase in 
the synaptic vesicles glycoprotein 2A (SV2A) up to 40 folds which correlates to the increase 
induced with statin treatment in non-neuronal cells (Kallin et al., 2007).  
Based on these data, statins have been proposed to be potential disease-modifying 
drugs for PD (Reiss and Wirkowski, 2007; van der Most et al., 2009; Wang et al., 2011; 
Malfitano et al., 2014). However, direct or indirect effects of statins on the dopaminergic 
system, the most affected neurotransmitter system in PD (Lotharius and Brundin, 2002), 
remain poorly characterized. In this context, we have investigated in-vitro effects of statins on 
growth, phenotypic changes and the impact on dopamine (DA) transporter system in 
dopaminergic SH-SY5Y cells. 
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IV. 3.  Materials and methods 
IV. 3.1.  Materials 
SH-SY5Y (CRL-2266) and BE(2)-M17 (95011816) cells were obtained from ATCC 
(American Type Culture Collection, Molsheim, France) and ECACC (European Collection of 
Cell Cultures, Salisbury, UK), respectively. Reagents for cell cultures and Hank's balanced 
salt solution (HBSS) were purchased to Lonza (Verviers, Belgium). Coating reagent poly-D-
lysine and collagen were from Sigma-Aldrich (Diegem, Belgium) and Corning (Lasne, 
Belgium) respectively. Primary antibodies were βIII-tubulin (MMS-435P or PRB-435P) from 
Covance (Rotterdam, Netherlands), tyrosine hydroxylase (TH; AB152) from Millipore 
(Overijse, Belgium), synaptogyrin-3 (SYNGR3; sc-271046) from Santa Cruz Biotechnology 
(Dallas, TX, USA), SREBP-1 (SAB4502850), dopamine transporter (DAT; D6944) and β-
actin (A3853 and A2066) from Sigma-Aldrich, SV2A (119 002), synaptic vesicle 
glycoprotein 2C (SV2C; 119 202) and vesicular monoamine transporter 2 (VMAT2; 138 302) 
from Synaptic Systems (Goettingen, Germany). Secondary antibodies were from Life 
Technologies (Alexa Fluor 488- and 647-conjugated goat anti-mouse and/or anti-rabbit IgG; 
Gent, Belgium) or LI-COR (IR-dye 680RD or with 800CW donkey anti-mouse and/or anti-
rabbit; Leusden, Netherlands) for immunocytochemistry and western blotting, respectively. 
DAPI, Lipofectamine 2000, high capacity cDNA reverse transcription kit with MultiScribe 
MuLV transcriptase, Luminaris probe qPCR master mix (low ROX), TaqMan PCR probe 
(FAM-MGB), Pierce bicinchoninic acid (BCA) protein assay, reagent used for protein 
electrophoresis and serum for cell cultures were from Life Technologies. CellLytic-M, DA, L-
ascorbic acid, pargyline, reserpine were purchased to Sigma-Aldrich. Atorvastatin, GBR-
12935, fluvastatin, lovastatin, LY-294,002, pravastatin, simvastatin, tetrabenazine, Y-27632, 
wortmannin were purchased to Tocris (Abingdon, UK). Microscint-20 and 
dihydroxyphenylethylamine,3,4-[ring-2,5,6-3H] ([
3
H]DA, NET673; 34.8 Ci/mmol) were from 
Perkin Elmer (Zaventem, Belgium). 
IV. 3.2.  Cell cultures and drug treatments 
SH-SY5Y and BE(2)-M17 neuroblastoma cells were cultured in Dulbecco's modified 
Eagle medium (DMEM) supplemented with 10% (v/v) of FBS and maintained in a humidified 
incubator with 95% air and 5% CO2 at 37 °C. For immunocytochemistry, the cells were 
seeded (15 x 10
3
) 24 h before the studies on poly-D-lysine and collagen mix pre-coated 96-
well plates. The seeding cell density for DA functional transport was 50 x 10
3
 and 17 x 10
3
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cells per well for SH-SY5Y and BE(2)-M17 cells respectively. For gene expression studies, 
SH-SY5Y cells were plated in 48-well plates at 160 x 10
3
 cells per well for gene expression 
and in 6-well plates at 1.5 x 10
6
 for western blot analysis. The cells were stimulated with 
pharmacological agents by incubation (24 h and 48 h) alone or in combination with single or 
multiple increasing doses. 
IV. 3.3.  Immunocytochemistry and High-content image analysis 
The effects of pharmacological treatments on protein expression and neurite growth 
were analysed by immunofluorescence method using antibodies against the synaptic markers. 
Briefly, cells were washed with PBS followed by fixation with 4% paraformaldehyde for 30 
min (room temperature) and permeabilization (triton X-100 0.05% - 10 min). The non-
specific binding was blocked with blocking solution (3% of BSA and 5% of normal goat 
serum in PBS) for 1 h. The cells were incubated overnight at 4 °C with primary antibodies 
against DAT (1:500), SREBP-1 (1:500), SV2A (1:500), SV2C (1:500), SYNGR-3 (1:100), 
TH (1:500), VMAT2 (1:500) or βIII-tubulin (1:3000) in blocking solution. After washing (4 x 
5 min), the cells were incubated with species-specific corresponding secondary antibodies 
labelled with Alexa Fluor 488 or 647 in blocking solution. Nuclear counterstaining was 
performed by incubation with DAPI and by further washing steps (5 x 5 min). 
 Immunofluorescence signal was analysed using a high-content imaging microscopy 
system (BD Pathway-855 Bioimager System using BD Attovision software, Becton-
Dickinson, Erembodegem, Belgium) in PBS medium. Series (2 by 3) of images were acquired 
in 3 non-superposing image fields per well using a 20x objective (0.75NA, Olympus, 
Berchem, Belgium). The neurite length, the fluorescent intensity of neuronal markers and 
nuclear translocation were analysed using a specific image analysis algorithms developed 
using Cellenger software package (Definiens, München, Germany). Neurite growth was 
determined using parameters of neurite length and number previously classified as primary or 
secondary neurite. Number of nodes was also used as surrogate parameter of neurite 
branching. Cytoplasmic and nuclear intensity parameters were used for determination of 
protein levels and nuclear translocation. Both quantifications use the cell 
compartmentalization defined by segmentation of the nucleus and cytoplasm and nucleus 
using DAPI and βIII-tubulin staining respectively. For quantification of protein levels, the 
relative intensity of cytoplasm was measured and the background value was subtracted to the 
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results. The nuclear translocation was measured by quantification of the nuclear/cytoplasmic 
intensity ratio. 
IV. 3.4.  Western blot analysis 
 Cells were rinsed with PBS and lysed by 30 min incubation with CellLytic-M 
containing cOmplete protease inhibitor cocktail (Roche Diagnostics, Vilvoorde, Belgium) at 4 
°C. The cell lysates were centrifuged at 15,000 g for 20 min at 4 °C and supernatants were 
used for western blotting. Protein levels were determined with BCA kit and electrophoresis 
was performed using 30 µg of denatured (95 °C, 10 min) cell lysates in loading buffer (62.5 
mM Tris-HCl pH 6.8, 2 mM EDTA, 10% glycerol, 2% SDS, 0.002% bromophenol blue, 100 
mM DTT). Proteins were separated (2 h, 140V) in 4 to 12% SDS-Polyacrylamide gradient gel 
in NuPAGE MES SDS running buffer. Proteins were transferred onto PVDF membranes 
(Millipore, 0.45 µm) at 25V for 30 min in NuPAGE transfer buffer. PDVF-membranes were 
saturated (1 h) in LI-COR blocking buffer and incubated overnight (4°C) with primary 
antibodies in blocking buffer: SV2A (1:1,000), SV2C (1:1,000), DAT (1:1,000), SYNGR3 
(1:200), VMAT2 (1:1,000) and β-actin (1:5,000). After washing (3 x 15 min) with PBS-tween 
0.1% (PBST), the membranes were incubated (1 h) with secondary antibodies in blocking 
buffer. Protein bands were analysed after washing steps (3 x 15 min, PBST) by densitometry 
using a LI-COR Odyssey
 
CLX scanner. Relative protein levels were calculated after 
normalization to β-actin levels in the same sample. 
IV. 3.5.  Quantitative real-time polymerase chain reaction (qRT-
PCR) 
Total cellular RNA was isolated using the RNeasy mini kit (Qiagen, Venlo, 
Netherlands) according to the manufacturer's protocol. Briefly, cDNA was synthetized from 
1.5 µg of total RNA using high capacity cDNA reverse transcription kit
 
(20 µl). The 
quantitative real-time PCR experiments were performed using specific TaqMan gene 
expression probes for SV2A (Hs00372069_m1), SV2C (Hs00392676_m1), SREBP1 
(SREBF1; Hs01088691_m1), SREBP2 (SREBF2; Hs01081784_m1), SYNGR3 
(Hs00188379_m1), VMAT2 (SLC18A2; Hs00996835_m1), TH (Hs00165941_m1), DAT 
(SLC6A3; Hs00997364_m1) and β-actin (ACTB; Hs99999903_m1). The reactions were 
performed in ViiA 7 RT-PCR system (Applied Biosystems) using 25 ng of cDNA sample and 
the recommended concentration of the specific probe and qPCR master mix Luminaris. PCR 
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reactions were run in triplicate and the fold-changes in mRNA levels were calculated using 2
-
∆∆Ct
 method (Schmittgen and Livak, 2008) and normalized to β-actin mRNA levels. 
IV. 3.6.  Dopamine transport assay 
DA transport assay was determined according to Janowsky et al. protocol (Janowsky 
et al., 2001) with minor modifications. Briefly, the cell culture medium was replaced by 
HBSS (pH 7.4) containing 10 mM HEPES, 10 µM pargyline and 1 mM L-ascorbic acid. The 
transport was initiated by adding 12.5 nM [
3
H]DA in incubation buffer. Cells were incubated 
for 15 or 60 minutes in transport buffer and DA uptake was stopped by adding 300 µl of cold 
HBSS at 4°C. Buffer was quickly removed by aspiration. The incorporated radioactivity was 
determined by adding Microscint-20 scintillation liquid (50µl) and reading using TopCount 
NXT microplate luminescence and scintillation counter (Perkin Elmer). For transport 
inhibition experiments, cells were pre-incubated (30 min) with selected compound GBR-
12935, reserpine or tetrabenazine. For kinetic studies, cells were incubated with increasing 
concentrations (0.1-3 µM) of DA in presence of 50 nM of [
3
H]DA. Non-specific DA uptake 
was subtracted to the results and determined by incubation of cells with radioligand in the 
presence of 30 µM GBR-12935. The total protein concentration was measured using the BCA 
kit. 
IV. 3.7.  VMAT2 transient transfections 
Human VMAT2 cDNA was subcloned into the expression vector pcDNA3.1(+) 
(Invitrogen, Gent, Belgium) by double digestion of HindIII and KpnI enzymes by Genscript 
(Piscataway, NJ, USA). For inducing VMAT2 overexpression, cells were transfected with the 
plasmid 1.25 µg/ml of pcDNA3.1-VMAT2-Hu prepared in Lipofectamine 2000 (2 µg/ml). 
Plasmid solution and Lipofectamine 2000 were pre-diluted separately for 5 min in serum free 
medium and mixed for 30 min before to be added into the well. Cells were used 72 h after 
transfection. 
IV. 3.8.  Data analysis 
Results are presented as means ± S.E.M. from a minimum of three independent 
experiments in duplicate or triplicate unless otherwise stated. Data were analysed with 
GraphPad Prism software (La Jolla, CA, USA) using either Student's t-test or ANOVA with 
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Bonferroni's post hoc test. P<0.05 was considered significant to assess the difference between 
conditions. Half maximal effective concentration (EC50) or inhibitory concentration (IC50), 
maximal effect (Emax) or inhibition effect (Imax), Hill coefficient (nH) and basal level 
pharmacological parameters were generated with nonlinear regression and fitted to four-
parameter logistic curve (4PL); 
𝑌 = 𝑏𝑎𝑠𝑎𝑙 𝑙𝑒𝑣𝑒𝑙 +
𝑚𝑎𝑥𝑖𝑚𝑎𝑙 𝑒𝑓𝑓𝑒𝑐𝑡 − 𝑏𝑎𝑠𝑎𝑙 𝑙𝑒𝑣𝑒𝑙
1 + 10(𝐿𝑜𝑔𝐸𝐶50 𝑜𝑟 𝐼𝐶50−𝑋)𝑛𝐻
 
and normalized equation; 
𝑌 =
100
1 + 10(𝐿𝑜𝑔𝐸𝐶50 𝑜𝑟 𝐼𝐶50−𝑋)𝑛𝐻
 
The Michealis-Menten kinetics equation was applied to calculate the DA transport constants 
kinetics for maximal rate (Vmax) and substrate affinity (km); 
𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =
𝑉𝑚𝑎𝑥 [𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒]
𝐾𝑚 + [𝐷𝑜𝑝𝑎𝑚𝑖𝑛𝑒]
 
When necessary, fitting analysis for a 2-components curve was evaluated using a 
Fisher-test (F-test) for comparison between one-site and two-site nonlinear regression (high 
and low affinity sites). Pharmacological parameters were compared using extra sum-of-
squares F-test analysis. 
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IV. 4.  Results 
IV. 4.1.  Statin-induced neurite growth in SH-SY5Y 
neuroblastoma cells 
Trophic activity of statins on total neurite growth has been previously reported 
(Evangelopoulos et al., 2009; Jin et al., 2012; Raina et al., 2013; Samuel et al., 2014). 
However, their potential impact on the complexity of neuritic structures and the specificity 
versus the other neurotrophic compounds remains unclear. Using βIII-tubulin 
immunocytochemistry (Fig. 1a and b), we studied the impact of statins on both the neuritic 
growth and branching in SH-SY5Y cells. High-content image analysis demonstrated a 
significant neurite growth induced by lovastatin (Fig. 1c and g) and simvastatin (Fig. 1d and 
g) after 24 h of incubation. The statin treatment also induced a significant increase in the 
number of neurite branching nodes (Fig. 1h). Atorvastatin and fluvastatin also induced a 
similar increase in neurite length (Fig. 1g). An own designed image analysis algorithm 
allowing the detection of primary and secondary neurites revealed that the lovastatin- and 
simvastatin-induced neurite growth affected both the length (Fig. 1k) and the number (Fig. 
1m) of secondary neurites. No significant changes were found for the length (Fig. 1j) or the 
number (Fig. 1l) of primary neurites. These data confirm the trophic effect of statins and 
demonstrate that they specifically affect the genesis of secondary neurites, which increases the 
complexity of the neuritic network.  
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Figure 15. (Figure 1.) Statins-induced neurite outgrowth with a complex branching 
independent to the PI3K and RhoA downstream mevalonate pathway in SH-SY5Y cells 
after 24 h treatment 
(a) Representative image of βIII-tubulin (green) and DAPI (blue) staining in SH-SY5Y cells. b, 
segmentation mask comprising the layers of nucleus (green), cytoplasm (blue), primary (red) and 
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secondary (orange) neurite. (b-e) Treated cells with lovastatin (Lova) 30 µM, simvastatin (Simva) 30 
µM, Y-27632 50 µM and retinoic acid (RA) 10 µM. (g-h) quantification of neurite length (g, 
F(9,48)=34.18, P<0.0001) and nodes in neurite branching (h, F(9,47)=37.80, P<0.0001) per cell with 
primary neurite treated with RA 10 µM, Y-27632 50 µM and statins 30µM for lovastatin, simvastatin, 
atorvastatin (Atorva), pravastatin (Prava) and fluvastatin (Fluva). (i) mevalonate pathway and 
pharmacological tools used to study it (HMGCR, HMG-CoA reductase; GGPP, geranylgeranyl-
pyrophosphate; FPP, farnesyl-pyrophosphate). (j-k) primary (j: F(6,58)=13, P<0.0001) and secondary 
(k, F(6,52)=42.60, P<0.0001) neurite length/cell. (l-m), primary neurite/cell (l, F(6,59)=3.21, P=0.0085) 
and secondary neurite number/primary neurite (m, F(6,50)=36.82, P<0.0001). (n-q) dose-responses 
effects of compounds alone and in combination on neurite length; (n) Y-27632 combined with 
lovastatin; o, lovastatin combined with wortmannin; (p) wortmannin and LY-294,002; (q) Y-27632 
combined with wortmannin. Results represent means ± S.E.M. (n=3-12). (n-q) results were fitted by 
nonlinear regression with a 4PL equation. Statistical analyses were performed by one-way ANOVA 
followed by Bonferroni post hoc test; *P<0.05, **P<0.01, **P<0.001, ****P<0.0001, vs 
corresponding vehicle treated cells. B, basal level. Scale bar indicates 50 µm.  
IV. 4.2.  Differential trophic effects of statins in SH-SY5Y and 
potential downstream pathways 
Neurite growth induced by HMG-CoA reductase inhibition may result from various 
downstream cellular mechanisms of mevalonate pathway including the RhoA and PI3K 
pathways (Fig. 1i). These pathways regulate the polymerization of actin filaments involved in 
the neurite sprouting and have been proposed to contribute to statins trophic properties by 
inhibition of PI3K and Rho-associated protein kinase (ROCK, a downstream effector of 
RhoA) (Fig. 1i) (Schulz et al., 2004; Evangelopoulos et al., 2009; Racchetti et al., 2010; Jin et 
al., 2012; Raina et al., 2013). In this context, we examined the effects of ROCK and PI3K 
inhibitors on statin-induced neurite growth.  
Inhibition of ROCK by treatment with Y-27632 produced an increase in total neurite 
length (Fig. 1f and g). Nonlinear regression analysis revealed an EC50 of 3.1±0.23 µM (Fig. 
1n). Under identical experimental conditions, lovastatin exhibited a slightly lower potency 
(EC50 of 17.4±2.1 µM) (Fig. 1o). Moreover, treatment with Y-27632 resulted in a significant 
growth of primary and secondary neurites (Fig. 1j-m). Co-treatment conditions showed that 
Y-27632 dose-response curve for total length was shifted up by lovastatin in a dose-dependent 
manner and it was accompanied by a change in the slope of the curve with nH=1.12±0.04 for 
Y-27632 vs 0.86±0.06 for Y27632 + lovastatin 50µM (F(1,62)=7.35, P=0.0086) (Fig. 1n). 
Similar effects were observed for primary and secondary neurite length and number (Y-27632 
vs Y-27632 + lovastatin 50 µM: primary length, nH=1.3±0.09 vs 0.90±0.07, F(1,140)=11.53, 
P=0.0009; secondary length, nH=1.26±0.09 vs 1.00±0.08, F(1,140)=4.49, P=0.0358; primary 
number, nH=1.48±0.24 vs 0.84±0.16, F(1,140)=4.57, P=0.0342; secondary number: 
nH=1.32±0.09 vs 1.01±0.07, F(1,140)=6.42, P=0.0123) (Fig. 2a, d, g and j). However, no 
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changes were observed for the maximal response over baseline between the combined 
treatment (Y-27632 + lovastatin) and the Y-27632 alone (Y-27632 vs Y-27632 + lovastatin 
50 µM: total length, Emax=44.1±1.2 vs 46.2±2.4 µm, F(1,64)=0.21, P=0.6474; primary length, 
Emax=28.5±0.7 vs 24.6±2.3 µm, F(1.136)=1.5, P=0.2214; secondary length, Emax=11.8±0.7 vs 
13.7±1.5 µm, F(1.136)=2.01, P=0.1584; primary number, Emax=1.03±0.03 vs 0.54±0.03, 
reduction F(1.140)=94.65, P<0.0001; secondary number, Emax=0.35±0.02 vs 0.36±0.03, 
F(1.136)=0.01, P=0.9031) (Fig. 1n, 2a, d, g and j). These observations likely suggest a RhoA-
independent trophic effect of lovastatin. 
The treatment of SH-SY5Y cells with PI3K inhibitors induced a significant dose-
dependent neurite retraction with an Imax of 67.2±4.7% and 37.7±1.7% and IC50 of 4.4±0.6 
µM and 2.8±1.2 µM for wortmannin and LY-294,002 respectively (Fig. 1p). This reduction 
impacted both the number and length of primary and secondary neurites (one-way ANOVA, 
vehicle vs wortmannin, primary neurite length: F(3,44)=46.37, P<0.0001 and number: 
F(3,44)=25.77, P<0.0001; secondary neurite length: F(3,44)=13.87, P<0.0001 and number: 
F(3,44)=5.2, P=0.0036) (Fig. 2b, c, e, f, h, k and l). In order to determine the potential 
downstream role of PI3K pathway in the HGM-CoA- and ROCK-inhibition-mediated effects, 
we co-treated SH-SY5Y cells with lovastatin or Y-27632 and wortmannin. Both lovastatin- 
and Y-27632-induced neurite growth response curve were shifted down in presence of 
wortmannin and in a dose-dependently manner (Fig. 1o and q). In both cases, the absolute 
responses over baseline of the trophic compounds remained unchanged which suggests that 
PI3K pathway is not involved in statin- or ROCK-inhibition mediated regulation (lovastatin 
vs lovastatin + wortmannin 10µM: Emax=16.5±1.3 vs 17.6±0.52 µm, F(1,33)=0.70, P=0.4066; 
Y-27632 vs Y-27632 + wortmannin 10 µM: Emax=50.1±4.4 vs 44.3±1.7 µm, F(1,70)=1.88, 
P=0.1751) (Fig. 1o and q). However, lovastatin inhibited the retraction of primary neurite 
length and number induced by wortmannin with an Emax of 11.59±1.4 vs 17.6±1.4 µm 
(F(1,76)=5.23, P=0.025) and 0.088±0.058 vs 0.642±0.051 primary neurite/cell (F(1,80)=47.39, 
P<0.0001) for lovastatin and lovastatin + wortmannin 10 µM respectively (Fig. 2b and h). In 
contrast, Y-27632 did not revert the absolute wortmannin-induced retraction of primary 
neurite (Emax=31.6±1.5 vs 32.8±1.3 µm, F(1,136)=0.348, P=0.5560; Emax=0.84±0.068 vs 
0.88±0.07 primary neurite/cell, F(1,124)=0.14, P=0.7094) (Fig. 2c and i). 
To identify potential differences with other trophic compounds, we also investigated 
the effects of retinoic acid (RA), an agonist of RA receptors (RAR) (Fig. 1i) (Constantinescu 
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et al., 2007; Lopes et al., 2010), which plays a role in the dopaminergic differentiation and the 
growth of SH-SY5Y cells (Fig. 1e and g). Treatment of SH-SY5Y cells with RA induced 
specific and stronger effect on the length and the number of secondary neurites but a minor 
effect on the primary neurite length (Fig. 1k, l and m). 
Our data demonstrate that ROCK inhibition and RAR activation induce a trophic 
effect in SH-SY5Y cells while PI3K inhibition clearly induces neurite retraction. In contrast 
to statins, ROCK inhibition and RAR activation induce an overall extension of both primary 
and secondary neurites. Taken together, our results suggest that lovastatin-induced trophic 
effects are independent of RhoA and PI3K pathways and counteract neurite retraction 
following PI3K inhibition. 
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Figure 16. (Figure 2.) Lovastatin but not ROCK inhibitor reduces neurite retraction 
induced PI3K inhibitor after 24 h of treatment in SH-SY5Y cells 
Effects of Y-27632 or lovastatin dose-responses alone and in combination with lovastatin or 
wortmannin treatment on neurite growth complexity. (a, d, g and j) Y-27632 combined with 
lovastatin. b, e, h, and k, lovastatin combined with wortmannin. (c, f, i, and l) Y-27632 combined with 
wortmannin. Primary neurite length (a-c), secondary neurite length (d-f), primary neurite number (g-i) 
and secondary neurite number (j-l) were analysed for co-treatments. Results represent means ± S.E.M. 
(n=3) and fitted by nonlinear regression with a 4PL equation. B, basal level. 
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IV. 4.3.  Statins-induced up-regulation of presynaptic markers  
The trophic effects of statins found on neurite growth may trigger phenotypic changes 
of the synapse. Thus, we investigated the levels of several key proteins of the synapse and 
particularly of the dopaminergic pre-synaptic system using both immunofluorescence and 
gene expression analysis. We observed an increase in VMAT2, SV2A, SV2C, TH, SYNGR3 
and DAT protein levels in SH-SY5Y cells after treatment with lovastatin or simvastatin (Fig. 
3a). High content image analysis demonstrated that both lovastatin and simvastatin induced a 
dose- and time-dependent increase in synaptic protein levels which reached maximal effect 48 
h after treatment (Fig. 3b-g). The maximum increase in fluorescence intensity was observed 
by lovastatin (30 µM) with a rank order among studied markers such as SYNGR3 > SV2C > 
SV2A = VMAT2 > TH > DAT (Fig. 3b-g). Only minor differences were noted for 
simvastatin (SYNGR3 > SV2C = TH > SV2A > VMAT2 > DAT, 30 µM). The potency of the 
effect was similar for both statins after 24 h with an EC50 of 4.12±2.09 µM for lovastatin and 
2.07±1.17 µM for simvastatin which remained unchanged at 48 h (Fig. 3b-g). Under the same 
conditions, the trophic compounds, Y-26732 or RA, did not lead to any significant 
amplification of fluorescence signal for the studied markers (Fig. 3b-g). 
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Figure 17. (Figure 3.) Expression of dopaminergic synaptic markers is enhanced by the 
statins in SH-SY5Y cells 
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(a) representative fluorescence images of synaptic proteins SV2A, SV2C, VMAT2, TH, SYNGR3 and 
DAT after 48 h treatment with lovastatin (Lova) 30 µM, simvastatin (Simva) 30µM, Y-27632 50 µM 
and retinoic acid (RA) 10 µM. The ratiometric pseudo-color images were generated to enhance the 
contrast of fluorescence intensity. (b-g) quantification of SV2A (b), SV2C (c), VMAT2 (d), TH (e), 
SYNGR3 (f) and DAT (g) expression levels in cells treated for 24 h or 48 h with lovastatin and 
simvastatin dose-responses and Y-27632 50 µM and RA 10 µM. Results represent means ± S.E.M. 
(n=3-6). Statistical analyses were performed by two-way ANOVA (SV2A: treatment effect: 
F(12,127)=7.54, P<0.0001; Time: F(1,127)=20.72, P<0.0001; Interaction: F(33,96)=3.1, P=0.9991. SV2C: 
treatment effect: F(12,101)=19.84, P<0.0001; Time: F(1,101)=55.04, P<0.0001; Interaction: F(12,101)=7, 
P<0.0001. VMAT2: treatment effect: F(12,149)=7.67, P<0.0001; Time: F(1,149)=22.30, P<0.0001; 
Interaction: F(12,149)=2.33, P=0.009. TH: treatment effect: F(12,86)=8.67, P<0.0001; Time: F(1,86)=32.26, 
P<0.0001; Interaction: F(12,86)=3.96, P=0.009. SYNGR3: treatment effect: F(12,92)=28.20, P<0.0001; 
Time: F(1,92)=33.71, P<0.0001; Interaction: F(12,86)=3.92, P<0.0001. DAT: treatment effect: 
F(12,88)=7.35, P<0.0001; Time: F(1,88)=11.49, P=0.001; Interaction: F(12,88)=1.75, P=0.0699) followed by 
Bonferroni post hoc test; */#/$/† were represented when a point of the curve was at least P<0.05 vs 
corresponding baseline for lovastatin 48 h (*), simvastatin 48 h (#), lovastatin 24 h ($), simvastatin 48 
h (†) treatments. B, basal level. Scale bar indicates 20 µm.  
 
Immunoblot analysis of cell protein extracts showed that lovastatin induced an 
increase in VMAT2, SV2C and SYNGR3 protein expression levels with a maximal 
significant effect at 48 h (Fig. 4a and c-e). No detectable changes were found for SV2A (Fig. 
4a and b) and DAT (data not shown). Moreover, no significant changes were observed after 
treatment with the ROCK inhibitor Y-27632 (Fig. 4). 
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Figure 18. (Figure 4.) Lovastatin induces an increase in synaptic protein makers related 
to dopaminergic system in SH-SY5Y cells 
(a) representative immunoblots of SV2A (82 kDa), SV2C (82 kDa), VMAT2 (75 kDa), SYNGR3 (25 
kDa), DAT (68 kDa) and β-actin (41 kDa) from cells treated 24h and 48 h with the Y-27632 (Y) 
50µM and lovastatin dose-response. (b-e) Optical density measurements corresponding to SV2A (b), 
SV2C (c), VMAT2 (d) and SYNGR3 (e) immunoblots and normalized over β-actin. Results represent 
means ± S.E.M. (n=3). Statistical analyses were performed by one-way ANOVA (SV2C 48h: 
F(5,12)=15.36, P<0.0001; VMAT2 24 h: F(5,12)=4.41, P=0.0164; VMAT2 48 h: F(5,12)=6.83, 
P=0.0031; SYNGR3 24 h: F(5,12)=26.30, P<0.0001; SYNGR3 48 h: F(5,12)=19.76, P<0.0001) 
followed by Bonferroni post hoc test; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, vs 
corresponding vehicle treated cells. V, vehicle.  
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We investigated whether statin-induced increase in synaptic proteins was due to an up-
regulation of gene transcriptions or to an effect in protein stabilities. Quantitative PCR using 
mRNA-specific probes showed significantly higher levels of mRNAs coding for the synaptic 
proteins SV2A, SV2C, VMAT2 and SYNGR3 after 6 h of treatment with lovastatin (Fig. 5a-d). 
The increased levels of SV2A mRNA remained stable at 24 h of incubation (Fig. 5a) while 
they decreased over time for SV2C and VMAT2 from 6 h to 48 h (Fig. 5b and c). We observed 
a significant up-regulation of SYNGR3 mRNA levels at all treatment times (Fig. 5d). No 
changes in the mRNA levels for TH were detected following lovastatin treatment (Fig. 5e). 
SREBP-2 mRNA levels, but not those of SREBP-1, were enhanced after 12 h of incubation by 
the statin (Fig. 5f and g). The ROCK inhibitor Y-27632 did not modify mRNA levels of any 
of the studied synaptic proteins (Fig. 5a-e) RA treatment stimulated mRNA levels of SREBP-
1, TH, SYNGR3 with maximal effects at 12 h, 24 h and 48 h respectively (Fig. 5d-f). A very 
low level of DAT mRNA was detected which did not allow an accurate quantification in SH-
SY5Y cells (data not shown). 
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Figure 19. (Figure 5.) Lovastatin up-regulates mRNA expression levels of dopaminergic 
synaptic proteins 
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(a-g), time-course study (6-48 h) of SV2A (a), SV2C (b), VMAT2 (c), SYNGR3 (d), TH (e), SREBP-
1 (f) and SREBP-2 (g) mRNA expression normalized over β-actin in SH-SY5Y cells treated with 
lovastatin 30 µM, Y-27632 50 µM, RA 10 µM. Results represent means ± S.E.M. (n=3). Statistical 
analyses were performed by two-way ANOVA (SV2A: treatment effect: F(3,53)=93.43, P<0.0001; 
Time: F(3,53)=7.78, P=0.0002; Interaction: F(9,53)=6.46, P<0.0001. SV2C: treatment effect: F(3,53)=49.81, 
P<0.0001; Time: F(3,53)=5.426, P=0.0025; Interaction: F(9,53)=5.28, P<0.0001.VMAT2: treatment 
effect: F(3,47)=80.07, P<0.0001; Time: F(3,47)=29.41, P<0.0001; Interaction: F(9,47)=13.69, P<0.0001. 
SYNGR3: treatment effect: F(3,52)=47.16, P<0.0001; Time: F(3,52)=1.20, P=0.320; Interaction: 
F(9,52)=2.60, P=0.0148. TH: treatment effect: F(2,36)=35.29, P<0.0001; Time: F(3,36)=6.64, P=0.0011; 
Interaction: F(3,36)=5.91, P=0.0002. SREBP-1: treatment effect: F(2,16)=42.35, P<0.0001; Time: 
F(3,16)=326.6, P<0.0001; Interaction: F(3,16)=39.43, P<0.0001. SREBP-2: treatment effect: F(2,16)=40.88, 
P<0.0001; Time: F(1,16)=2.23, P=0.1240; Interaction: F(6,16)=2.21, P=0.0964) followed by Bonferroni 
post hoc test;*/#P<0.05, **/##P<0.01, ***/###P<0.001, ****/####P<0.0001, * vs corresponding 
vehicle treated cells, # vs corresponding 6 h of treatment. B, basal level. 
Altogether, these data suggest that increases of SYNGR3, VMAT2, SV2A and SV2C 
protein levels are rather associated to an increase in transcription of their corresponding 
genes. In contrast, the increase in protein levels observed for TH and DAT is independent of 
transcriptional activation. The statin-induced effects are at variance with those observed after 
treatment with other neurite growth inducers (RA and Y-27632) used in present study. 
IV. 4.4.  Statin modulates intracellular [3H]dopamine uptake and 
the pharmacological properties of VMAT2 in SH-SY5Y 
cells 
The statin-induced changes in neurite growth and in presynaptic marker expressions 
suggested a strong drive towards a dopaminergic phenotype with significant changes affecting 
several key elements of the DA transport cycle. These findings clearly supported further 
investigation of the potential impact of statins on the functionality of DA system. DAT, 
VMAT2 and SYNGR3 belong to a functional cycle for mobilizing different pools of DA in 
pre-synaptic structures DA (Eriksen et al., 2010).  
Under our experimental conditions, the intracellular [
3
H]DA uptake in SH-SY5Y cells 
was time-dependent and showed two kinetic phases reaching a first plateau at 15 min (S1) and 
a second at 60 min (S2) incubation time (velocity at S1 vs S2: 152±51 vs 59±54 pmol/mg of 
protein/min, t(30)=4.872, P<0.0001) (Fig. 6a). [
3
H]DA uptake kinetic was sensitive to the DAT 
inhibitor GBR-12935 and to the VMAT2 inhibitor reserpine (RSP). Full inhibition of DA 
uptake was observed by GBR-12935 at both S1 and S2 uptake phases while RSP was more 
efficacious at S2 (Fig. 6b). These results showed a differential kinetics of DA transport in SH-
SY5Y cells which was fully sensitive to DAT function but with a major contribution of DA 
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vesicular transport at longer incubation times demonstrated by a VMAT2 inhibition 
sensitivity. 
Treatment with lovastatin decreased the Vmax of [
3
H]DA cellular uptake (S1) in SH-
SY5Y cells at 24 h with a Vmax=10.4±0.3 vs 7.2±0.5 pmol/mg protein/min in vehicle- and 50 
µM lovastatin-treated cells respectively (F(1,26)=28.91, P<0.0001) (Fig. 6c). This effect was 
also observed at 60min incubation time with a Vmax=7.17±0.3 vs 4.4±0.2 pmol/mg 
protein/min for vehicle- and lovastatin-treatments respectively (F(1,26)=53.08, P<0.0001) (Fig. 
6d). Incubation of SH-SY5Y cells with lovastatin for longer time (48 h) induced similar 
reductions (Fig. 6e and f). The lovastatin-induce reduction of [
3
H]DA uptake was dose-
dependent and accounted for 31.4±5% and 34.1±10.5% of maximal effect at 24 h and 48 h 
post-treatment at S1 phase. Significant higher levels of reduction were observed at the S2 
phase of [
3
H]DA uptake with 37.5±3.8% (24 h) and 57.6±6.2% (48 h) (S1 vs S2 values; t-test 
t(10)=2.3 P=0.042) (Fig. 6c-f). Pre-incubation of cells with selective transport inhibitors GBR-
12935 did not reveal any difference in their inhibitory potency between lovastatin- or vehicle-
treated cells at 24 h (Fig. 6g). GBR-12935 showed an IC50=424±50 vs 348±77 nM in vehicle 
and lovastatin treated cells respectively (F(1,32)=0.69, P=0.4106). Lack of change was also 
observed for VMAT2 inhibitor RSP (IC50=916±140 vs 584±64 pM, F(1,52)=2.11, P=0.1520) 
(Fig. 6h). In contrast, DA-transport inhibition by the VMAT2 allosteric inhibitor 
tetrabenazine (TBZ) displayed a biphasic curve (nH=-0.39) in cells treated (24 h) with 
lovastatin (Fig. 6i). Nonlinear regression analysis revealed a high (IC50=62.9±278 nM) and 
low (IC50=26.6±19.4 µM) sensitivity inhibition component after statin treatment. TBZ-
inhibition curve in vehicle treated cells showed one site (IC50=20.4±5.6 µM) (Fig. 6i).  
Longer lovastatin treatment times (48 h) induced the appearance of a RSP-insensitive 
[
3
H]DA uptake components (Fig. 6k). RSP was less efficacious in for inhibiting [
3
H]DA 
uptake in lovastatin-treated than in vehicle treated cells (Imax=77.9±2.1 vs 36.7±3.7%, 
F(1,52)=12.34, P=0.0009) (Fig. 6k). Uptake inhibition curves also revealed a negative impact of 
lovastatin in TBZ efficacy (Imax=76.2±2.1 vs 47.5±3.5%, F(1,64)=4.5, P=0.0377) (Fig. 6l). The 
effect of lovastatin treatment on RSP- and TBZ-inhibitory efficacy was clearly dose-
dependent (Fig. 6k and l). Lovastatin (50 µM) also induced a decrease of the potency of 
VMAT2 inhibitors. Inhibition curves for [
3
H]DA uptake significantly shifted to the right for 
RSP (IC50=182±15.6 vs 699±192 pM, F(1,56)=29.35, P<0.0001) and for TBZ (IC50=4.6±0.9 vs 
10.5±4.37 µM, F(1,68)=4.4, P=0.0396) in lovastatin-treated compared to vehicle-treated cells 
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(Fig. 6k). The inhibitory efficacy of DAT inhibitor GBR-12935 remained unaffected by 
lovastatin treatment (Imax=99.7±1.2 vs 99.4±2.3%, F(1,52)=0.02, P=0.8951) (Fig. 6j). In 
summary, lovastatin decreases total cellular levels of DA uptake and modulates VMAT2 
pharmacological properties as evidenced by i) the transient appearance of a new TBZ-highly 
sensitive inhibition component, at shorter treatment time, and ii) an insensitivity to reference 
VMAT2 inhibitors at longer incubation times.  
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Figure 20. (Figure 6.) Lovastatin decreases the dopamine (DA) uptake and changes the 
pharmacological properties of VMAT2 in SH-SY5Y cells 
 
(a) Representative kinetics of [
3
H]DA uptake for 60 min in SH-SY5Y cells treated with reserpine 
(RSP) 1µM or GBR-12935 10 µM. (b) [
3
H]DA uptake for 15 min or 60 min in cells pre-treated with 
RSP 1 µM, tetrabenazine (TBZ) 10 µM and GBR-12935 10 µM. Statistical analyses were performed 
by two-way ANOVA followed by Bonferroni post hoc test (treatment effect: F(3,286)=1050, P<0.0001; 
Time: F(1,286)=35.57, P<0.0001; Interaction: F(3,286)=3.28, P<0.0001): all treatments reduced 
(####P<0.0001) the DA uptake compared to vehicle-treated cells; ****P<0.0001 for comparison 
between 15 min and 60min. (c-f) Saturation studies of [
3
H]DA uptake for 15 min (c and e) or 60 min 
(d and f) in cells pre-treated with lovastatin (Lova) incubated 24 h (c and d) or 48 h (e and f). 
Michaelis–Menten equation was applied to saturation curves. g-l, dose-responses of GBR-12935, RSP 
and TBZ incubated 30 min followed by the [
3
H]DA uptake for 60 min in cells pre-treated with 
lovastatin incubated 24 h (g-i) or 48 h (j-l). (g, h, j, k and l) Results were fitted by nonlinear regression 
with a 4PL equation. (i) Results of vehicle (two sites: F(2,28)=1.64, P=0.21) and lovastatin (two site: 
F(2,28)=3.27, P<0.05) treatments were fitted with one-site and two-site equation respectively. Results 
represent a means ± S.E.M. (n>3). B, basal level.  
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IV. 4.5.  VMAT2 overexpression in BE(2)-M17 cells induces 
changes of TBZ sensitivity similar to those observed with 
lovastatin 
The statin-induced changes observed in DA transport of SH-SY5Y cells could result 
from an imbalance of the different elements of the DA transport cycle due to changes in 
protein expressions. To investigate this hypothesis, we assessed the impact of the ectopic 
overexpression of VMAT2 on the DA transport in a heterologous expression system. 
Preliminary transfection experiments using SH-SY5Y cells did not lead to a suitable VMAT2 
overexpression level. Subsequently, we selected the BE(2)-M17 neuroblastoma cells, which 
also display a pronounced dopaminergic phenotype. Immunoblot analysis confirmed the 
expression of VMAT2 in wild-type BE(2)-M17 cells (Fig. 7a). VMAT-2 gene transfection 
induced a significant increase in the levels of native and glycosylated VMAT2 protein forms 
(Fig. 7a). DA-transport experiments revealed an increase in DA-uptake (248±16.2 %) in 
VMAT2-transfected cells versus the corresponding wild-type cells (Fig. 7b). Pre-incubation 
of untransfected cells with selective transport inhibitors showed a potent and dose-dependent 
inhibition of [
3
H]DA transport by RSP and TBZ (Fig. 7c and d). In VMAT2-transfected 
BE(2)-M17 cells, RSP showed a modest shift of its inhibitory potency compared with 
untransfected cells (IC50=1.53±0.23 vs 5.25±0.57 nM, F(1,76)=49.41, P<0.0001) (Fig. 7c) 
while TBZ displayed a clear biphasic inhibition of [
3
H]DA transport compared with 
untransfected cells (nH=-0.62±0.12 vs -0.19±0.12, F(1,120)=6.05, P=0.0154) (Fig. 7d). 
Nonlinear regression demonstrated no changes of the TBZ-sensitive low-affinity component 
between untransfected and transfected cells (IC50=25.8±11.8 vs 18.8±12.3 µM, F(1,110)=0.29, 
P=0.5851) while an increase in the efficacy for the high affinity site was observed (Fig. 7d) 
(IC50=37.8±75 vs 27.4±12.9 nM, F(1,110)=0.073, P=0.7864; Ihigh-affinity-site=101.3±5.6 vs 
76.4±6.2%, t-test(8)=2.93, P=0.0187) (Fig. 7d). Overall, these results show that VMAT2 
overexpression in BE(2)-M17 cells increased the DA uptake level and modulate VMAT2 
sensitivity to TBZ mimicking the impact of statins found on VMAT2 in SH-SY5Y cells. 
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Figure 21. (Figure 7.) VMAT2 overexpression increases the capacity of dopamine 
transport and modulates the sensitivity of VMAT2 inhibitors in BE(2)-M17 cells 
(a) Representative immunoblot of VMAT2 revealing the truncated (45 kDa), the native (55 kDa) and 
the glycosylated (75 kDa) forms of VMAT2 in wild-type (WT) and VMAT2 transfected cells. b, 
[
3
H]DA uptake in WT and VMAT2 transfected cells. Statistical analysis was performed by student’s t-
test (t(26)=10.54, P<0.0001, n=14). (c-d) Dose-responses of reserpine (c, RSP) and tetrabenazine (d, 
TBZ) pre-incubated 30 min followed by the [
3
H]DA uptake for 60min in WT and VMAT2 transfected 
cells. c, RSP results were fitted by nonlinear regression with a normalized equation. (d) Two-site 
fitting was applied for WT (F(2,53)=3.96, P<0.05) and VMAT2 transfected cells treated with TBZ 
(F(2,51)=17.88, P<0.0001) after comparison with one-site fitting. Results represent a means ± S.E.M. 
(n=3-5). B, basal level. 
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IV. 4.6.  Nuclear translocation of SREBP-1 is triggered by statins 
in SH-SY5Y cells   
The activation of SREBP transcription is a cell signalling pathway constituting a direct 
feedback loop for the transcriptional modulation of key enzymes involved in the mevalonate 
pathway (Fig. 1i) (Kallin et al., 2007). We aimed to determine the potential activation of 
SREBP-1 transcription factor by statins. Immunoblot analysis of vehicle-treated SH-SY5Y 
cells revealed the expression of full and mature (translocated) forms of SREBP-1 (Fig. 8a). 
The incubation of cultured cells with lovastatin (24 h) induced an increase in the level of the 
mature form of SREBP-1 (Fig. 8a). Immunofluorescence detection and high-content imaging 
analysis confirmed that lovastatin induced a dose- and time-dependent increase in the number 
of cells with positive nuclear staining of SREBP-1 antibody (Fig. 8b) as well as an increase in 
the fluorescence intensity ratio (cytoplasm/nucleus) (Fig. 8c and d). The results showed 
lovastatin-induced translocation of the SREBP-1 protein from the cytosol to the nucleus as 
early as 6 h after treatment. The maximal effect of the statin was reached 48 h after treatment 
with an EC50 of 4.1±1.67 µM (Fig. 8c and d). Similar effects were observed with the 
simvastatin (Fig. 8d). In conclusion, statins lead an increase in SREBP translocation into the 
nucleus in SH-SY5Y cells concomitantly to an increase in neurite growth, gene expressions of 
dopaminergic markers and modulation of DA transport. 
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Figure 22. (Figure 8.) Statins lead the nuclear translocation of SREBP-1 in SH-SY5Y cells 
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(a) Representative immunoblot of SREBP-1 nuclear translocation revealing the precursor of SREBP-1 
(P SREBP-1, 125 kDa) and mature nuclear SREBP-1 (N SREBP-1, 68 kDA) in cells treated with 
lovastatin dose-response or Y-27632 (Y) 50 µM. (b) Representative immunofluorescence images of 
SREBP-1 and βIII-tubulin staining in SH-SY5Y cells. Image Processing and classification of positive 
cells for the nuclear translocation of SREBP-1. (c) Effect of lovastatin dose-response kinetics (6 to 48 
h) on SREBP-1 nuclear translocation. Results were fitted by nonlinear regression with a 4PL equation 
(lovastatin: treatment effect: F(5,46)=19.78, P<0.0001; Time: F(3,46)=17.68, P<0.0001; Interaction: 
F(15,46)=2.95, P<0.0024). (d) Kinetics effect of lovastatin and simvastatin (Simva) 30µM treatments on 
SREBP-1 nuclear translocation (lovastatin vs simvastatin effect: F(1,4)=1.64, P=0.2696; Time: 
F(3,12)=143.7, P<0.0001; Interaction: F(3,12)=0.82, P<0.5083). Results represent the mean ± S.E.M. 
(n=3-7). Statistical analyses were performed by two-way ANOVA followed by Bonferroni post hoc 
test: */# were represented when a point of the curve was at least P<0.05 compared to baseline (*) or 6 
h of treatment (#). In kinetics bar graph ****P<0.0001, vs corresponding vehicle treated cells. B, basal 
level. Scale bar indicates 25 µm. 
IV. 5.  Discussion 
We here report that treatment of SH-SY5Y cells with statins induces (i) a neurotrophic 
effect on synaptic structures reflected by an increase in neurite length and complexity of 
neurite branching (ii) a reversal of neurite retraction mediated by PI3K inhibition (iii) an 
induction of the dopaminergic phenotype by increasing transcription and protein levels of the 
pre-synaptic markers (SV2C, SV2A, VMAT2 and SYNGR3) and by increasing protein levels 
of TH and DAT (iv) a modulatory effect on the DA transport system characterized by a 
decrease the DA uptake and by changes of the pharmacological properties of VMAT2 and (v) 
an activation of SREBP pathway which could participates to the observed trophic effects. 
Neurotrophic action of statins observed in our study affected neurite branching rather 
than elongation of primary neurites of SH-SY5Y. Our data agree and extend previous findings 
showing that simvastatin induces an overall neurite growth in SH-SY5Y cells (Raina et al., 
2013). The increased branching induced by statin strength data in primary cortical neurons 
showing the induction of neuritic terminal branching by atorvastatin (Watanabe et al., 2012).
 
Statin-induced neurite growth clearly differentiates from the neurotrophic effect observed by 
ROCK-inhibition (Racchetti et al., 2010) or RAR stimulation (Constantinescu et al., 2007; 
Lopes et al., 2010). These neurotrophic compounds only affected overall elongations while 
statins increased network complexity. Moreover, our data suggest that statin’s effect is likely 
independent from RhoA or PI3K signalling pathways (Evangelopoulos et al., 2009; Jin et al., 
2012; Raina et al., 2013; Samuel et al., 2014). Interestingly, our findings show that statins are 
able to reverse the neurite retraction induced by PI3K-inhibition suggesting a 
neuroregenerative potential. Pathophysiology of PD is characterized by cellular mechanisms 
leading to dopaminergic cell death and axonal terminal degeneration (Coleman, 2005). 
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Compelling evidences suggest that neurodegeneration begins at the presynaptic terminal in 
the distal axons followed by a retrograde degeneration up to the soma (Coleman, 2005). 
Actually, at early stages of PD, only 30% of DA neurons are lost in substantia nigra while 50-
60% of axon terminals are lost in the striatum (Cheng et al., 2010). Moreover, axonal 
degeneration and neurite retraction have been demonstrated in toxin-induced, α-synuclein 
overexpression and mutated leucine-rich repeat kinase 2 (Chan et al., 2011; Winner et al., 
2011; Koch et al., 2015). We could hypothesize that statins might counteract PD 
neurodegeneration through (i) a blockade of retrograde axonal degeneration and/or (ii) by 
promoting neurite branching. Other neurotrophic principles and mechanisms such as GDNF 
factor (Rosenblad et al., 1999), ROCK inhibition (Zhao et al., 2015) or ROCK 
downregulation (Saal et al., 2015) have been shown to promoting axonal regeneration in 
models for PD. 
In addition to the neurotrophic effects, we observed a statin-induced up-regulation of 
synaptic vesicular elements, which may also support potential neuroprotective effect in PD. 
Several reports have previously suggested the interest of VMAT2 as a target for 
neuroprotection in PD (Guillot and Miller, 2009; Yulug et al., 2015). It has been proposed that 
the decline of VMAT2 expression could be a pathological event preceding the nigrostriatal 
dopaminergic degeneration (Chen et al., 2008). Moreover, the decrease of VMAT2 activity 
enhanced the susceptibility to MPTP neurotoxicity and induced a PD-like pathology in 
VMAT2 knockout animals (Takahashi et al., 1997; Gainetdinov et al., 1998) and in animals 
treated with VMAT inhibitor RSP (Staal and Sonsalla, 2000). In this context, VMAT2 up-
regulation induced by statins may facilitate the transport of excessive intracytosolic DA or 
other DA-related neurotoxic agents into vesicles which, in turn, may reduce oxidative stress 
and subsequent cell toxicity (Speciale et al., 1998; Chen et al., 2005; Brighina et al., 2013; 
Lohr et al., 2014). Similarly, the statin-induced expression of the putative transporter SV2C 
might also contribute to modulate cytosolic DA levels (Dardou et al., 2011, 2013). 
The present data demonstrate that statin-treatment triggered nuclear translocation of 
SREBP-1 in SH-SY5Y cells, a result in agreement with previous reports on statin-induced 
SREBP-transcriptional activity in non-neuronal cells (Roglans et al., 2002; Rise et al., 2007). 
The nuclear translocation of SREBP-1 is concomitant to neurotrophic and phenotypic effects 
on the dopaminergic markers, pointing out this transcription factors as downstream regulator 
of those effects. Currently, it has been shown that the liver X receptor, a transcriptional 
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regulator of SREBP-1 genes (Chen et al., 2004; Cha and Repa, 2007) controls the midbrain 
neuronal dopaminergic phenotype and promotes differentiation of embryonic stem cells 
towards a TH-positive and VMAT2-positive phenotype (Sacchetti et al., 2009; 
Theofilopoulos et al., 2013). Interestingly, a previous study in non-neuronal cells (Hep G2) 
reported an increase in SV2A mRNA levels induced by lovastatin and by SREBP-1 
transfection. Statin-induced expression of vesicular transporters reported here strongly 
suggest a potential common downstream pathway for both neuronal and non-neuronal cells 
(Kallin et al., 2007). Whether the statin-induced regulation of the presynaptic genes is a 
consequence of direct activation of SREBP-dependent transcriptional activity or other 
downstream pathway remains to be demonstrated.  
The impact of statins in [
3
H]DA transport in SH-SY5Y cells strongly suggest a 
dynamic sensitivity of the DA-transport system, subsequent to changes in the expression 
levels of presynaptic proteins. The statin-induced effects on DA transport activity may 
potentially impact the neurodegenerative processes in PD by interfering with several 
mechanisms. A reduction of DA transport associated to an increase in VMAT2 and SYNGR3 
expressions may decrease cytosolic DA content, and reduce uptake of potential extracellular 
neurotoxic agents thus reducing intracellular oxidative stress (Kurosaki et al., 2003; Rappold 
et al., 2011; Segura-Aguilar et al., 2014; Masoud et al., 2015). Moreover, a reduced DA 
uptake may prolong the exposure to DA in the synaptic cleft, thus sustaining post-synaptic 
stimulation that would help to manage severity of the motor symptoms (Bezard and Gross, 
1998; Bezard et al., 2003). The statin-induced expression of key elements of the DA transport 
cycle such as SYNGR3 could explain the observed changes in DA transport. Actually, 
previous studies showed that overexpression of SYNGR3 triggered changes in the DA 
transport system by regulating VMAT2 and DAT function (Egana et al., 2009). Given the 
potential reduction of cholesterol levels in our conditions, a direct effect of low cholesterol in 
the DA transport system could not be ignored. It has been shown that low levels of cholesterol 
impact DAT time residency in membrane lipid rafts, DAT internalization process and 
subsequently cause a decrease in DA uptake (Foster et al., 2008; Jones et al., 2012).  
Our findings suggest the interest of statins for the treatment of neurodegeneration in 
PD. However, the therapeutic potential of statins in PD patients remains to be demonstrated. 
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In conclusion, the present data strengthen the therapeutic potential of statins in PD by 
unravelling (i) their trophic effects including protection and regeneration of neurites, (ii) their 
ability to induce the dopaminergic phenotype and (iii) their modulation of DA transport. 
Further investigation of the cellular and molecular effects of statins in the synaptic machinery 
may extend the understanding of their downstream signalling mechanisms and of the 
proposed therapeutic uses for these molecules. 
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IV. 7.  Supplemental data 
Table 8. (Supplemental Table 1) Pharmacological parameters of the Y-27632, lovastatin 
and wortmannin dose-responses alone or in combination on the total neurite length in 
SH-SY5Y cells 
 
Total length of neurite outgrowth per cell: pharmacologic parameters 
1
st
 drug 
(µM) 
Basal value 
 without dose-
response (µm) 
2
nd
 drug 
Dose-
response 
EC50 (µM) nh  Emax (µm) 
Emax 
(∆ µm over 
basal value) 
Lova 
- 28.6  ± 1.5   
Y-27632 
3.2  ± 0.3   0.9 ± 0.1   70.5  ± 3.2   41.9  ± 3.5   
13 31.0  ± 0.4   1.8  ± 0.2 * 1.0 ± 0.1   70.2  ± 3.4   39.2  ± 3.4   
25 37.0  ± 1.3 * 2.1  ± 0.2   0.4 ± 0.2   76.6  ± 3.3   39.6  ± 3.5   
50 45.2  ± 2.3 *** 3.8  ± 0.5   0.4 ± 0.2   82.8  ± 2.2   37.6  ± 3.2   
  
F(3,8)=23.3 
P=0.0003 
F(3,8)=8.3 
P=0.0076 
F(3,8)=3.7 
P=0.0591 
F(3,8)=3.8 
P=0.0585 
F(3,8)=0.3 
P=0.8440 
Wort 
- 28.5  ± 2.4   
Lova 
17.3  ± 2.4   2.3 ± 0.6   44.1  ± 1.2   15.5  ± 2.7   
2.5 20.0  ± 1.3 * 16.6  ± 1.9   2.3 ± 0.5   36.6  ± 1.7 * 16.8  ± 2.1   
5 18.0  ± 1.1 ** 17.0  ± 1.7   2.6 ± 0.5   35.2  ± 1.9 * 17.2  ± 2.2   
10 15.3  ± 1.7 ** 17.5  ± 2.4   1.9 ± 0.4   33.8  ± 1.5 ** 18.5  ± 2.3   
  
F(3,8)=11.26 
P=0.0003 
F(3,8)=0.03 
P=0.9909 
F(3,8)=0.25 
P=0.8544 
F(3,8)=8.2 
P=0.0078 
F(3,8)=23.1 
P=0.0003 
Wort 
- 27.6  ± 1.8   
Y-27632 
4.5  ± 0.4   1.0 ± 0.1   72.3  ± 4.9   44.6  ± 5.3   
2.5 19.3  ± 1.9 * 3.1  ± 0.3   1.0 ± 0.1   61.0  ± 3.7   41.7  ± 4.2   
5 16.1  ± 1.3 ** 2.9  ± 0.2 * 1.0 ± 0.1   56.9  ± 1.6   40.8  ± 2.1   
10 20.2  ± 1.9   4.4  ± 0.4   1.1 ± 0.1   61.5  ± 3.2   41.3  ± 3.7   
  
F(3,8)=7.9 
P=0.0093 
F(3,8)=6.3 
P=0.0168 
F(3,8)=0.2 
P=0.8980 
F(3,8)=3.4 
P=0.0725 
F(3,8)=0.2 
P=0.9053 
Compounds were incubated 24 h in SH-SY5Y cells. 
Results represent the means ± S.E.M. (n=3) and pharmacological parameters were determined by a 
nonlinear regression with a 4PL or normalized fitting. Statistical analysis were performed by one-way 
ANOVA followed by Bonferroni post hoc test: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 were 
represented for comparison between vehicle (without 1
st 
drug) and 1
st 
drug treatment (± dose-
response of 2
nd
 drug).  
See figure 1n, o and q for curves. 
Lova, Lovastatin; Wort, wortmannin; ∆, difference. 
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Table 9. (Supplemental Table 2) Pharmacological parameters of the Y-27632, lovastatin 
and wortmannin dose-responses alone or in combination on the primary and secondary 
neurite length in SH-SY5Y cells 
  
Length of the primary and secondary neurites : pharmacologic parameters 
1
st
 drug 
(µM) 
Basal value 
 without dose-
response (µm) 
2
nd
 drug 
dose-response EC50 (µM) nh  Emax (µm) 
Emax 
(µm ∆ over basal 
value) 
Primary neurite length 
Lova 
- 27.1  ± 1   
Y-27632 
1.9  ± 0.1   1.3  ± 0.0   54.9  ± 1.4   27.8  ± 1.7   
13 28.6  ± 0.7   1.4  ± 0.1   1.6  ± 0.0   55.1  ± 1.7   26.5  ± 1.8   
25 34.0  ± 0.9 ** 1.3  ± 0.1   0.9  ± 0.0 *** 58.8  ± 1.8   24.7  ± 2   
50 39.7  ± 1 **** 2.2  ± 0.3   0.9  ± 0.0 *** 61.2  ± 1   21.5  ± 1.4   
  F(3,8)=39.7 P=0.0001 F(3,8)=6 P=0.0191 F(3,8)=22 P=0.0003 F(3,8)=4. P=0.0493 F(3,8)=2.5 P=0.1367 
Wort 
- 27.2  ± 1.5   
Lova 
15.3  ± 1.8   2.3  ± 0.5   38.3  ± 0.7   11.1  ± 1.7   
2.5 19.4  ± 1 ** 15.9  ± 1.5   2.3  ± 0.4   33.0  ± 1.2 * 13.6  ± 1.5   
5 17.5  ± 0.8 *** 15.1  ± 1.2   3.2  ± 0.7   32.0  ± 1.3 * 14.4  ± 1.5   
10 14.9  ± 1.1 *** 17.1  ± 1.9   1.9  ± 0.3   30.7  ± 1.2 ** 15.8  ± 1.6   
  F(3,8)=22 P=0.0003 F(3,8)=0.3 P=0.8196 F(3,8)=1.1 P=0.4011 F(3,8)=8.8 P=0.0065 F(3,8)=1.6 P=0.2723 
Wort 
- 26.4  ± 0.7   
Y-27632 
3.0  ± 0.2   1.1  ± 0.1   56.6  ± 1.7   30.2  ± 1.9   
2.5 19.4  ± 1 *** 2.4  ± 0.2   1.0  ± 0.1   49.7  ± 1.8 * 30.2  ± 2.1   
5 18.7  ± 0.8 *** 2.5  ± 0.1   1.3  ± 0.1   48.3  ± 1.3 * 29.5  ± 1.5   
10 17.2  ± 0.6 *** 3.2  ± 0.2   1.1  ± 0.1   48.4  ± 1.4 * 31.2  ± 1.6   
  F(3,8)=26.8 P=0.0002 F(3,8)=4.6 P=0.0377 F(3,8)=2 P=0.1893 F(3,8)=6.4 P=0.0162 F(3,8)=0.1 P=0.9252 
Secondary neurite length 
Lova 
- 1.3  ± 0.13   
Y-27632 
8.0  ± 0.5   1.3  ± 0.1   11.8  ± 0.64   10.5  ± 0.66   
13 2.2  ± 0.21   5.0  ± 0.5 * 1.1  ± 0.1   11.2  ± 0.69   8.9  ± 0.73   
25 2.5  ± 0.31 * 4.2  ± 0.5 ** 0.9  ± 0.1   13.3  ± 0.77   10.7  ± 0.83   
50 4.2  ± 0.31 *** 5.7  ± 0.7   1.0  ± 0.1   15.4  ± 0.8 * 11.2  ± 0.86   
  F(3,8)=22.6 P=0.0003 F(3,8)=8.6 P=0.0069 F(3,8)=2.6 P=0.1257 F(3,8)=6.6 P=0.0149 F(3,8)=1.6 P=0.2698 
Wort 
- 1.3  ± 0.15   
Lova 
23.0  ± 3.6   2.5  ± 0.8   4.5  ± 0.59   3.2  ± 0.61   
2.5 0.6  ± 0.13 ** 19.1  ± 2.4   2.6  ± 0.7   3.1  ± 0.35   2.6  ± 0.38   
5 0.5  ± 0.13 ** 17.0  ± 2.1   3.0  ± 0.9   2.5  ± 0.33 * 2.1  ± 0.35   
10 0.3  ± 0.06 ** 19.1  ± 2.4   2.0  ± 0.4   2.7  ± 0.15 * 2.3  ± 0.17   
  F(3,8)=12.2 P=0.0024 F(3,8)=0.9 P=0.4964 F(3,8)=0.3 P=0.7902 F(3,8)=5.2 P=0.0278 F(3,8)=1.4 P=0.315 
Wort 
- 1.2  ± 0.12   
Y-27632 
5.6  ± 0.4   1.4  ± 0.1   12.0  ± 1.12   10.8  ± 1.13   
2.5 0.7  ± 0.27   6.1  ± 0.4   1.6  ± 0.1   8.5  ± 0.72   7.8  ± 0.77   
5 0.6  ± 0.1   6.0  ± 0.4   1.5  ± 0.1   8.2  ± 0.55 * 7.6  ± 0.56   
10 0.6  ± 0.04   5.6  ± 0.4   1.5  ± 0.1   8.4  ± 0.86 * 7.8  ± 0.87   
  F(3,8)=3.7 P=0.0617 F(3,8)=0.4 P=0.7357 F(3,8)=0.4 P=0.7672 F(3,8)=4.8 P=0.0337 F(3,8)=3.2 P=0.0818 
Compounds were incubated 24 h in SH-SY5Y cells. 
Results represent the means ± S.E.M. (n=3) and pharmacological parameters were determined by a 
nonlinear regression with a 4PL or normalized fitting. Statistical analysis were performed by one-way 
ANOVA followed by Bonferroni post hoc test: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs 
corresponding vehicle-treated cells (without 1
st 
drug).  
See figure 2 for respective curves. 
Lova, Lovastatin. Wort, wortmannin. ∆, difference. 
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Table 10. (Supplemental Table 3) Pharmacological parameters of the Y-27632, lovastatin 
and wortmannin dose-responses alone or in combination on the primary and secondary 
neurite number in SH-SY5Y cells 
Number of the primary and secondary neurites : pharmacologic parameters 
1
st
 drug 
(µM) 
Basal value 
 without dose-response 
(neurite) 
2
nd
 drug 
Dose-response EC50 (µM) nh  Emax (neurite) 
Emax 
(neurite number ∆ 
over basal value) 
 Primary neurite number/cell 
Lova 
- 2.23  ± 0.04   
Y-27632 
1.1 ± 0.12   1.5 ± 0.2   3.06  ± 0.06   0.83  ± 0.07   
13 2.20  ± 0.03   0.9 ± 0.12   1.1 ± 0.1   2.88  ± 0.04   0.68  ± 0.05   
25 2.39  ± 0.07   0.9 ± 0.14   1.1 ± 0.1   3.03  ± 0.06   0.64  ± 0.09   
50 2.47  ± 0.04 * 1.4 ± 0.33   0.9 ± 0.1   2.98  ± 0.07   0.51  ± 0.08   
  F(3,8)=7.4 P=0.0108 F(3,8)=1.7 P=0.2373 F(3,8)=2.6 P=0.1214 F(3,8)=1.8 P=0.2220 F(3,8)=3.2 P=0.0852 
Wort 
- 2.29  ± 0.11   
Lova 
9.6 ± 12.16   1.4 ± 1.5   2.38  ± 0.06   0.10  ± 0.13   
2.5 1.78  ± 0.06 * 12.2 ± 2.3   1.8 ± 0.5   2.28  ± 0.07   0.50  ± 0.08 * 
5 1.65  ± 0.05 ** 11.2 ± 1.63   3.0 ± 1.1   2.16  ± 0.08   0.51  ± 0.07 * 
10 1.47  ± 0.12 *** 9.6 ± 2.32   1.6 ± 0.5   2.06  ± 0.07   0.59  ± 0.07 * 
  F(3,8)=15.2 P=0.0011 F(3,8)=0.4 P=0.9883 F(3,8)=0.5 P=0.6663 F(3,8)=3.9 P=0.0539 F(3,8)=5.6 P=0.0222 
Wort 
- 2.21  ± 0.05   
Y-27632 
1.7 ± 0.44   1.2 ± 0.3   3.04  ± 0.11   0.83  ± 0.12   
2.5 1.73  ± 0.05 ** 1.3 ± 0.17   1.0 ± 0.1   2.69  ± 0.08   0.96  ± 0.09   
5 1.78  ± 0.08 ** 1.5 ± 0.24   1.3 ± 0.2   2.62  ± 0.1   0.84  ± 0.12   
10 1.68  ± 0.09 ** 1.2 ± 0.22   1.3 ± 0.2   2.57  ± 0.14 * 0.89  ± 0.16   
  F(3,8)=12.1 P=0.0024 F(3,8)=0.5 P=0.6714 F(3,8)=0.4 P=0.7684 F(3,8)=3.7 P=0.0598 F(3,8)=0.2 P=0.8756 
Secondary neurite number/primary neurite 
Lova 
- 0.062  ± 0.003 
Y-27632 
9.8 ± 0.57   1.3 ± 0.1   0.371  ± 0.018   0.310  ± 0.018   
13 0.098  ± 0.009 * 6.6 ± 0.62 ** 1.0 ± 0.1   0.339  ± 0.012   0.240  ± 0.015 * 
25 0.101  ± 0.009 * 5.0 ± 0.45 *** 1.0 ± 0.1   0.396  ± 0.01   0.295  ± 0.014   
50 0.141  ± 0.009 *** 5.0 ± 0.51 *** 1.0 ± 0.1   0.447  ± 0.013 * 0.306  ± 0.016   
  F(3,8)=16.6 P=0.0009 F(3,8)=17.1 P=0.0008 F(3,8)=3.5 P=0.0696 F(3,8)=11.3 P=0.0030 F(3,8)=4.2 P=0.0462 
Wort 
- 0.060  ± 0.005 
Lova 
22.0 ± 3.48   2.5 ± 0.8   0.155  ± 0.016   0.095  ± 0.017   
2.5 0.035  ± 0.008 17.9 ± 2.21   2.4 ± 0.6   0.127  ± 0.01   0.092  ± 0.013   
5 0.032  ± 0.007 * 19.1 ± 2.15   3.1 ± 0.8   0.115  ± 0.012   0.083  ± 0.014   
10 0.030  ± 0.004 * 16.7 ± 2.6   2.1 ± 0.6   0.107  ± 0.006 0.077  ± 0.007 
  F(3,8)=5.1 P=0.0294 F(3,8)=0.7 P=0.5627 F(3,8)=0.3 P=0.8292 F(3,8)=3.3 P=0.0789 F(3,8)=0.4 P=0.7647 
Wort 
- 0.061  ± 0.007 
Y-27632 
12.1 ± 1.17   1.5 ± 0.2   0.323  ± 0.027 0.026  ± 0.013   
2.5 0.039  ± 0.015   8.3 ± 0.67 * 1.3 ± 0.1   0.267  ± 0.022 0.031  ± 0.017   
5 0.033  ± 0.007 6.4 ± 0.65 ** 1.5 ± 0.2   0.218  ± 0.021 * 0.021  ± 0.008 
10 0.038  ± 0.009 7.3 ± 0.96 * 1.3 ± 0.2   0.201  ± 0.015 * 0.022  ± 0.013   
  F(3,8)=1.5 P=0.2790 F(3,8)=7.9 P=0.087 F(3,8)=0.4 P=0.7672 F(3,8)=6.4 P=0.0161 F(3,8)=0.1 P=0.9460 
Compounds were incubated 24 h in SH-SY5Y cells. 
Results represent the means ± S.E.M. (n=3) and pharmacological parameters were determined by a 
nonlinear regression with a 4PL or normalized fitting. Statistical analysis were performed by one-way 
ANOVA followed by Bonferroni post hoc test: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs 
corresponding vehicle-treated cells (without 1
st 
drug). 
See figure 2 for respective curves. 
Lova, lovastatin; Wort, wortmannin; ∆, difference. 
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Table 11. (Supplemental Table 4) Lovastatin treatment reduces the [
3
H]dopamine uptake 
in SH-SY5Y cells 
Timing 
incubation 
Lovastatin   24 h   48 h 
DA uptake 
 
15 min 
 
60 min 
 
15 min 
 
60 min 
Vmax  
 (pmol/mg 
protein/min) 
Vehicle - 
 
10.5  ± 0.31    7.2  ± 0.29    8.2  ± 0.45    5.9  ± 0.2   
Lova 
(µM) 
5 
 
11.8  ± 0.50    6.8  ± 0.32    7.9  ± 0.88 
 
 3.9  ± 0.14 * 
10 
 
11.8  ± 0.90    6.5  ± 0.37    6.5  ± 0.45    3.6  ± 0.27 ** 
50 
 
7.2  ± 0.49 *  4.5  ± 0.21 ***  5.4  ± 0.81 
 
 2.5  ± 0.36 *** 
      
 
F(3,8)=12.91, 
P<0.002 
  
F(3,8)=16.06, 
P<0.001 
          
F(3,8)=34.77, 
P<0.0001 
                                     
Km  
(nM) 
Vehicle -  277  ± 30     188  ± 30     240  ± 49     203  ± 26   
Lova 
(µM) 
5  297  ± 49    209  ± 38   344  ± 129   198  ± 27  
10  320  ± 84    204  ± 45    289  ± 74    240  ± 56   
50   212  ± 56     160  ± 31     490  ± 231     339  ± 165   
Michaelis-Menten fitting equation was applied for calculations of kinetics parameters. Km: substrate 
concentration that gives half maximal rate of DA transport (nM). Vmax: maximal rate of DA transport 
(pmol/mg of protein/min). DA uptake saturation concentration range: 15 nM to 3 µM.  
Results represent the means ± S.E.M. (n = 3) and significant differences were measured by one-
way ANOVA followed by Bonferroni post hoc test; *P<0.05, **P<0.01, ***P<0.001 for comparison 
between vehicle and treated cells were represented in respective column. Lova: lovastatin. DA: 
dopamine 
See figure 6 for respective curves 
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Table 12. (Supplemental Table 5) Pharmacological inhibition parameters of GBR-12935, 
RSP and TBZ dose-response treatments on [
3
H]dopamine uptake in SH-SY5Y cells 
treated with lovastatin and in BE(2)-M17 cells transfected with VMAT2 
SH-SY5Y cells: [3H]DA uptake: pharmacologic parameters 
Lovastatin 
Dose-
response  
IC50  nH  Imax (%)  Incubation 
time 
(µM) 
24 h 
- - GBR-12935 
 (IC50: nM) 
424  ± 50   -1.9  ± 0.3   100.0  ± 0.8   
+ 50 348  ± 77   -1.9  ± 0.7   99.0  ± 4.8   
- - RSP 
(IC50: pM) 
916  ± 140   -0.9  ± 0.1   85.4  ± 3.2   
+ 50 584  ± 64   -0.9  ± 0.1   77.5  ± 2.2   
- - TBZ 
(IC50: µM) 
20.4  ± 5.6   -0.7  ± 0.1   74.9  ± 3.4   
+ 50 26.6  ± 19.4   -0.4  ± 0.1   73.0  ± 5.2   
+ 50 
High affinity site 
(IC50: nM) 
62.9  ± 278               
48 h 
- - 
GBR-12935 
 (IC50: nM) 
252  ± 8.4   -2.0  ± 0.1   99.7  ± 1.2   
+ 
5 189  ± 7.9 ** -1.9  ± 0.1   99.1  ± 1.2   
10 181  ± 11.8 *** -1.9  ± 0.2   99.3  ± 2.3   
50 170  ± 11.8 ** -1.9  ± 0.2   99.4  ± 2.3   
- - 
RSP 
 (IC50: pM) 
182  ± 15.6   -1.5  ± 0.2   77.9  ± 2.1   
+ 
5 150  ± 24.6   -1.2  ± 0.2   59.7  ± 2.7 ** 
10 199  ± 34.3   -1.3  ± 0.2   50.2  ± 2.5 **** 
50 699  ± 192 ** -1.1  ± 0.3   36.7  ± 3.7 **** 
- - 
TBZ 
 (IC50: µM) 
4.6  ± 0.9   -0.6  ± 0.1 
 
77.9  ± 3.2   
+ 
5 2.6  ± 0.57   -0.5  ± 0.0 
 
73.0  ± 10.1   
10 5.4  ± 1.25   -0.6  ± 0.1 
 
61.4  ± 3.3   
50 10.5  ± 4.37   -0.8  ± 0.2   48.1  ± 4.7 * 
                          
BE(2)-M17 cell : [3H]DA uptake: pharmacologic parameters 
 Transfection 
& affinity site 
Dose-
response  
IC50  nH  Imax (%) 
WT RSP 
(IC50: pM) 
1.53  ± 0.23   -1.2  ± 0.4   53.1  ± 2.1   
VMAT2 5.25  ± 0.57 *** -1.2  ± 0.5   78.7  ± 3 *** 
WT 
Low affinity TBZ 
 (Affinity IC50: 
low in µM and 
high in nM) 
25.8  ± 11.8   -0.8  ± 0.2   65.7  ± 3.8   
High affinity 71.9  ± 10.6               
VMAT2 
Low affinity 18.8  ± 12.3 
 
-0.3  ± 0.0 * 82.1  ± 2.9 ** 
High affinity 27  ± 11.7 *             
[
3
H]DA concentration: 15 nM for 60 min. GBR-12935, RSP and TBZ were incubated 30 min prior 
the DA uptake. -, no co-treatment. +, co-treatment.  
Results represent the means ± S.E.M. (n=3-5) and pharmacological parameters were determined 
by a nonlinear regression with a 4PL or normalized fitting.  
SH-SY5Y: statistical analysis were performed by one-way ANOVA in SH-SY5Y cells (IC50: GBR-
12935 and lovastatin 48h: F(3,12)=13.43, P=0.0004; IC50: RSP and lovastatin 48h: F(3,12)=7.06, 
P=0.0054; Imax: RSP and lovastatin 48h: F(3,12)=37.29, P<0.0001; Imax: TBZ and lovastatin 48h 
F(3,12)=4.850, P=0.0195) followed by Bonferroni post hoc test; *P<0.05, **P<0.01, ***P<0.001, 
****P<0.0001 for comparison between vehicle and lovastatin treatment.  
Be(2)-M17: statistical analysis were performed by a student’s t-test for comparison between wild-
type and VMAT2 transfection in Be(2)-M17 (IC50 RSP: t(8)=6.05, P=0.0003 n=5; IC50 TBZ high 
affinity site: t(8)=15.78, P=0.0216 n=5; TBZ nH: t(8)=2.50, P=0.0365 n=5; RSP Imax: t(8)=6.99, 
P=0.0001 n=5; TBZ Imax: t(8)=3.42, P=0.0089 n=5).  
See figure 6 g-l and figure 7 c-d for respective curves. 
DA, dopamine; RSP, reserpine; TBZ, tetrabenazine; VMAT2, transfection with VMAT2; WT, wild-
type. 
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V.  Sterol regulatory element-binding protein-1 (SREBP-
1) activation modulates dopaminergic phenotype of 
neuroblastoma cells 
V. 1.  Abstract 
Statins may reduce the risk of Parkinson’s disease (PD) suggesting a neuroprotective 
role to counteract the degeneration of dopaminergic neurons. Several cellular signalling 
cascades are modulated by the statin-mediated inhibition of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase. The transcriptional activation of the sterol regulatory 
elementary binding protein (SREBP) is one of the major cellular signalling pathways 
mediated by cholesterol-lowering effect of statins. We previously demonstrated that statins 
induce an up-regulation and functional changes of presynaptic dopaminergic proteins in 
neuroblastoma cells and hypothesized that SREBP activation could mediate these effects, 
leading to decreased incidence of PD amongst statin users. Here, we test this hypothesis, 
reporting that the SREBP activator U18666A, increases the translocation of SREBP-1 into 
the nucleus, inducing an increase in presynaptic dopaminergic marker expression such as 
vesicular monoamine transporter 2 (VMAT2), synaptic vesicle glycoprotein 2A (SV2A) and 
2C, synaptogyrin-3 (SYNGR3) and tyrosine hydroxylase. siRNA-mediated SREBP-1 
downregulation also abolishes the expression of VMAT2 and SV2C. Our results thus show 
that U18666A induces cell differentiation, through SREBP-1 activation, towards 
dopaminergic phenotype, suggesting that SREBP-1 transcriptional activity may mediate, at 
least in part, the neuroprotective effects observed following statins treatment in PD, shedding 
light upon SREBP-1 as a potential new target for developing disease-modifying treatment in 
PD. 
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V. 2.  Introduction 
Epidemiological studies show an inverse association between the use of statins and 
the incidence of Parkinson’s disease (PD) (Wolozin et al., 2007; Wahner et al., 2008; Gao et 
al., 2012; Lee et al., 2013) suggesting an underlying neuroprotective mechanism of statins. 
Such potential effect has been then confirmed in experimental PD models using neurotoxic 
agents such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Ghosh et al., 2009; 
Castro et al., 2013) and 6-hydroxydopamine (Yan et al., 2011; Xu et al., 2013). The 
protection is thought to occur through their action against proinflammatory processes, 
oxidative stress and α-synuclein aggregation (Ghosh et al., 2009; Roy and Pahan, 2011; 
Kumar et al., 2012; Xu et al., 2013), via the PI3K/Akt and the Ras homolog gene family 
member A (RhoA) pathways (Schulz et al., 2004; Evangelopoulos et al., 2009; Racchetti et 
al., 2010; Jin et al., 2012; Raina et al., 2013). We recently proposed an alternate mechanism 
by which statins induce differentiation of neuroblastoma SH-SY5Y cells towards a 
dopaminergic phenotype (Schmitt et al., 2015), i.e. statins would oppose ongoing 
degeneration in PD. Statins indeed up-regulate the expression of the presynaptic 
dopaminergic markers cells such as vesicular monoamine transporter 2 (VMAT2), 
synaptogyrin 3 (SYNGR3) or synaptic vesicles glycoprotein 2C (SV2C) that are the key 
players of the intravesicular dopamine regulation (Schmitt et al., 2015). Promoting uptake by 
vesicles may reduce the toxicity of oxidized dopamine and of neurotoxic agents (Egana et al., 
2009; Dardou et al., 2013; Segura-Aguilar et al., 2014).  
We hypothesized that sterol regulatory element binding proteins-1 (SREBP-1) 
activation, mediated by cholesterol-lowering effect of statins, could mediate these effects, 
leading to decreased incidence of PD amongst statin users. SREBPs are transcription factors 
responsible for the upregulation of enzymes involved in the lipid and cholesterol synthesis 
synthesis (Kim and Spiegelman, 1996; Shimano et al., 1999; Eberlé et al., 2004; Espenshade, 
2006; Jeon and Osborne, 2012; Shao and Espenshade, 2014). Under conditions of sufficient 
cholesterol levels, the cholesterol sensor of SREBP cleavage activating protein (SCAP) 
prevents the activation of SREBP (Yabe et al., 2002; Yang et al., 2002; Eberlé et al., 2004; 
Engelking et al., 2005; Espenshade, 2006; Jeon and Osborne, 2012). When the cholesterol is 
low, e.g. under statin exposure, SREBP is released and cleaved by the site-1 protease (S1P) 
and site-2-zing metalloproteinase in a truncated active form. This SREBP proteolytic 
activation allows its translocation into the nucleus where it leads to a transcriptional 
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activation of lipid-biosynthesis enzymes (Eberlé et al., 2004; Espenshade, 2006; Jeon and 
Osborne, 2012) and probably the synaptic markers. 
However, the direct link between SREBP-1 activation and the induction of 
dopaminergic marker expression remains to be demonstrated and characterized. To this end, 
we investigated the role of SREBP in the modulation of the dopaminergic phenotype (at 
protein and mRNA levels) in neuroblastoma cells using genetic and pharmacologic 
modulators of SREBP.  
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V. 3.  Materials and methods 
I. 1.1.  Materials  
SH-SY5Y (CRL-2266) and BE(2)-M17 (95011816) cells were obtained from ATCC 
(American Type Culture Collection, Molsheim, France) and ECACC (European Collection of 
Cell Cultures, Salisbury, UK), respectively. Reagents for cell culture were purchased to 
Lonza (Verviers, Belgium). Coating reagent poly-D-lysine and collagen were from Sigma-
Aldrich (Diegem, Belgium) and Corning (Lasne, Belgium) respectively. Primary antibodies 
were βIII-tubulin (MMS-435P or PRB-435P) from Covance (Rotterdam, Netherlands), 
tyrosine hydroxylase (AB152) from Millipore (Overijse, Belgium), SYNGR3 (sc-271046) 
from Santa Cruz Biotechnology (Dallas, TX, USA), SREBP-1 (SAB4502850), β-actin 
(A3853 and A2066) from Sigma-Aldrich, synaptic vesicle glycoprotein 2A (119 002), SV2C 
(119 202) and VMAT2 (138 302) from Synaptic Systems (Goettingen, Germany). Secondary 
antibodies were from Life Technologies (Alexa Fluor-488 and 647-conjugated goat anti-
mouse and/or anti-rabbit IgG; Gent, Belgium). DAPI, lipofectamine RNAiMAX, high 
capacity cDNA reverse transcription kit with MultiScribe MuLV transcriptase, Luminaris 
probe qPCR master mix (low ROX), Taqman PCR probe (FAM-MGB) and serum for cell 
culture were from Life Technologies. U18666A and PF-429242 were purchased to Tocris 
(Abingdon, UK). Mock and SREBP-1 siRNAs were from GE Healthcare Dharmacon 
(Diegem, Belgium). 
I. 1.2.  Cell cultures and drug treatments 
SH-SY5Y and BE(2)-M17 neuroblastoma cells were cultured in Dulbecco's modified 
Eagle medium (DMEM) medium supplemented with 10% (v/v) of foetal bovine serum and 
maintained in a humidified incubator with 95% air and 5% CO
2
 at 37 °C. For 
immunocytochemistry, the cells were seeded (15 x 10
3
) 24 h before the studies on poly-D-
lysine and collagen mix pre-coated 96-well plates. For gene expression studies, cells were 
plated in 48-well plates at 160 x 10
3
 cells per well per well for SH-SY5Y cells. For siRNA 
study, BE(2)-M17 cells were plated in 48-well at 50 x 10
3
 cells. The cells were stimulated 
with pharmacological agents by incubation with single or multiple increasing doses. 
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I. 1.3.  Immunocytochemistry and high-content image analysis 
The Immunocytochemistry and high-content image analysis protocol was previously 
described (Schmitt et al., 2015).The effects of pharmacological treatments on SREBP-1 
nuclear translocation and protein expression were analyzed by immunofluorescence method 
using antibodies against the synaptic markers and SREBP-1. Briefly, cells were washed with 
phosphate-buffered saline (PBS) followed by fixation with 4% paraformaldehyde for 30 min 
(room temperature) and permeabilization (triton X-100 0.05% -10 min). The non-specific 
binding was blocked with blocking solution (3% of bovine serum albumin and 5% of normal 
goat serum in PBS) for 1 h. The cells were incubated overnight at 4 °C with primary 
antibodies against SV2A (1:500), SV2C (1:500), VMAT2 (1:500), SREBP-1 (1:500), 
SYNGR-3 (1:100) or βIII-tubulin (1:3000) in blocking solution. After washing (4 x 5 min), 
the cells were incubated with species-specific corresponding secondary antibodies labelled 
with Alexa Fluor 488 or 647 in blocking solution. Nuclear counterstaining was performed by 
incubation with DAPI and by further washing steps (5 x 5 min).  
Immunofluorescence signal was analysed using a high-content imaging (HCI) 
microscopy system (BD Pathway-855 Bioimager System using BD Attovision, Becton-
Dickinson, Erembodegem, Belgium) in PBS medium. Series (2 by 3) of images were 
acquired in 3 non-superposing image fields per well using a 20x objective (0.75NA, 
Olympus, Berchem, Belgium). The fluorescent intensity of neuronal markers and nuclear 
translocation were analysed using a specific image analysis algorithms developed using 
Cellenger software package (Definiens, München, Germany).. Cytoplasmic and nuclear 
intensity parameters were used for determination of protein levels and nuclear translocation. 
Both quantifications use the cell compartmentalization defined by segmentation of βIII-
tubulin staining for the cytoplasm and DAPI for the nucleus. For quantification of protein 
levels, the relative intensity of cytoplasm was measured minus the background value. The 
nuclear translocation was measure by quantification of the nuclear/cytoplasmic intensity 
ratio.  
I. 1.4.  Quantitative real-time polymerase chain reaction (qRT-
PCR) 
The qRT-PCR protocol was previously described (Schmitt et al., 2015).Total cellular 
RNA was isolated using the RNeasy mini kit (Qiagen, Venlo, Netherlands) according to the 
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manufacturer’s protocol. Briefly, cDNA was synthetized from 1.5 µg of total RNA using 
high capacity cDNA reverse transcription kit
 
(20 µl). The quantitative real-time PCR 
experiments were performed in MicroAmp- 96-wellPCR plates using specific Taqman gene 
expression probes for SV2A (Hs00372069_m1), SV2C (Hs00392676_m1), SREBP1 
(Hs01088691_m1), SREBP2 (Hs01081784_m1), SYNGR3 (Hs00188379_m1), VMAT2 
(SLC18A2; Hs00996835_m1), TH (Hs00165941_m1) and β-actin (ACTB; Hs99999903_m1). 
The reactions were performed in ViiA
™
 7 RT-PCR system (Applied Biosystems) using 25 ng 
of cDNA sample and the recommended concentration of the specific probe and qPCR master 
mix Luminaris. PCR reactions were run in triplicate and the fold-changes in mRNA levels 
were calculated using 2
-∆∆Ct
 method (Schmittgen and Livak, 2008) and normalized to β-actin 
mRNA levels. 
I. 1.5.  SREBP-1 SiRNA transfection 
For inducing SREBP-1 downregulation, cells were transfected with SREBP-1 siRNA 
On-TARGETplus SMARTpool (L-006891-00, human SREBF1, 4 target sequences: 
GCAACACAGCAACCAGAAA – CGGAGAAGCUGCCUAUCAA – 
GAAUAAAUCUGCUGUCUUG – GCGCACUGCUGUCCACAAAA) SiRNA 25 nM final 
and with non-targeting control pool (Mock, D-001810-10-05, 4 target sequences: 
UGGUUUACAUGUCGACUAA – UGGUUUACAUGUUGUGUGA –
UGGUUUACAUGUUUUCUGA – UGGUUUACAUGUUUUCCUA) prepared in 
Lipofectamine RNAiMAX (2 µg/ml). Plasmid solution and Lipofectamine RNAiMAX
 
were 
pre-diluted separately for 5 min in serum free medium and mixed for 30 min before added 
into the well. Cells were used 72 h after transfection. 
I. 1.6.  Data analysis 
Results are presented as means ± S.E.M. from a minimum of three independent 
experiments in duplicate or triplicate unless otherwise stated. Data were analysed with 
GraphPad Prism software (La Jolla, CA, USA) using either Student's t-test or ANOVA with 
Bonferroni's post hoc test. P<0.05 was considered significant to assess the difference between 
conditions. Half maximal effective concentration (EC50) or inhibitory concentration (IC50), 
maximal effect (Emax) or inhibition (Imax), Hill coefficient (nH) and basal level 
pharmacological parameters were generated with nonlinear regression and fitted to four-
parameter logistic curve (4PL);  
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𝑌 = 𝑏𝑎𝑠𝑎𝑙 𝑙𝑒𝑣𝑒𝑙 +
𝑚𝑎𝑥𝑖𝑚𝑎𝑙 𝑒𝑓𝑓𝑒𝑐𝑡 − 𝑏𝑎𝑠𝑎𝑙 𝑙𝑒𝑣𝑒𝑙
1 + 10(𝐿𝑜𝑔𝐸𝐶50 𝑜𝑟 𝐼𝐶50−𝑋)𝑛𝐻
 
and normalized equation; 
𝑌 =
100
1 + 10(𝐿𝑜𝑔𝐸𝐶50 𝑜𝑟 𝐼𝐶50−𝑋)𝑛𝐻
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V. 4.  Results 
V. 4.1.  U18666A-induced translocation of SREBP-1 into nucleus 
in SH-SY5Y cells 
We investigate the effects of U-18666A on the nuclear translocation of SREBP-1. 
U18666A is an known activator of SREBP in non-neuronal cells (Lange et al., 1999; Worgall 
et al., 2002; Zhang et al., 2004; Colgan et al., 2007). We first validated its ability to induce 
SREBP translocation in neuronal SH-SY5Y cells. Using SREBP-1 immunocytochemistry 
(Figure 1A), we studied the impact of U18666A upon the nuclear translocation of 
transcription factor. High-content analysis demonstrated a significant increase in U18666A–
induced SREBP-1 translocation (Figure 1A) in a dose- and time-dependent manner in SH-
SY5Y cells after 12 h of incubation (Figure 1B and Supplementary Table S1). A maximal 
effect was observed after 48 h of incubation with an EC50 of 7±0.5 µM (Figure 1B and 
Supplementary Table S1). We then assessed the impact of PF-429242, which is thought to 
inhibit the SREBP cleavage activity of S1P enzyme (Hay et al., 2007; Hawkins et al., 2008) 
leading to an impairment of translocation (Hay et al., 2007; Hawkins et al., 2008; Olmstead et 
al., 2012; Shao and Espenshade, 2012). In our conditions, PF-429242 showed only a partial 
effect on SREBP-1 translocation at 48 h of incubation (Figure 1A, C and Supplementary 
Table 1S), culminating at 30±4.3% of the activation effect with U18666A treatment (48h, 30 
µM, t-test t(4)=10.5, P=0.0006). Overall, these data confirm that U18666A induces a 
significant and fast translocation of SREBP-1 while PF-429242 achieves 30% of this effect 
offering the possibility to investigate impact of different intensities of translocation upon 
induction of dopaminergic phenotype in neuroblastoma cells. 
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Figure 23. (Figure 1.) U18666A triggers nuclear translocation of SREBP-1 in SH-SY5Y 
cells 
(A) Representative immunofluorescence images of SREBP-1 and β-tubulin staining in SH-SY5Y 
treated with 10 µM of U18666A and PF-429242. Classification of cells as positive or negative for the 
SREBP-1 nuclear translocation. (B-C) Dose-response kinetics (6 to 48 h) of (B) U18666A and (C) 
PF-429242 treatments on SREBP-1 nuclear translocation. Results represent the mean ± S.E.M. (n=4) 
and were fitted by nonlinear regression with a 4PL equation. Statistical analyses were performed by 
two-way ANOVA (U18666A: dose-response effect: F(5,24)=192.6, P<0.0001; Time: F(3,24)=239.8, 
P<0.0001; Interaction: F(15,24)=76.43, P<0.0001; PF-429242 dose-response effect: F(5,48)=10.06, 
P<0.0001; Time: F(3,48)=13.56, P<0.0001; Interaction: F(15,48)=2.742, P<0.0001) followed by 
Bonferroni post hoc test: */# were represented when a point of the curve was at least P<0.05 
compared to baseline (*) or 6 h of treatment (#). Scale bar indicates 20 µM. B, basal level. 
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V. 4.2.  Activation of SREBP-1 translocation upregulates the 
presynaptic dopaminergic-related proteins 
The activation of SREBP-1 translocation induced by U18666A may positively 
changes the transcriptional expression of neuronal markers. Using both gene expression 
analysis and immunofluorescence, we thus investigated the mRNA expression levels of 
several key proteins of dopaminergic system previously examined in the statin-induced 
dopaminergic differentiation study. Quantitative PCR using mRNA-specific probes showed 
that SREBP-1 and SREBP-2 mRNA expression levels were expectedly enhanced from 6 h of 
incubation with U18666A while they were inhibited after incubation with PF-429242 (Figure 
2A and 2B). U18666A-induced increase in SV2A mRNA (Figure 2C) reached maximal 
effect at 24 h and 48 h of incubation in SH-SY5Y cells while 24 h of incubation induced a 
significant increase in VMAT2 mRNA that continuously increased up to 48 h after treatment 
(Figure 2E). A significant higher transcription level of SYNGR3 mRNA was observed after 6 
h of incubation with U18666A and the expression level remained stable over time up to 48 h 
(Figure 2F). However, no detectable changes were found for mRNA levels of SV2C and TH 
(Figure 2D and G). Of note, PF-429242 did not modify mRNA levels for any of the studied 
synaptic proteins. 
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Figure 24. (Figure 2.) U18666A treatment up-regulates mRNA levels of dopaminergic 
synaptic proteins 
 (A -G) Time-course study (6-48 h) of (A) SV2A, (B) SV2C, (C) VMAT2, (D) SYNGR3, (E) TH, (F) 
SREBP-1 and (G) SREBP-2 mRNA expressions normalized over β-actin in SH-SY5Y cells treated 
with 10µM of U18666A and PF-429242 Results represent means ± S.E.M. (n=3). Statistical analyses 
were performed by two-way ANOVA (SV2A: treatment effect: F(2,36)=74.76, P<0.0001; Time: 
F(3,36)=2.341, P=0.0895; Interaction: F(9,53)=1.633, P=0.1663. SV2C: treatment effect: F(2,36)=7.971, 
P=0.0014; Time: F(3,36)=0.5808, P=0.6315; Interaction: F(6,36)=0.3024, P=0.9316.VMAT2: treatment 
effect: F(2,36)=93.82, P<0.0001; Time : F(3,36)=51.88, P<0.0001; Interaction: F(6,36)=37.82, P<0.0001. 
SYNGR3: treatment effect: F(2,36)=17.13, P<0.0001; Time: F(3,36)=0.366, P=0.7774; Interaction: 
F(6,36)=0.632, P=0.7034. TH: treatment effect: F(2,36)=4.457, P=0.0186; Time: F(3,36)=1.066, P=0.3757; 
Interaction: F(6,36)=0.5608, P=0.7584. SREBP-1: treatment effect: F(2,12)=33.72, P<0.0001; Time: 
F(3,36)=0.2187, P=0.8815; Interaction: F(6,12)=0.5545, P=0.7582. SREBP-2: treatment effect: 
F(2,12)=888, P<0.0001; Time: F(3,12)=22.04, P<0.0001; Interaction: F(6,12)=30.16, P<0.0001) followed 
by Bonferroni post hoc test: ;*/#P<0.05, **/##P<0.01, ***/###P<0.001, ****/####P<0.0001, * vs 
corresponding vehicle treated cells, # vs corresponding 6 h of treatment. B, basal level. 
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We then determined if U18666A-induced increased transcriptional activity is 
accompanied by an increased mRNA translation. High content image analysis demonstrated 
that U18666A induced a dose-dependent increase in synaptic protein levels after 48 h of 
treatment (Figure 3A-E and Supplementary Table S2). The maximum increase of 
fluorescence intensity was observed by U18666A with a rank order among studied markers 
such as SV2C>SV2A=VMAT2=TH>SYNGR3. The potency of U18666A corresponds to a 
general EC50 of 9.7±1 µM (Figure 3A-E and Supplemental Table S2), whereas no significant 
effect on synaptic protein level was observed for PF-429242 treatment (Figure 3A-E and 
Supplemental Table S2) as expected from the transcriptional results. 
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Figure 25. (Figure 3.) Dopamine-related synaptic markers are increased by the U18666A 
treatment in SH-SY5Y cells 
(A-F) Quantification of (A) SV2A, (B) SV2C, (C) VMAT2, (D) SYNGR3 and (E) TH expression levels 
in cells treated for 24 h or 48 h with U18666A and PF-429242. Results represent means ± S.E.M. 
(n=3). Significant differences were measured by two-way ANOVA (SV2A: dose-response effect: 
F(5,24)=16.77, P<0.0001; Compounds effect: F1(,24)=20.06, P=0.0002; Interaction: F(5,24)=6.274, 
P=0.0007. SV2C: dose-response effect: F(5,24)=18.97, P<0.0001; Compounds effect: F(1,24)=22.55, 
P<0.0001; Interaction: F(5,24)=4.734, P=0.0038. VMAT2: dose-response effect: F(5,24)=9.977, 
P<0.0001; Compounds effect: F(1,24)=15.33, P=0.0007; Interaction: F(5,24)=3.383, P=0.0187. TH: dose-
response effect: F(5,23)=25.09, P<0.0001; Compounds effect: F(1,23)=42.11, P<0.0001; Interaction: 
F(5,23)=12.67, P<0.0001. SYNGR3: dose-response effect: F(5,23)=13.53, P=0.0012; Compounds effect: 
F(1,23)=15.53, P=0.0167; Interaction: F(5,23)=3.653, P<0.0140) followed by Bonferroni post hoc test: 
*P<0.05, **P<0.01, **P<0.001, ****P<0.0001, vs corresponding vehicle treated cells. B represents the 
basal level: cells without treatment. B, basal level. 
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Overall, these data suggest that the increase in VMAT2, SYNGR3, and SV2A levels 
are consequent to an increased transcriptional activity of SREBP. Furthermore, the observed 
increase for TH and SV2C proteins is independent of such transcriptional event, possibly 
dependent of differential protein stabilities. Finally, as modest transcription still occurs even 
in presence of PF-429242, our data suggest that either low level of active SREBP is enough 
to sustain the transcription of synaptic proteins or other factors are responsible for such 
baseline transcription. 
V. 4.3.  SREBP-1 transcription factor is necessary to sustain the 
expression of VMAT2 and SV2C 
Pharmacological enhancement of SREBP-1 activity provokes the differentiation 
towards the dopaminergic phenotype of SH-SY5Y cells (Schmitt et al., 2015). Lowering 
SREBP-1 levels was the next step to ascertain its direct role in such phenomenon. However, 
Preliminary experiments using SH-SY5Y cells did not lead to a suitable transfection level of 
siRNA. We thus selected the BE(2)-M17 neuroblastoma cells also known to present a 
pronounced dopaminergic phenotype. RT-PCR analysis confirmed the total downregulation 
of SREBP-1 reaching 88.9±4.1% after 72 h of incubation with the specific SiRNA while no 
changes in SREBP-1 levels was observed with mock SiRNA (Figure 4). The selectivity of 
SREBP-1 SiRNA concentrated at 25 nM was confirmed because of the expression of 
SREBP-2 isoform remained stable after siRNA transfection (Figure 4). SREBP-1 SiRNA 
treatment reduced the expression level of 70.7±3.2% and 35.1±12.1% for VMAT2 and 
SV2C, respectively (Figure 4). However, an increase of 176.3±25% was detected for SV2A 
mRNA in the downregulation of SREBP-1 (Figure 4). These findings support the 
involvement of SREBP-1 in the maintenance of the basal expression level of presynaptic 
dopaminergic protein VMAT2 and SV2C.  
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Figure 26. (Figure 4.) Downregulation of SREBP-1 modulates the mRNA expression of 
presynaptic proteins VMAT2, SV2C and SV2A 
RT-PCR analysis of the dopaminergic presynaptic proteins in BE(2)-M17 treated with 25nM SREBP-1 or mock 
sIRNA incubated 72 h. Results represent means ± S.E.M. (n=4). Significant differences were measured by one-
way ANOVA (F8,27)=3.27, P<0.0098) followed by Bonferroni post hoc test: *P<0.05 and **P<0.01, vs mock 
SiRNA. B, basal level in mock SiRNA. 
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V. 5.  Discussion 
Present study demonstrates that SREBP-1 nuclear translocation is associated to an 
increase of transcriptional expression of presynaptic markers SV2A, VMAT2 and SYNGR3 
while its downregulation reduces the expression of vesicular transporter VMAT2 and SV2C. 
We show here that the treatment of SH-SY5Y neuroblastoma cells with U18666A, a 
SREBP-1 activator, triggered SREBP-1 nuclear translocation. It has been shown that 
U18666A induces a reduction of cholesterol concentration and the maturation of SREBP-1 
that in turn translocates to the nucleus (Lange et al., 1999; Worgall et al., 2002; Zhang et al., 
2004; Colgan et al., 2007). Our data show for the first time the activation of this cholesterol 
pathway-dependent transcriptional mechanism. This finding agrees and extend previous 
report in non-neuronal cells (e.g. HELA cells) (Colgan et al., 2007). In our study, U18666A 
also induced the expression of SREBP demonstrating a simultaneous modulation of the 
transcriptional signal and of the modulator itself. The lack of effect of PF-429242, a S1P 
inhibitor, on SREBP-1 translocation and the reduction of its expression confirms the presence 
in SH-SY5Y cells of the SREBP autoregulatory mechanism also observed in other cell lines 
(Sato et al., 1996; Amemiya-Kudo et al., 2000; Xiao and Song, 2013). Actually, it has been 
shown that pharmacological activation of SREBP-1 induces its mRNA transcription through 
the direct binding of SREBP protein on its promoter (Sato et al., 1996; Amemiya-Kudo et al., 
2000), while SREBP inactivation by PF-429242 treatment (Hawkins et al., 2008) or by 
knocking down S1P gene in mice causes a lower expression of SREBP (Yang et al., 2001). 
The slightly higher ratio of the nuclear SREBP-1 induced by PF-429242 could be explained 
by a reduction of immature SREBP levels into the cytoplasm.  
The effects of U18666A treatment reported here are similar to our previously reported 
data on statin-induced SREBP-1 nuclear translocation (Schmitt et al., 2015). It is worth 
noting that in identical conditions U18666A efficacy is higher than that of statins (Schmitt et 
al., 2015). Several putative mechanism of SREBP activation could explain this difference of 
efficacy. Indeed, statins only inhibit the cholesterol synthesis from HMG-CoA without 
affecting neither its metabolism nor its transport (Sirtori, 2014) while U18666A is able to 
inhibit (i) the 2,3-oxidosqualene-lanosterol cyclase enzyme which is the direct upstream 
enzyme of the cholesterol synthesis (Mark et al., 1996; Zhang et al., 2004; Cenedella, 2009); 
(ii) the low density lipoprotein (LDL)-stimulated cholesterol esterification, which impairs the 
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transformation of the cholesteryl ester into the free cholesterol in the endoplasmic reticulum 
(ER) (Liscum et al., 1989; Sparrow et al., 1999); (iii) the late endosomal/lysosomal 
trafficking of LDL free cholesterol to the ER and Golgi (Härmälä et al., 1994; Sparrow et al., 
1999; Worgall et al., 2002; Zhang et al., 2004; Cenedella, 2009). Therefore compared to 
statins, U18666A may completely deplete cells of free cholesterol in the ER where SREBP is 
located leadings to its swift and efficient translocation into the nucleus (Schmitt et al., 2015). 
The present results also first demonstrate the U18666A-induced modulation of the 
dopaminergic synaptic markers expression. These new findings are in line with our previous 
study demonstrating a similar effect of statins (Schmitt et al., 2015) and agree with the 
reported upregulation of SV2A observed after SREBP-1 transfection in non-neuronal cells 
(Kallin et al., 2007). Both statins and SREBP-1 activator U18666A induce: (i) an overall up-
regulation of presynaptic dopaminergic protein levels (SV2A, SV2C, VMAT2, TH and 
SYNGR3) and (ii) a stable increased VMAT2, SYNGR3 and SV2A mRNA expression. 
However, our results showing a U18666A-mediated time-dependent upregulation of VMAT2 
expression suggest a delayed time frame compared to the statin-induced signalling taking 
place at an earlier stage (Schmitt et al., 2015). These observations suggest that the 
upregulation of SREBP expression induced by U18666A participates to the expression of the 
dopaminergic markers by modulating the gene expression levels such as VMAT2, SYNGR3 
and SV2C. Our data using SREBP-1 siRNA demonstrate that the role and sensitivity of this 
control mechanism in the presynaptic dopaminergic phenotype. Downregulation of SREBP-1 
induced a significant reduction of VMAT2 and SV2C. These new findings are in agreement 
with the observed regulation of these dopaminergic biomarkers induced by U18666A. 
Interestingly, the treatment with SREBP-1 siRNA increased the levels of SV2A. It remains 
unclear whether upregulation of SV2A mRNA levels induced by the SREBP-1 
downregulation found here results from the selective action of SREBP-1 activity or it results 
from a SV2 compensation isoform mechanism triggered by the decrease of SV2C expression 
level (Xu and Bajjalieh, 2001). 
 SREBP transcriptional activity inducing an increase of VMAT2 expression 
could have a neuroprotective impact in PD neurodegeneration (Speciale et al., 1998; 
Bernstein et al., 2014; Lohr and Miller, 2014; Yulug et al., 2015). It has been shown that 
upregulation of VMAT2 expression reduces damages and oxidative stress through the 
sequestration into the vesicles of neurotoxic agents (e.g. MPTP) and cytosolic oxidative 
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dopamine (Speciale et al., 1998; Chen et al., 2005; Brighina et al., 2013; Lohr et al., 2014). In 
contrast, VMAT2 knockout mice and treatment with VMAT2 inhibitors results in an 
increased MPTP toxicity (Takahashi et al., 1997; Gainetdinov et al., 1998; Staal and Sonsalla, 
2000). Moreover, the transcriptional control of SV2C and SYNGR3 by SREBP-1 suggested 
by our findings may also participate in the modulation of cytosolic dopamine levels as 
suggested by previous findings (Egana et al., 2009; Dardou et al., 2011, 2013; Segura-Aguilar 
et al., 2014).  
Altogether, our results with U18666A activator are closely similar of those effects 
observed with the statins, which suggests that both substances use the same downstream 
cholesterol-dependent SREBP-1 pathway for regulation of synaptic markers (Schmitt et al., 
2015). This likely excludes the involvement of downstream pathways of the statins such as 
PI3K/Akt and RhoA pathways in the up-regulation of dopaminergic markers (Schulz et al., 
2004; Evangelopoulos et al., 2009; Racchetti et al., 2010; Jin et al., 2012; Raina et al., 2013). 
In conclusion, we demonstrated the role of SREBP-1 in the expression and 
transcriptional activity of dopaminergic biomarkers. Altogether, our data strengthen previous 
findings on the regulation of dopaminergic phenotype by statins in SH-SY5Y cells. Further 
investigation on the cellular and molecular mechanisms driven by SREBP transcriptional 
activity may help to better understand its role in the regulation of dopamine phenotype as 
well as its potential neuroprotective and neurorestorative role of statins in Parkinson’s 
disease. Overall, our results open new ways for neuroprotection as therapeutic uses in PD of 
SREBP modulators. 
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V. 7.  Supplemental data 
Table 13. (Supplemental Table 1) Pharmacological parameters of U18666A and PF-
429242 dose-responses on SREBP-1 nuclear translocation in SH-SY5Y cells  
Nuclear translocation of SREBP-1: pharmacologic parameters 
Conditions U18666A  PF-429242  
Time 
incubation 
EC50 (µM) nh  
Emax  
(% over vehicle) 
EC50 (µM) nh  
Emax 
(% over vehicle) 
6 h Not significant over vehicle 
Not significant over vehicle 12 h  3.5  ± 2.3 0.6  ± 0.2 112.1  ± 0.4 
24 h 5.6  ± 1.9 0.9  ± 0.2 115.2  ± 2.2 
48 h 7.0  ± 0.5 2.0  ± 0.2 158.3  ± 3.4 8.7  ± 1.52 1.59  ± 0.37 117.4  ± 2.3 
SREBP-1 compound dose-responses up to 30µM were incubated in SH-SY5Y cells. 
Results represent the means ± S.E.M. (n=3) and pharmacologic parameters were determined by 
nonlinear regression with a 4PL and normalized fitting of fluorescence intensity ratio between 
cytoplasm and nucleus in SREBP-1 immunocytochemistry (background subtracted). Significant 
differences were measured by two-way ANOVA (U18666A, treatment F(5,24)=192.6, P<0.0001; Time: 
F(3,24)=239.8, P<0.0001; Interaction: F(15,24)=76.43, P<0.0001; PF-429242 treatment: F(5,48)=10.06, 
P<0.0001; Time: F(3,48)=13.56, P<0.0001; Interaction: F(15,48)=2.742, P<0.0001). 
Table 14. (Supplemental Table 2) Pharmacological parameters of U18666A and PF-
429242 dose-responses on the dopaminergic markers expression level in SH-SY5Y cells 
Presynaptic dopaminergic protein expression level: pharmacologic 
parameters 
Conditions U18666A do PF-429242  
Proteins EC50 (µM) 
nh  
 
Emax  
(% over vehicle) 
EC50 (µM) nh  
Emax  
(% over vehicle) 
SV2A 12.2  ± 4.2 2.7 ± 2.3 326.3  ± 55.3 
Not significant over vehicle 
SV2C 8.3  ± 3.4 1.6 ± 0.8 363.4  ± 57.3 
VMAT2 10.2  ± 3 1.6 ± 0.6 324.0  ± 66.5 
TH 11.5  ± 3.1 2.0 ± 0.9 321.2  ± 41.9 
SYNGR3 6.6  ± 1.8 2.0 ± 0.8 246.0  ± 69.4 
SREBP-1 compound dose-responses up to 30µM were incubated 48 h in SH-SY5Y cells. 
Results represent the means ± S.E.M. (n=3) and pharmacologic parameters were determined by 
nonlinear regression of fluorescence intensity in immunocytochemistry assay reported in Figure 3. 
Significant differences were measured by two-way ANOVA (SV2A, dose-response effect: 
F(5,24)=16.77, P<0.0001; Compound effect: F(1,24)=20.06, P=0.0002; Interaction: F(5,24)=6.274, 
P=0.0007. SV2C, dose-response effect: F(5,24)=18.97, P<0.0001; Compound effect: F(1,24)=22.55, 
P<0.0001; Interaction: F(5,24)=4.734, P=0.0038. VMAT2: dose-response effect: F(5,24)=9.977, 
P<0.0001; Compound effect: F(1,24)=15.33, P=0.0007; Interaction: F(5,24)=3.383, P=0.0187. TH: dose-
response effect: F(5,23)=25.09, P<0.0001; Compound effect: F(1,23)=42.11, P<0.0001; Interaction: 
F(5,23)=12.67, P<0.0001. SYNGR3: dose-response effect: F(5,23)=13.53, P=0.0012; Compounds effect: 
F(1,23)=15.53, P=0.0167; Interaction: F(5,23)=3.653, P<0.0140). 
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For several decades, the drug treatment of PD aiming to replace the massive 
pathological deficit of dopamine has been a major therapeutic success because it alleviates 
the motor symptoms and represents a huge benefit for patients (Giugni and Okun, 2014). 
However, today there is no cure for the progression of neurodegenerative process. Several 
therapeutic strategies are currently under consideration such as neuroprotection and 
neurorestoration, aiming to halt disease progression and to recover locomotor functions and 
normal physiological conditions (Henchcliffe and Severt, 2011). All these so-called disease-
modifying treatments are in the preclinical stages or early in clinical trials. Unfortunately, the 
first approaches aiming to stop the neurodegenerative processes (rasagiline) have not been 
fully satisfactory in clinical studies and their neuroprotective potential remains to be fully 
demonstrated (Henchcliffe and Severt, 2011). In this context, there is an unmet clinical need 
priming for searching new therapeutic targets and treatment strategies as well as for 
identifying new preclinical models for PD with a stronger translational potential (Martinez, 
2014). Moreover, a better understanding of the neurodegenerative mechanism underlying the 
disease and its progression remains a major challenge for targeting better therapeutic 
approaches (Brundin et al., 2015). 
During the last decade, an intense effort of discovery research in PD intends to 
identify therapeutic approaches for modifying the course of the disease (Brundin et al., 2015). 
Several signalling pathways have been shown as important intervention points for stopping or 
slowing down neurodegeneration in PD (Ramanan and Saykin, 2013). The targets that 
modulate either the neurotrophic or neuroprotective mechanism or both could be of major 
interest because of their potentials for protecting the dopaminergic cells against neurotoxic 
challenges and for inducing the neurorestoration of lost cells and synaptic connexions 
(Blaudin de Thé et al., 2015). Among others, neurotrophic factors (e.g. GDNF, BDNF) and 
transcription factors modulating neurodifferentiation (e.g. NURR1 and RAR) are an area of 
major interest in PD research (Blaudin de Thé et al., 2015). In this context, the cholesterol 
pathway and more particularly the inhibition of HMG-CoA by statins has been proposed to 
have a significant therapeutic potential for neuroprotection and neurorestoration in 
neurological diseases, especially in PD, and has been the main focus of this project (Reiss 
and Wirkowski, 2007).  
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Epidemiological studies and preclinical researches have showed the neuroprotective 
potential of statins, which suggests that the medical use of statins may reduce the risk of 
developing PD (Becker and Meier, 2009). Compelling data demonstrate that statins have 
neuroprotective effects by reducing dopaminergic cell death in cultured systems as well as in 
animals (van der Most et al., 2009). The suggested pathways and mechanisms leading to 
statin-induced neuroprotective include a reduction of oxidative stress, neuroinflammation and 
aggregation of α-synuclein (Roy and Pahan, 2011); all of them are processes demonstrated to 
be increased in PD pathology (Yacoubian and Standaert, 2009). The potential 
neurorestorative effect of statins remains poorly investigated. Thus, we aimed to determine 
the effect of statins and the associated downstream signalling pathways in the genesis of 
synaptic structures and in the expression and functionality of presynaptic dopaminergic 
markers. The data generated in the present study demonstrate new regulatory effects of statins 
in the neuritogenesis, synaptic protein expression and function of dopaminergic transport 
system in the human dopaminergic neuroblastoma SH-SY5Y cell line. 
The neurotrophic effects of statins found in our study confirm and extend previous 
data showing statin-induced neurite growth (Raina et al., 2013). We demonstrate that statins 
induce neurite branching rather primary neurite elongation, an effect that differentiates these 
compounds from other neurotrophic principles. Statin-reported effects on neurite growth 
could be mediated by downstream impact in the RhoA system or by indirect interference with 
PI3K/Akt pathway. Both have been shown to affect branching complexity of neuronal 
processes (Higuchi et al., 2003; Hynds et al., 2003; Petrinovic et al., 2010). Combination 
experiments demonstrated that the effects of statin in our study are, at least in part, 
independent of RhoA system and fully independent of PI3K pathways. Nevertheless, we have 
demonstrated that statin treatment induced a reversal of neurite retraction induced by 
inhibitors of the PI3K pathway. However, we cannot elucidate the role of the enhancement of 
synaptic protein expression or the decrease of cholesterol by the statins on the neurite growth 
and branching complexity (Tarsa and Goda, 2002; Pfrieger, 2003; Wang et al., 2008). 
Overall, the effects of statins on neurite growth demonstrate a neurorestorative and 
neuroprotective potential of these compounds against the axonal degeneration in PD. 
In addition to the effects of statins in neurite growth of SH-SY5Y cells, we have 
found a significant increase in the levels of presynaptic markers of the dopaminergic system. 
Synaptic vesicle proteins levels such as SV2C, SV2A, VMAT2 and SYNGR3 were increased 
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after statin treatment. We could demonstrate that the increases of protein level were 
associated to gene expression up-regulation for the vesicular transporter SV2C and VMAT2. 
Further investigation allowed us to strengthen the direct implication of cholesterol 
downstream pathway in these phenotypic changes by demonstrating the effects of SREBP 
direct modulators in protein levels of VMAT2, SV2C, SYNGR3 and SV2A. The activation of 
SREBP genes by the nuclear factor LXR using specific ligand could be an interesting way to 
measure the involvement of SREBP in the regulation of synaptic proteins (Repa et al., 2000; 
Yoshikawa et al., 2001). Furthermore, our findings obtained by using siRNA suggest that 
SREBP-1 may be necessary for the expression of SV2C and VMAT2. In summary, our data 
suggest that the changes in synaptic protein markers are a unique modulatory action of statins 
on not only the dopaminergic phenotype, but also on other neurotransmitter systems. To our 
knowledge, this effect has not been yet reported.  
An important objective of our project was to determine the impact of statins in the 
function of the dopamine transport system. Our findings demonstrate statin-induced decrease 
of total dopamine transport capacity and specific changes in the pharmacological sensitivity 
of VMAT2. Our findings suggest that the decrease of dopamine uptake could be likely 
associated to an imbalance in the dopamine transport cycle likely affected by changes in DAT 
and VMAT2 pharmacology and expression levels as well as by the differential increase in the 
protein levels of SV2C and SYNGR3. However, these data could also be in line with 
previous reports showing that a low cholesterol level in lipid rafts reduce the DAT uptake 
capacity (Adkins et al., 2007; Cremona et al., 2011). Moreover, activation of PI3K pathway 
has been shown to modulate DAT internalization by phosphorylation and could lead to less 
DAT at the membrane surface and subsequent a reduction transport capacity (Torres et al., 
2003b). In this context, we could suggest that statins can mediate the internalization of DAT 
by PI3K pathway activation. This remains to be confirmed by measuring the levels of DAT at 
cell surface and its phosphorylation levels.  
In summary, the present project aimed to study the effect of statins in the biology of 
dopaminergic system. The findings obtained in present project demonstrate the modulation 
by statins of A) the genesis of neuronal synaptic elements B) the expression and/or the levels 
of dopaminergic system proteins VMAT2, SYNGR3, SV2C, DAT, TH and C) the 
modulation of functional dopamine transport cycle. Investigation of downstream pathways 
involved in above mechanisms allowed us to also show that neurotrophic effects of statins are 
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partially independent of RhoA and PI3K pathways while a SREBP-dependent pathway is 
involved in the modulation of dopaminergic system biomarkers. Overall, these results suggest 
a therapeutic action of statins against neurodegenerative processes taking place in PD. The 
neuroprotective and neurotrophic effects of statins as well as their impact in the function of 
dopamine transport extend the previous studies which have shown efficacy in oxidative stress 
and neuroinflammation and strengthen the suggested therapeutic potential of statins in PD. 
The results obtained during the development of the present project have contributed to 
identify new mechanisms and downstream pathways triggered by the treatment of SH-SY5Y 
neuroblastoma cells by statins. However, the findings have open new questions that should be 
investigated to understand the biology of cholesterol pathway and its impact on 
neurodegenerative processes and on the therapeutic potential of statins. Further investigations 
could be triggered regarding the neurorestorative effects of the statins. It would be important 
to know whether statin have neurorestorative effect by the unique impact in the network 
complexity or by the regulation of the synapse’s functionality. In this context, the 
investigation of the molecular impacts mediated by statins on dopaminergic synaptic proteins, 
such as protein turnover, membrane residence and post-transcriptional modifications may 
help to explain the modulation of the dopamine transport cycle. The importance of 
cholesterol pathway for the integrity and multiple functionalities of protein anchored in the 
neuronal cell membranes support additional research in order to demonstrate the regulatory 
points possibly requires at transcriptional levels in the SREBP pathway. Moreover, it would 
be very important to demonstrate that such effects could be observed in PD animal models 
and particularly if they could hinder and reverse neurodegenerative mechanisms, and if so, 
they may add translational value for the human neurodegeneration. 
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